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RESUMEN 
 
 
La terapia génica constituye hoy en día una alternativa segura y eficaz para el tratamiento de 
determinadas enfermedades monogénicas que afectan al sistema hematopoyético. Sin 
embargo, puesto que el riesgo de mutagénesis insercional debido al uso de vectores 
integrativos no se puede descartar completamente, la terapia génica de edición se ha 
propuesto como una alternativa más segura, ya que la inserción del gen terapéutico está 
dirigida a un locus específico del genoma. Las aproximaciones de edición génica se basan en el 
uso de nucleasas específicas que generan roturas de doble cadena en un sitio específico del 
genoma, mejorando así la eficacia de la recombinación homóloga con construcciones 
donadoras que albergan el gen de interés flanqueado por los brazos de homología 
correspondientes. En este estudio se han optimizado las condiciones para editar líneas 
celulares linfoblastoides (LCLs) y células madre hematopoyéticas (CMHs), inicialmente de 
donantes sanos, con el objetivo final de corregir mediante terapia génica de edición las 
progenitores hematopoyéticos de pacientes con anemia de Fanconi del subtipo A (AF-A). 
En particular, hemos establecido un método eficaz para editar LCLs y CMHs en un sitio seguro 
en el genoma, el locus AAVS1. Nuestro protocolo se basa en la transducción de estas células 
con vectores lentivirales defectivos en integración que portan un donador con el gen de 
interés, seguido de la nucleofección de estas células con nucleasas de dedos de zinc (ZFNs) 
utilizadas como ARNm. Utilizando un vector donador control que lleva el gen marcador GFP 
hemos logrado una eficiencia media de corrección génica dirigida en células CD34+ de 
donantes sanos del 9,43%. Por otra parte, hemos confirmado que la edición génica también es 
eficaz en CMHs multipotentes con capacidad de repoblación a largo plazo en ratones 
inmunodeficientes. Para mejorar la eficacia de la edición génica, hemos investigado la 
posibilidad de utilizar nanopartículas de oro, que incrementaron la eficiencia de transducción 
de vectores lentivirales integrativos y no integrativos en las células CD34+. Sin embargo, este 
incremento no dio lugar a una mejora en la edición génica, debido a la toxicidad asociada a la 
nucleofección de las células tratadas con las nanopartículas. A continuación, mediante el uso 
de un vector donador terapéutico, portador del gen FANCA, hemos demostrado la corrección 
del fenotipo de LCLs de pacientes con AF-A mediante edición génica, que confirmamos por la 
formación de focos de reparación de FANCD2 y la reversión de la sensibilidad de estas células 
frente a un agente entrecruzante del ADN, tal como mitomicina C (MMC). Para mejorar la 
eficacia de edición génica en células hematopoyéticas de pacientes AF-A, también 
investigamos el efecto mediado por la inhibición transitoria de la anti-recombinasa PARI. 
Aunque la inhibición de PARI aumentó los focos de reparación de RAD51, no observamos 
aumento significativo en  la eficiencia de la edición génica. Por último, hemos demostrado que 
nuestro protocolo de edición génica también permite, aunque con menor eficacia, la inserción 
del gen terapéutico en progenitores hematopoyéticos de pacientes con AF-A, permitiendo así 
la reversión parcial de su sensibilidad a MMC. 
Nuestro estudio demuestra por primera vez que la terapia génica de edición en el locus seguro 
AAVS1 es factible en las células hematopoyéticas, incluyendo progenitores hematopoyéticos 
primarios, de pacientes con anemia de Fanconi del subtipo A, abriendo nuevas perspectivas 
para la terapia génica dirigida de esta enfermedad, así como de otras enfermedades 
monogénicas del sistema hematopoyético. 
SUMMARY 
 
 
 
Gene therapy nowadays constitutes a safe and efficient treatment for a number of monogenic 
diseases affecting the hematopoietic system. Risks of insertional mutagenesis derived from the 
use of integrative vectors cannot, however, be completely excluded. Therefore, gene targeting 
has been proposed as a safer alternative, since the insertion of the therapeutic gene is driven 
to a specific locus in the genome. Gene targeting approaches are based on the use of specific 
nucleases which generate double strand breaks (DSBs) in a specific site of the genome, 
markedly enhancing the efficacy of homologous recombination (HR) with donor constructs 
harboring the gene of interest flanked by the corresponding homology arms. In this study we 
have optimized the conditions to target human lymphoblastic cell lines (LCLs) and also 
hematopoietic stem cells (HSCs) from healthy donors, with the final aim of correcting by gene 
editing the hematopoietic progenitor cells from Fanconi anemia subtype A (FA-A) patients. 
In particular, we have established a robust method to target both LCLs and HSCs in a safe 
harbor site in the genome, the AAVS1 locus. Our approach is based on the transduction of 
these cells with integrase-defective lentiviral vectors carrying a donor with the gene of 
interest, followed by the nucleofection of these cells with zinc finger nucleases used as mRNA. 
Using a control donor vector carrying the GFP reporter gene we have obtained, on average, 
9.43% gene targeting efficiency in cord blood CD34+ cells from healthy donors. Moreover, we 
confirmed that gene targeting was also efficient in HSCs with long term and multipotent 
repopulation capacity, as demonstrated by transplants into immunodeficient mice. To improve 
the gene targeting efficiency, we investigated the feasibility of using gold nanoparticles, which 
were shown to improve the transduction efficiency of integrase-defective and competent 
lentiviral vectors in HSCs. This increment, however, did not lead to a higher gene targeting 
efficiency, due to the toxicity associated with the nucleofection of cells treated with these 
nanoparticles. In our next step, we moved from healthy donor HSCs to FA hematopoietic cells. 
Using a therapeutic donor vector carrying the FANCA gene, we demonstrated that gene 
targeting can correct the phenotype in a FA-A LCL. This was deduced from the restoration of 
FANCD2 foci formation and the reversion of the sensitivity of FA-A cells to interstrand cross 
linkers, such as mitomycin C (MMC). To improve the gene targeting efficiency in FA-A 
hematopoietic cells, we also investigated the effects mediated by the transient inhibition of 
anti-recombinase PARI. Although the inhibition of PARI increased RAD51 foci, no significant 
increase of homology directed repair efficiency was observed. In a final set of experiments we 
demonstrated that our gene targeting approach has also taken place in hematopoietic 
progenitor cells from FA-A patients, leading to a partial reversion in their hyper-sensitivity to 
MMC. 
Our study demonstrates for the first time that gene targeting in the AAVS1 safe harbor locus is 
feasible in hematopoietic cells from Fanconi anemia-A patients, opening up new perspectives 
for the future gene therapy of this and other monogenic diseases of the hematopoietic system. 
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1. Conventional gene therapy 
Gene therapy (GT) consists in the delivery of genetic material into patient’s cells to treat a 
disease. It can be achieved either by the introduction, the substitution or the alteration of 
genes. This approach is especially relevant for the treatment of monogenic diseases in which 
the therapeutic gene can correct the genetic defect1-3. Therapeutic genes can be introduced in 
the cells using different mechanisms such as retroviral vectors (RVs) and lentiviral vectors (LVs) 
that will integrate into the genome and will allow the long term expression of the transgene. 
Classically, viral vectors are widely used for this purpose because of their higher efficiency; 
however, there are also non-viral methods to introduce the genetic material inside the cells, 
which include transposons, liposomes, inorganic nanoparticles and others4. The outcome of 
gene therapy can be improved if the correction of mutated cells confers them a proliferative or 
survival advantage over non-modified ones. This is the case of Fanconi anemia (FA) patients 
with somatic mosaicism, in which the reversion of the pathogenic mutation mediates a 
proliferation advantage of corrected cells, representing a model of natural gene therapy (see 
section 2.5. of the introduction)5.  
According to the modality of treatment, GT can be classified as in vivo or ex vivo GT. The in vivo 
modality consists in the introduction of a therapeutic gene directly into the patient by the 
inoculation of the vector that carries the transgene. On the other hand, the ex vivo GT is based 
on the in vitro modification of cells previously collected from the patient, which are then 
reinfused back (Figure 1). Moreover, and according to the integration nature of the transgene 
in the cell genome, we can distinguish two types of GT: Conventional GT, in which the 
integration of the new genetic material is not directed to specific loci; and the Targeted GT in 
which the integration is site-specific. Both of them will be discussed in the next sections. 
Figure 1: Schematic representation of in vivo versus ex vivo gene therapy. In vivo gene therapy consists 
in the direct inoculation of the vector carrying the therapeutic gene in the patient. Ex vivo gene therapy 
In vivo GT
Therapeutic gene
Therapeutic vector
Patient
Ex vivo GT
Therapeutic gene
Therapeutic vector
Defective 
cells from 
patient
In vitro modification 
of patient’s cells
Modified patient’s 
cells
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consists in the isolation of target cells from the patient, followed by the in vitro treatment with the 
therapeutic vector and finally the reinfusion of these modified cells in the patient. GT: Gene Therapy. 
1.1. Conventional ex vivo gene therapy 
As previously mentioned, conventional GT is characterized by the integration of a therapeutic 
gene in a non-targeted way. Viral vectors are widely used to conduct this kind of GT. 
Conventional ex vivo GT is the strategy most widely used in hematopoietic stem cell (HSC) 
gene therapy, as it reduces the immunological response3. Moreover, HSCs are the principal 
target cells for this approach due to the feasibility to isolate them ex vivo, genetically modify 
and transplant them again by intravenous infusion. Once genetically modified HSCs engraft 
into the bone marrow (BM) of the patient; these cells can produce new and healthy blood cells 
of all lineages for the whole life of the patient. Autologous HSC GT has been successfully used 
in different clinical trials during the last years (Table 1). Monogenic hematological disorders 
are currently the main indication, and these include primary immunodeficiencies: such as 
adenosine deaminase deficiency-severe combined immunodeficiency (ADA-SCID), X-linked 
SCID (X-SCID), chronic granulomatous disease (CGD) and Wiskott-Aldrich syndrome (WAS); 
erythroid diseases like β-thalassemia and sickle cell disease (SCD) and bone marrow failure 
(BMF) syndromes like FA. Storage disorders like metachromatic leukodystrophy (MLD) and 
adrenoleukodystrophy (ALD) have been also treated by autologous HSC GT due to the ability of 
HSC to deliver the therapeutic enzyme to the nervous system. 
Disease Target cells Transduced 
cells 
Vector Treated 
patients 
Efficacy Adverse 
effects 
ADA-SCID
6-8
 Lymphoid cells 
and natural 
killer cells (NK) 
HSC γ-RV 42 Long-term cure 
comparable to 
HSCT 
No 
X-SCID
9-11
 Lymphoid cells 
and NK 
HSC γ-RV 25 Long-term cure 
comparable to 
HSCT 
Yes 
X-SCID
12-14
 Lymphoid cells 
and NK 
HSC SIN γ-
RV 
9 (on 
going) 
Recovery of PB 
T cells that were 
functional and 
eliminated the 
infections 
No 
CGD
15
 Neutrophils HSC γ-RV 23 Transient or no 
clinical benefit. 
Long-term 
efficacy in the 
three cases of 
clonal 
expansion 
followed by 
inactivation of 
the transgene  
Yes 
WAS
16,17
 Lymphoid 
cells, NK and 
platelets 
HSC γ-RV 10 Clear benefit at 
2 year follow-up 
Yes 
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Disease Target cells Transduced 
cells 
Vector Treated 
patients 
Efficacy Adverse 
effects 
WAS
18-20
 Lymphoid 
cells, NK and 
platelets 
HSC SIN LV 4 (on 
going) 
Improvement in 
platelet counts, 
immune 
functions and 
clinical scores 
No 
β-
thalassemia
21
 
Erythroid cells HSC SIN LV 4 Therapeutic 
benefit. 
Transfusion 
independence 
No 
ALD
22
 Macrophages 
and microglia 
HSC SIN LV 4 Clear 
therapeutic 
benefit 
comparable to 
HSCT 
No 
MLD
23
 Macrophages 
and microglia 
HSC SIN LV 9 (on 
going) 
Stopped the 
manifestation 
or progression 
of the disease 
beyond the 
predicted age of 
symptom onset 
No 
Table 1: Ex vivo HSC GT clinical trials. NK: natural killer. γ-RV: gamma-retroviral vectors. HSCT: 
hematopoietic stem cell transplantation. SIN LV: self-inactivating lentiviral vectors. SIN γ-RV: self-
inactivating gamma retroviral vectors. PB: peripheral blood. Modified from Naldini
2
 and Gosh et al
1
. 
The viral vectors most widely used for hematopoietic GT are γ-retroviral (γ-RV) and lentiviral 
vectors (LVs). Both belong to the same family of virus (Retroviridae) that possesses RNA based 
genome and present the same basic structure, 5’ and 3’ ends which flank the three viral genes 
(Figure 2): 
• Gag gene encodes for capsid, matrix and nucleocapside proteins. 
• Pol gene encodes the reverse transcriptase, the integrase and the protease. 
• Env gene encodes the proteins for the viral envelope. 
Figure 2: Retroviral RNA genome. Retroviral genome consists in two single stranded RNA molecules with 
a Cap structure in the 5’ end and a poly-adenylated tail in the 3’ end. 5’ and 3’ ends contain some 
regulatory regions of the virus which flank the three viral genes: gag, pol and env.  
The viral cycle goes from single stranded RNA (ssRNA) through a dsDNA intermediate that is 
able to integrate into the host genome, allowing this proviral DNA to replicate together with 
the host DNA. The main differences between LVs and γ-RVs are the followings:  
• The genome of the LVs is more complex than γ-RVs one, as it presents accessory 
proteins that are involved in the regulation of the viral cell cycle. 
Cap A(n)R U5 PBS L gag PPT U3 R
5’ End 3’ End
pol env
Viral genes
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• LVs can transduce non-diving cells. 
• LVs present a safer integration profile than γ-RVs, as they integrate preferentially 
inside transcription units of actively transcribed genes, in contrast to γ-RVs that 
presents a preferential integration in regions close to the transcription start sites of 
genes and CpG islands24,25. 
The major problem derived from the use of these vectors is the genotoxicity due to insertional 
mutagenesis, which has been clearly demonstrated with γ-RVs in different clinical trials, but 
not with LVs. Insertional mutagenesis is derived from the enhancer activation of the 
neighboring genes by viral LTRs, which are formed by reverse transcription of retroviral RNA at 
either end of the proviral DNA. LTRs are segmented into U3, R and U5 regions of the 5’ and 3’ 
ends of retroviral RNA genome (Figure 2) and participate in the integration of the provirus into 
the host genome. Once the provirus has been integrated, the LTR on the 5’ end serves as the 
promoter of the entire retroviral genome and is the one responsible for the transactivation of 
neighboring genes. Several cases of hematological malignancies were described in the first γ-
RV-based GT clinical trials: T-cell acute lymphoblastic leukemia cases in SCID-X1 and WAS 
patients have been associated with LTR-mediated up-regulation of a proto-oncogene 
(LMO226,27), while clonal dominance and myelodysplastic syndromes (MDSs) described in γ-RV-
treated CGD patients occurs by up-regulation of myeloproliferative genes like MECOM and 
PRDM16
15. In order to limit the trans-activation potential of these vectors and to increase their 
safety some modifications have been performed. One of the most important ones consists in 
the inactivation of the U3 region (located in the 3’ end of the viral genome) leading to the 
generation of self-inactivating (SIN) vectors and the use of more physiological promoters. Now 
is well proven that, by deleting the viral LTR, the risk of insertional mutagenesis through 
enhancer activation of the neighboring genes is significantly reduced1. Even more, the 
integration pattern of LVs is much safer and no adverse events have been detected in patients 
treated with these LVs with a follow up of 9 years. In spite of all these advantages, some 
studies have reported that LV integration can lead to the production of aberrantly spliced 
transcripts and deregulated gene expression in the integrated genes28-30, although this 
phenomenon has not been observed in patients. Furthermore, it has been also described a 
partial clonal dominance in a LV-treated β-thalassemia patient as a consequence of increased 
expression of a truncated HMGA2 mRNA that escaped regulation by a miRNA directed to the 3’ 
end of the full-length mRNA. However, this dominance was confined to erythroid cells, did not 
result in leukemic progression as in some γ-RV based cases and the clone stabilized 5 years 
post-gene therapy21. Nowadays, GT using LV vectors has become a reliable therapeutic option 
to treat some monogenic diseases with no adverse effects described up to now.  
2. Directed/targeted gene therapy 
Directed gene therapy or targeted gene therapy is characterized by the integration of the 
genetic material in a specific site of the genome. Using gene targeting approaches it is possible 
to interrupt, insert or replace a specific sequence in the genome in a determined locus and in a 
specific way. Directed GT increases the safety of GT, as the modification of the genome only 
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occurs in a specific region, avoiding thus the risk of insertional oncogenesis or deregulation of 
gene expression. 
Nucleases are the tools selected to produce a double strand break (DSB) in a specific site in the 
genome and will be discussed in the section 2.3. of the introduction. These DSBs generated by 
nucleases are repaired by two endogenous DNA repair mechanisms: homologous 
recombination (HR) or non-homologous end joining (NHEJ); which will be explained in detail in 
the section 2.1. of the introduction. HR occurs at a very low frequency (in 1 out of 106-108 
cells31,32) in mammalian cells and is only active in S-G2-phases of the cell cycle while NHEJ is the 
preferential pathway to repair this kind of lesions and is active during all the cell cycle. So, the 
cell cycle status is a crucial parameter to consider in gene targeting strategies33. The repair of 
these DSBs by NHEJ leads to stable gene disruption or to somatic knockout of a gene if both 
alleles are targeted. However, if the repair of DSBs generated by nucleases occurs through HR, 
it can cause insertions or substitutions in the endogenous cellular DNA through a process 
called homology-directed repair (HDR). 
2.1. Endogenous mechanisms of double strand break DNA 
repair 
Double strand breaks are, together with interstrand-crosslinks (ICLs), one of the most 
deleterious lesions that can occur in the DNA. DSBs can be produced by endogenous sources 
like reactive oxygen species, cellular metabolism, and replication associated errors; or by 
exogenous sources including ionizing radiation or chemotherapeutic agents. Unrepaired or 
misrepaired DSBs can result in senescence, induced apoptosis or chromosomal aberrations, 
including translocations and deletions that can finally produce cancer34. The two main 
pathways involved in DSB repair are NHEJ and HR35. 
2.1.1. Non-homologous end joining 
Non-homologous end joining is an error prone mechanism that is preferentially used for the 
cell to repair DSBs (one thousand fold more frequent than HR36). This pathway is active during 
the different cell cycle phases but predominantly acts during G0 and G1 phases37. NHEJ implies 
the ligation of both DNA ends with minimal end processing38 and usually generates small 
insertions or deletions called INDELs. NHEJ pathway can be subdivided in DNA-PKcs 
dependent/canonical NHEJ (D-NHEJ) and alternative/backup NHEJ (B-NHEJ) (Figure 3). 
Canonical NHEJ (D-NHEJ) is produced when the heterodimer Ku70/Ku80 binds to DNA ends. 
This binding prevents nucleolitic processing of DNA ends which are required for initiation of 
other DSB repair pathways. The Ku heterodimer recruits DNA-PKc, which is the catalytic 
subunit of a DNA dependent kinase. The binding and dimerization of DNA-PKcs immobilizes 
the two DNA ends and thus facilitates the rejoining reaction39. Then, a limited end-processing 
by nucleolitic enzymes such as Artemis, PNKP, APLF, WRN, aprataxin or DNA polymerases µ 
and λ is required to generate ligatable ends40. Finally, the DNA ligase IV and XRCC4 ligate the 
two DNA ends to complete the repair of the damaged DNA41. 
Alternative NHEJ (B-NHEJ) is more prone to generate mutations than the canonical pathway, 
and thus frequently generates translocations and other genomic rearrangements. It is a 
backup pathway that is activated after failure of D-NHEJ42,43 and is much slower than D-NHEJ.  
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This pathway benefits from microhomology at the break sites, which is more probably found if 
the DNA ends become resected, although microhomology is not strictly required. The major 
protein implicated in B-NHEJ is PARP-1, which may effectively compete with Ku heterodimer 
for DNA end-binding44. MRN complex (formed by MRE11- NBS1-RAD50) and CtIP are proteins 
involved in the DNA end-resection during HR and also facilitates B-NHEJ45,46. It is hypothesized 
that PARP-1 recognizes the DNA ends, the MRN complex and CtIP proteins resect them and 
then ligase III is recruited to the DSB to restore DNA integrity47. Some other proteins such as 
WRN has been reported to form a complex with ligase III, which activates the ligation 
process48. 
Figure 3: Non-homologous end joining (NHEJ) pathway to repair double strand breaks (DSBs) through 
all cell cycle independently of the presence of homologous template. DSB could be repaired by D-NHEJ: 
DNA-PKcs dependent/canonical NHEJ in which the heterodimer Ku70/80 binds to DNA ends and recruits 
DNA-PKcs that immobilizes the two DNA ends. After a limited processing of these DNA ends, DNA ligase 
IV (LIG-IV) and XRCC4 ligate both DNA ends. DSB could be also repaired by B-NHEJ: alternative/backup 
NHEJ, in which PARP-1 recognizes the DNA ends. The MRN complex and CtIP resect them and finally 
ligase III together with WRN protein ligate the ends. Modified from Mladenov et al
49
. 
2.1.2. Homologous recombination 
This pathway is also involved in the repair of DSBs, but in this case using an error-free process. 
It uses the homologous DNA strand as a template to repair the DNA with high fidelity. Due to 
the necessity of homologous template, HR is only active during S and G2 phases of the cell 
cycle, when the sister chromatid is available, although it is theoretically possible that HR also 
takes place during the other phases of the cell cycle using the homologous chromosome as a 
template. Nevertheless, the recurrence of HR out of the S-G2 phases is considered a very rare 
phenomenon due to the compartmentalization of nuclear domains of homologous 
chromosomes50. Another impediment is that it is hypothesized that HR is actively suppressed 
in G1 cells, in an effort to prevent loss of heterozygosity51.  
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Homologous recombination requires three major steps: end resection; strand invasion and 
finally resolution (Figure 4). Firstly, the MRN complex binds to the DSB where it cooperates 
with CtIP to promote end-resection. Exonuclease Exo1, DNA2 and BLM helicase are also 
recruited to the DSB by BRCA1/FANCS where they help in the formation of 3’ single-stranded 
DNA (ssDNA) overhangs. These ssDNA ends are covered by RPA. Then, RPA is replaced by 
RAD51 in a process that requires multiple mediator proteins such as BRCA2/FANCD1, RAD51B, 
RAD51C/FANCO, RAD51D and PALB2/FANCN. Once the RAD51/FANCR nucleoprotein filament 
is formed, it invades the intact double-stranded DNA (dsDNA) from the sister chromatid to 
search for homology and form a transient structure known as D-loop. When homology is 
found, RAD51 is released from the 3’ overhang of the invading strand and this overhang is 
used as primer for elongation. Finally, the D-loop can be resolved in two different ways: the 
most frequent pathway is called synthesis-dependent strand annealing (SDSA) which is 
characterized by elongation of invading 3’-end throughout a limited distance, followed by 
displacement of the newly synthesized stretch and re-ligation with the original DNA end, 
resulting in the repair of the DSB. The other pathway, called double strand break repair (DSBR), 
is regulated by BLM and needs a second end-capture event, leading to the formation of a 
double Holliday junction. Depending on the resolution of this junction by BTR complex (formed 
by BLM, Topoisomerase IIIα, RMI1 and RMI2), it will result in either crossover or non-crossover 
outcomes49,52. 
Figure 4: Homologous recombination (HR) pathway is involved in the repair of double strand breaks 
when homologous template is available. When a DSB is produced in S-G2 phases of cell cycle the MRN 
complex binds to DNA ends and BRCA1 protein recruits CtIP which collaborates with MRN in the DNA 
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end-resection (BLM-EXO1 are also recruited by BRCA1 and help in the formation of 3’ ssDNA overhangs). 
ssDNA ends are covered by RPA, which is then replaced by RAD51 in a process that requires BCRA2 and 
PALB2 proteins. RAD51 nucleoprotein filament invades the intact dsDNA from the sister chromatid 
forming the D-loop when homology is found. D-loop can be resolved by SDSA: synthesis-dependent 
strand annealing or DSBR: double strand break repair. SDSA is characterized by elongation of invading 
3’-end followed by displacement of newly synthesized stretch and re-ligation with the original DNA. DSBR 
needs a second end-capture event forming a double Holliday junction, which is resolved by BTR complex 
leading to crossover or non-crossover outcomes. Modified from Mladenov et al
49
. 
This pathway is strictly regulated, in part by regulation of protein expression at different stages 
of the cell cycle. Thus RAD51/FANCR, BRCA1/FANCS, BRCA2/FANCD1, BLM and CtIP are 
present at low levels in G1 and completely absent in G0 cells. The expression of these proteins 
begins with the start of DNA replication and increases further with the progression of cells 
through S phase49. Another important regulation of HR is done by the phosphorylation of some 
regulatory proteins after DNA damage. For example CtIP is phosphorylated by ATM, which is a 
sensor of DNA damage that activates the DSB processing. Another protein that is 
phosphorylated is BRCA2/FANCD1, this phosphorylation regulates its association with 
RAD51/FANCR and NBS1, and consequently the DNA damage checkpoints. 
2.1.3. Interaction between homologous recombination and non-
homologous end joining 
The cross-talk between HR and NHEJ is very important, as both pathways repair the same kind 
of DNA lesion. One example is the regulation of end-resection by 53BP1 and BRCA1/FANCS. 
53BP1 inhibits the initiation of DNA end-resection and thus favors repair by NHEJ. On the other 
hand, BRCA1/FANCS promotes end resection favoring repair by HR. It has been proven that in 
BCRA1/FANCS deficient cells there is a persistent inhibition of end-resection, which can be 
abolished by removal of 53BP153. It has also been described a cell-cycle dependent inhibitory 
function of 53BP1 on BRCA1/FANCS accumulation at DSB in G1 which could also account for 
suppression of HR in this phase54. Finally, there is also a clear link between HR and B-NHEJ 
since: factors that are important for end resection such as CtIP and MRN complex, mediate HR 
and B-NHEJ55,56 and factors that inhibit end-resection such as 53BP1, suppress both 
pathways54,57. Finally, proteins implicated in extensive end-resection such as BLM and Exo1, 
favor HR over B-NHEJ55,57. 
2.2. Gene targeting mediated by homology-directed repair 
Gene targeting mediated by homology directed repair (HDR) needs the introduction of a donor 
that presents homology to a specific locus and carries the specific sequence to be inserted. The 
basic structure of this donor consists in two homology arms (HAs) complementary to the 
region to be integrated, which flank the cassette of interest to be integrated in the specific 
locus (Figure 5). Although this is the basic structure of a donor, it can also carry selectable 
markers or promoters depending on the gene targeting strategy. Gene targeting mediated by 
HDR therefore includes the generation of a DSB in a specific locus by nucleases, the 
recognition of the complementary regions of the donor and the specific locus, and finally the 
HDR which facilitates the integration of the transgene in the selected locus of the genome 
(Figure 5). 
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Figure 5: Schematic representation of the donor construct in directed GT before and after integration 
in a locus. An arbitrary sequence is represented. The targeted sequence in the genomic locus is cleavage 
by a nuclease. Since the donor which carries the transgene presents homology to the targeted region in 
the genome, the endogenous cells machinery of DSB DNA repair can incorporate the transgene in the 
targeted locus in a process called HDR. HA L: homology arm left. HA R: homology arm right. HDR: 
homology-directed repair. 
There are mainly three different gene targeting strategies that could be considered to correct 
a gene by HDR58 (Figure 6):  
a) Gene correction: With this kind of approach one or more bases from the mutated 
original strand are replaced by integration of the corrected ones. This strategy is the 
one to be chosen when the goal is to introduce or repair point or small mutations. If 
the mutations that cause the disease are not recurrent or are produced in different 
genes, as is the case of FA, this strategy will be restricted to a limited number of 
patients. 
b) Knock-in: A partial cDNA of the gene of interest is introduced in its endogenous locus. 
Commonly, a splicing acceptor is located before the cDNA to anchor the previous 
endogenous splicing donor. The endogenous elements of the locus will regulate the 
expression of the endogenous/exogenous resulting the chimeric cDNA/gene. It is used 
when it is necessary to maintain the endogenous regulation of transgene59. 
c) Safe harbor integration: Consists in the insertion of a whole expression cassette 
(promoter, transgene and regulatory signals) in a safe place of the genome. This 
approach could be used not only for repairing different kind of mutations produced in 
the same gene, but also for mutations produced in different genes, as it is the case in 
FA. 
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Figure 6: Different strategies for gene editing. a) Gene correction in which the mutated bases of a 
specific gene can be replaced. b) Knock-in in which a wild type (WT) part of the cDNA from a specific 
gene is integrated in a region previous to the mutation. c) Safe harbor in which the transgene with a 
promoter is inserted in a safe place in the genome. Modified from Garate et al
58
. 
2.2.1. Safe harbor loci in the genome 
One of the goals of gene targeting strategies is to prevent that the insertion of the transgene in 
the genome causes insertional oncogenesis or alter the expression of neighboring genes. It is 
easy to think that the best option should be to integrate the transgene in the locus of the 
mutated gene (knock-in strategy), as it conserves their endogenous regulation. However, the 
DSB generated by nucleases in this locus could be in part repaired by NHEJ instead of HDR, and 
deletions could take place leading to the alteration of the physiological regulation of the gene. 
Moreover, the insertion of the transgene could lead to alterations in the expression of the 
neighboring genes and it is not always possible to find specific sequences in the mutated gene 
for nucleases that cover all the mutations present in a specific disease. 
Taking into account all these aspects, an alternative is the insertion of the transgene in a safe 
harbor place in the genome. It has been demonstrated that the integration of a transgene in 
these regions do not cause any adverse effect60. The main characteristics of safe harbor places 
are: 
• The transgene integrated in this safe harbor can be expressed in all cell types of 
interest. 
• The insertion in this locus or the expression of the transgene should not cause any 
adverse effect. 
• The insertion should not disrupt codifying genes or highly conserved regions of the 
genome. 
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• The insertion should not change or alter the expression of the locus and the 
neighboring loci. Therefore, the interaction between enhancers and promoters in the 
transgene and the locus and neighboring areas should be as minimal as possible. 
Safe harbor sites could be allocated in genes or in genetic deserts. Both strategies present 
advantages and disadvantages. The main advantage of considering a locus as a safe harbor is 
that the chromatin conformation in this area is usually opened, allowing the expression of the 
integrated transgene. However, the transgene incorporation could trans-activate the 
endogenous genes or deregulate its expression due to the disruption of a regulator area in the 
intron in which they are usually incorporated.  Moreover, genes that could be used as safe 
harbor locus should be expressed widely all over cell types or at least in the cells of interest. 
On the other hand, genetic deserts do not present in principle, the problem of transactivation 
or deregulation of endogenous genes, although these areas could contain regulatory regions 
driving expression of very distal genes. The main limitation of these areas is that the chromatin 
is usually very compacted, making gene targeting more difficult and also reducing the 
expression of the integrated transgenes. Moreover, potential conformational changes 
produced in the chromatin in these areas after gene editing should be taken into account in 
terms of a possible deregulation of the cell status. 
Safe harbor sites should be functionally validated, enhancing the effect of the insertion in 
neighboring genes in vitro, and determining possible changes in the epigenetic marks in the 
locus after the introduction of the transgene. Finally, these in vitro studies should be 
confirmed in vivo to conclude that the targeting in this locus does not produce any alteration 
in the tissue and in the organism, including risks of malignant transformation.  
The two safe harbor most frequently used are the chemokine (C-C motif) receptor 5 (CCR5) 
and the adeno-associated virus site 1 (AAVS1): 
a) CCR5: is located in chromosome 3 (3p21.31) and codifies the principal co-receptor of 
the HIV-1. The first evidence that pointed out that this locus could act as a safe harbor 
came from the resistance of individuals to HIV-1 infection, due to a null mutation in 
this gene (CCR5Δ32)61. The mutation of this gene did not induce any pathology and has 
been already used in the first clinical trial using nucleases to treat HIV-1 patients; in 
which no side effects have been observed so far62. The endogenous expression of this 
gene is variable along cell types: high in T lymphocytes, monocytes and macrophages, 
but it is not expressed in B lymphocytes or dendritic cells63. Moreover, the knockout 
mice for Ccr5 presents impaired leukocyte migration and increased susceptibility to 
some infections64.  Another disadvantage of this locus is that the expression of a 
reporter gene, GFP, in T cells is lower in this site as compared with the expression of 
the same reporter gene in another safe harbor locus: the AAVS165. Furthermore, the 
high homology of this locus with the CCR2 gene make the design of nucleases more 
complicated increasing the off-target events66.  
b) AAVS1: is located in chromosome 19 (19q13.42). It was described as the common 
integration site of the adeno-associated human virus67, which disrupts the protein 
phosphatase I regulatory inhibitor subunit 12C (PPP1R12C). This gene codifies a 
protein whose function is not well understood, and no side effects have been 
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described derived from its interruption. Moreover, it has been described that 
approximately 80% of the population presents detectable levels of antibodies against 
some AAV serotypes, which means that they probably harbor integrations of this virus 
in the AAVS1 locus without any pathogenic or side effect68. This region has been used 
in gene targeting experiments in T-cells, neural stem cells, embryonic stem cells, 
fibroblasts and iPSC69-75. These studies support a stable and robust expression of the 
different transgenes integrated in the AAVS1 locus all over the different cell types. 
Moreover, it has been demonstrated that the integration of a transgene in this locus 
does not induce any adverse effect65. The chromatin of this locus has an open and 
active conformation, and the insertion in the AAVS1 locus does not alter the 
expression of surrounding genes, probably due to the presence of an insulator, which 
prevents the transactivated expression of surrounding genes76. All these characteristics 
make the AAVS1 locus as the best safe harbor locus for gene targeting approaches 
described up to now. 
2.3. Designed nucleases 
Nucleases are the tools that generate the DSBs in a specific locus in the genome for gene 
targeting. There are four different types of nucleases that have been widely used in gene 
targeting: meganucleases (MGNs), zinc-finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs) and clustered, regularly interspaced, short palindromic repeat 
associated to Cas9 nuclease (CRISPR/Cas9) system (Figure 7). All of them possess a DNA 
recognition region and a catalytic domain which generates the DSB in a specific locus. 
Figure 7: Different types of nucleases. MGN: meganuclease. They recognize long sequences of DNA 
cutting by homology. ZFN: zinc-finger nuclease. They are formed by two subunits: homology domain 
composed by groups of three ZF domains which recognize a specific nucleotide and the catalytic domain 
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formed by FokI endonuclease which needs to dimerize in order to cut. TALEN: transcription activator-like 
effector nuclease. They are also formed by a catalytic domain composed by the FokI endonuclease and a 
DNA binding domain formed by a tandem of highly repeated sequences which recognizes each 
nucleotide. CRISPR/Cas9 systems are formed by Cas9 protein which presents the cleavage activity and a 
gRNA which recognizes a specific region in the genome and directs the cut of the Cas9. 
Although they are designed to recognize a specific sequence in the genome, they could also 
produce DSBs in other parts different from their target sites that have been called off-targets. 
Although this phenomenon is rare, it could decrease the cutting efficiency of the nucleases in 
the on-target sites and increase the genomic instability of the cells77. This off-target activity of 
the nucleases is linked to regions in the genome that share a high homology to the target sites. 
This issue needs to be studied deeply when a new nuclease is designed. Due to the deep 
characterization65 and the previous experience that our laboratory had with ZFNs designed by 
Sangamo Biosciences (Richmond, California, USA) to target the AAVS1 locus75, our current 
studies were performed with this nuclease. 
2.3.1. Meganucleases 
MGNs belong to a family of natural endonucleases that are present in all organisms. They 
recognize long sequences of DNA (between 12-45 bp)78,79 cutting the homology arm that do 
not contain the recognized sequence80. The main limitation of these enzymes is that they can 
only be designed to cut regions in which the restriction site of the enzyme is present. Despite 
the identification of hundreds of different wild type (WT) MGNs, their target sites do not cover 
the entire human genome. To overcome this problem engineered MGNs are produced by 
modifications of the WT ones, fusing different domains to generate chimeric proteins81. 
However, and despite the description of some artificial MGNs, their design is very complicated 
and their use is restricted. There is only one paper in which these enzymes are used to target 
murine HSCs82. 
2.3.2. Transcription activator-like effector nucleases 
TALENs were firstly described in a Xhantomonas pathogen83. They are formed by a catalytic 
domain composed by non-specific DNA cleavage domain of the FokI restriction enzyme joined 
to a specific DNA binding domain84. The DNA binding domain of these proteins is formed by a 
tandem of 10-30 highly repeated sequences. The specificity of each repeat unit is driven by 
polymorphisms at positions 12 and 13 called repeat-variable di-residues (RVDs) which confers 
specificity of each repetition to a single nucleotide on the target sequence85. The recognition of 
the target sequence is therefore based on the affinity of the amino acids (aas) sequence and 
the DNA sequence. A lot of different TALENs have been generated since the code of TALE-to-
DNA interactions was discovered in 200986 due to their relatively easy design84. However, the 
highly repeated nature of these enzymes hampers their packaging into viral vectors for 
delivery and their size (more than 3 kb) complicates their delivery into cells. 
The catalytic part of the enzyme is given by the FokI enzyme. Since this restriction enzyme is 
only active as a dimer87, these artificial nucleases are composed of active pairs in which the 
two monomers bind adjacent target subsites separated by a DNA spacer that allows for the 
formation of an active dimer to cleave the target locus88. 
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Although not many studies have compared TALENs and ZFNs directly, two studies suggested 
that TALENs and ZFNs present similar gene targeting efficiencies but TALENs produce less off-
target mutagenesis than ZFNs66,89.  
2.3.3. CRISPR/Cas9 system 
The CRISPR/Cas9 system is part of the adaptive immune system in prokaryotes to protect 
these cells against viral infections or plasmids90,91. This system incorporates sequences from 
invading DNA between CRISPR repeat sequences encoded as arrays within the bacterial host 
genome. Transcripts from the CRISPR repeat arrays are processed into CRISPR RNAs (crRNAs), 
each harboring a variable sequence transcribed from the invading DNA, known as the 
“protospacer” sequence, and part of the CRISPR repeat. crRNAs are then used to target and 
destroy any foreign DNA sequences that enter the cells. The bacterial Cas9 nuclease and a 
crRNA form a ternary complex with a second RNA component, the trans-activating crRNA 
(tracrRNA), which has a fixed sequence. The protospacer-encoded portion of the crRNA directs 
Cas9 to cleave complementary target sequences. If they are adjacent to short sequences 
known as protospacer adjacent motifs (PAMs), Cas9 introduces a DSB 3 bp upstream of the 
PAM92. The RNA components of the CRISPR/Cas9 system can be combined into a single guide 
RNA (gRNA)93 that is delivered in a simple two-component system with the Cas9 in cells to 
conduct gene targeting approaches. The advantages of the CRISPR/Cas9 system are the high 
efficiency to generate DSBs into the genome of mammalian cells and the simplicity of its 
engineering. The Cas9 nuclease is used to target different regions of the genome and only the 
protospacer region (20 nucleotides) of the gRNA needs to be modified. The off-target activity 
of CRISPR/Cas9 system seems to be higher than the other nucleases94, and a lot of efforts are 
nowadays being done to unravel this problem. One example is the reduction of gRNA 
protospacer length up to three nucleotides, which appears to make the gRNA less tolerant to 
mismatches and less likely to bind to the off-target sites95. 
2.3.4. Zinc-finger nucleases 
Zinc-finger nucleases are artificial enzymes that were formed by engineered Cys2-Hys2 zinc 
finger (ZF) domain fused to the nuclease domain of the restriction enzyme FokI. In this 
configuration, the DNA-binding ZF domain directs the nonspecific FokI cleavage domain to a 
specific DNA target site. Even though academic consortia have developed open-source libraries 
for ZFN design96,97, engineering of site-specific ZFNs remains difficult for non-specialists. 
The ZF domain is the most common DNA binding motif in eukaryotes. It consists in 30 residues 
that fold into a ββα-structure coordinated by a zinc ion98. Each ZFN is composed by 3-4 ZF 
domains organized in tandem arrays which recognize a target DNA sequence from 9 to 12 bp; 
and at the same time each ZF domain presents an α-helix which recognizes a specific DNA 
triplet. As the cleavage activity of FokI requires dimerization and it has been demonstrated 
that this dimer cut more efficiently when enzymes are in inverted orientation88, ZFNs are 
designed to work as pairs of two monomers in reverse orientation. Each monomer binds to 
half-sites that are separated by a spacer sequence. Due to the off-target activity observed in 
some studies using ZFNs99,100, variants of the endonucleases have been developed to overcome 
this problem. These consist of a mix of two distinct ZFNs with different FokI domains that are 
obligated heterodimers, so each ZFN pair introduces a DSB only when the two distinct ZFNs are 
able to bind adjacent DNA regions101,102. 
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The origin of these nucleases was in 1996103. From the very beginning ZFNs have been used in 
a high variety of species for different applications: 
a) Genetic inactivation or interruption: this process occurs when the repair of the DSB 
generated by ZFNs is mediated by NHEJ. It has been used to silence a target gene. This 
tool has been extensively used to generate knockout models in different species: 
zebrafish104, mice105, rats106,107, rabbits108 or pigs109. However, the most important work 
in this direction is related to the treatment of the human immunodeficient virus type 1 
(HIV-1) infection. These studies are based on the disruption of CCR5, one of the co-
receptors used by the HIV to enter into the cells. Preclinical studies have been 
conducted in CD4+ T lymphocytes, which are the main target cells for the virus110 or in 
HSPCs111. Based on the good results obtained in these preclinical studies, seven 
different clinical trials have been or are been performed based on this strategy. One of 
them, a phase I clinical trial (NCT00842634) has been already performed using 
autologous genetically modified CD4+ T-cells that were injected in HIV-1 infected 
patients. This phase I clinical trial has shown the safety of this approach in patients62. 
b) Safe harbor: ZFNs have been also used to insert a gene in a specific site of the genome, 
with the aim of evaluating the safety of the insertion and correcting in vitro the 
phenotype of specific diseases. For example the GFP reporter gene has been inserted 
in the CCR5112 and the AAVS165,113 in cell lines65,112 and primary cells113. As it has been 
mentioned, the insertion of therapeutic genes in safe harbor loci has also been 
conducted in different cell types such as primary fibroblasts75, induced pluripotent 
stem cells (iPSC)114 or CD34+113 (antigen that identifies hematopoietic stem and 
progenitor cells (HSPCs), which marks a heterogeneous cell population with both 
short- and long-term repopulating cells). ZFNs designed for the AAVS1 locus are our 
selected tools to conduct our gene targeting experiments as they have been deeply 
characterized and are very specific69,99. However, although in previous reports no off-
targets using this ZFNs have been reported, one study in which the ZFNs designed by 
Sangamo Biosciences were compared with TALENs targeting the same region, the 
authors claim that AAVS1 ZFNs are less specific than TALENs66. 
c) Gene correction: in this case the correction takes place in the mutated locus producing 
the substitution of the particular mutation, for this reason it requires the design of 
specific ZFNs that needs a deep study of their efficiency and specificity. This approach 
has been used in HSPCs from patients with in sickle cell disease, to correct a single 
point mutation in β-globin gene115. 
d) Knock-in: the correction, as in the case of the previous strategy, takes place in the 
mutated locus, but this time introducing a partial cDNA of the mutated gene instead 
the correction of a specific mutation. This was the strategy selected to correct HSPCs 
from X-SCID patients in order to correct mutations in the interleukin 2 receptor 
gamma (IL2RG) gene113. 
2.4. Nuclease and donor delivery methods 
The delivery of nucleases and donors is nowadays one of the key challenges in gene 
targeting116. The main objective of delivering the nucleases effectively in the cells is to promote 
the activity of the enzyme to allow the generation of DSBs efficiently in a very short period of 
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time to avoid toxicity and off target activity due to the long term expression of the nuclease. 
Nowadays, the preferred approach is based on the delivery of donor as plasmid DNA, and the 
nuclease as plasmid DNA or in vitro-transcribed mRNA. Integrase-defective viral vectors also 
serve as a robust source to facilitates the delivery of either the nuclease or the donor construct 
in cell types that are very sensitive to transfection such as HSPCs117. 
The delivery of plasmid DNA is widely used118,119, as this molecule is easily engineered and its 
transfection in cultured cells is a standard technique carried out in laboratories all over the 
world. Linear donor sequences with less than 50 bp of homology120, as well as single stranded 
DNA oligonucleotides121 can also be used to induce mutations or correction at the target site. 
However the use of this kind of DNA structures limits the transgene size. Due to the negative 
charge of both plasmid DNA and the cell surface, the uptake of DNA into the cells is restricted, 
and the delivery needs to be supported by complexing DNA with chemicals such as calcium 
phosphate, coat lipids or cationic polymers118, or by subjecting the cells to an electric field 
which open pores in the nuclear and/or plasmatic membrane of the cells (electroporation). 
Nucleofection - a kind of electroporation - is a standard method for transferring DNA to hard-
to-transfect cell types such as HSPCs. However, this process could produce high cellular toxicity 
and even cell death. Moreover, the delivery of plasmid DNA has a risk of mediating random 
insertion into the genome of treated cells122. The risk of random plasmid integration depends 
on the plasmid quality, but it is also influenced by properties of the targeted cells, including 
the prevalence of DSBs and the status of their DNA repair pathways. Plasmid integration, 
although is a non-usual event, represents an obstacle for gene targeting approaches.  
Considering the risk of inserting plasmid DNA into the genome of treated cells, the transfection 
of in vitro-transcribed mRNA has been used as an alternative delivery of nucleases123,124. The 
main advantage of this kind of delivery is that mRNA establishes a short-term boost of enzyme 
activity with no risk of integration. Moreover, transfection of mRNA in cells is a less toxic 
process than DNA, as foreign DNAs generate more acute cellular responses than foreign 
mRNAs probably due to their higher stability in the cell. However, mRNA, as happens with 
DNA, is a biomolecule negatively charged and has the same requirements to enter in a cell as 
DNA. Another possibility is the delivery of nucleases as proteins; this approach presents the 
same advantages as mRNA delivery, since they also act in a hit-and-run fashion. Genetic fusion 
of recombinant proteins to a positively supercharged moieties called protein transduction 
domains (PTDs), favors their uptake by cellular internalization mechanisms125,126. However, the 
generation of high yields of soluble and active PTD-containing nucleases is difficult127. An 
alternative approach consists in the chemical conjugation of nucleases to PTDs for receptor-
mediated endocytosis128. Interestingly, owing to the net positive charge of their Cys2-His2 zinc-
finger motifs, ZFNs display an intrinsic cell penetrating capacity, which can lead to targeted 
mutagenesis in a variety of cell types127. Other delivery options under investigation include 
protein transfection procedures such as electroporation129. Chemical transfection agents are 
also being investigated for nuclease as protein direct transfer130. 
Viral delivery has been used as a key instrument in conventional genetic therapies4 and hold a 
great potential also for delivery of genome-modifying tools. Viral vectors not only constitute 
efficient gene transfer tools, but can also be used as protein and mRNA transfer tools131,132. 
Four different types of viral vectors have been used to deliver both nucleases and donors in 
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gene targeting experiments: baculoviral vectors (BVs), adeno-associated vectors (AAVs), 
adenoviral vectors (AdVs) and integrase-defective lentiviral vectors (IDLVs). BVs are known to 
infect invertebrates, but have been also tested in gene editing experiments involving the 
delivery of donor DNA and ZFNs in embryonic stem cells133. AAVs naturally persist in human 
cells and presents nonpathogenic character. The major problem of AAVs is the restriction in 
their packaging capacity that is incompatible with some therapeutic gene sizes. However some 
AAVs have been adapted, avoiding its integrative nature, for nuclease and donor delivery in 
human cell lines, embryonic stem cells and hemophilia B in vivo murine models134-137.  AdVs 
and IDLVs do not integrate in the genome of the targeted cell. AdVs are capable of packaging 
up to 37 kilobases (kbs) of DNA, however the transduction capacity of these vectors is highly 
dependent on the cellular type. They have been used in some gene targeting approaches to 
deliver the nuclease both in fibroblasts and CD4+ T cells75,110. Finally, IDLVs allow the expression 
of the donor in the cells due to the DNA intermediates that are generated after transduction 
both in cell lines and primary cells65,75,112,113.  
2.5. Gene targeting improvement 
Although with the emergence of nucleases the efficacy of gene targeting has improved, a big 
effort is needed in order to make this kind of approach more efficient for its use in the clinic. 
As we have previously mentioned, the delivery of the nucleases and the donor is a bottle neck 
for gene editing of hematopoietic stem cells, because these cells are hard to transfect and the 
only methods available so far to deliver nucleases and donor constructs are nucleofection, 
which is very toxic; and transduction with viral vectors. Other point that should be considered 
is that although the generation of a DSB in the genome with nucleases and the introduction of 
a donor favor the repair of the DSBs by HDR, this DNA repair pathway is still less frequent than 
NHEJ. Different studies have been developed in order to overcome these problems and to 
increase the efficiency of gene targeting, some of which have been studied during this thesis. 
2.5.1. Improvement of the transduction efficacy: nanoparticles 
One of the keys for the successful HSC GT is the development of methods that allow a highly 
efficient gene delivery under ex vivo conditions that do not significantly alter the biological 
properties of the HSCs. It is known that the short-term culture of CD34+ cells with the 
appropriate cytokines approximately doubles the transduction efficiency as compared to 
efficacies achieved under non-stimulating conditions138. However, the prolonged culture with 
cytokines results in a loss of human cell engraftment in immunodeficient mice, suggesting the 
necessity of achieving a compromise between the transduction efficiency and the engraftment 
potential during ex vivo culture. Some methods that have been widely used to enhance the LV 
transduction in HSCs are based on the increase of the multiplicity of infection (MOI) or the use 
of sequential transductions, but this cannot always be accomplished, mainly due to the limited 
quantity of LVs. One mechanism that has been recently shown to increase the transduction 
efficiency of lentiviral vectors is the brief ex vivo treatment of transduced cells with rapamycin; 
an inhibitor of mTOR complex139,140. It has been proven that this compound increases the LV 
entry, leading to increase levels of reverse-transcription and genomic integration. This increase 
in transduction also correlates with an increment in the transduction efficiency of the most 
primitive compartment of HSCs, preserving the long-term engraftment of these cells. This 
increment in transduction also been observed when IDLVs are used140. These studies pointed 
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out that the cytoplasmic entry of the LV could be the biggest restriction for the transduction of 
HSCs with LVs and rapamycin can solve the problem. 
Another possibility could be focus in the use of nanoparticles (NPs). They are small particles 
(between 1 and 100 nm in size) that could be formed by different inorganic materials. For 
biological applications of NPs, it is necessary their functionalization with one or several 
biomolecules, such as DNA/RNA, oligonucleotides, peptides and antibodies, fluorescent dyes, 
polymers, drugs, tumor markers, enzymes and other proteins that will introduce the required 
bio-functionalities141. All NPs are normally functionalized at least with polyethylene glycol 
(PEG) as this molecule stabilizes the NP and prolongs their half-life (Figure 8). NPs act as 
multifunctional devices capable of bypassing biological barriers for specific delivery of 
therapeutic agents. Among the numerous inorganic nanoparticles that are available nowadays, 
gold nanoparticles (AuNPs) are optimal non-toxic carriers for gene therapy due to their 
chemical properties and ease of surface modification with a variety of ligands142. Different 
studies using engineered AuNPs modified with small interfering RNA (siRNA) have 
demonstrated in vitro and in vivo cytoplasmic delivery of siRNA and efficient gene 
silencing143,144.  Conde and co-workers145 reported functionalization of siRNA by ionic coupling 
to a positively charged layer formed by quaternary ammonium groups (R4N
+). Ionic 
interactions between the negatively charged siRNA backbone (via phosphate groups) and 
quaternary ammonium positively charged groups ensured binding of siRNA onto the AuNP’s 
surface. This approach could be used to deliver any molecule that is negatively charged, as the 
viral particles. The ionic binding rate mainly depends on the amount of charges present on the 
NPs and the biomolecules. Moreover, there are some studies in which the combination of AdV 
with gold/iron-oxide magnetic nanoparticles increase the transduction efficiency of the viral 
vectors and allow gene transfer to adeno-resistant cells by using a magnetic field146. 
Figure 8: Schematic representation of gold nanoparticles (AuNP). a) Multifunctional AuNP which is 
functionalized with polyethylene glycol (PEG), peptides, antibodies, carbohydrates, siRNAs, fluorescence 
dyes or dsDNA. Modified from Conde et al
141
. 
In the present thesis we have proposed to study the possible application of these AuNPs to 
enhance the transduction efficiency of IDLVs and therefore the gene targeting in general. 
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2.5.2. Improvement in homology-directed repair frequency: PARI 
inhibition 
As previously mentioned, when a DSB is produced by natural or artificial nucleases, NHEJ is the 
preferential via to repair this DNA damage. Therefore, improving the efficiency of precise gene 
targeting remains a major challenge. A recent study reported the function of small molecules 
for enhancing the efficacy of gene targeting147. These compounds inhibit NHEJ or potentiate 
HDR when added to the medium after transduction with both CRISPR/Cas9 and a reporter 
donor in different cell types. Moreover other groups has inhibited key components of NHEJ 
such as DNA ligase IV, during their gene targeting experiments in order to increase the 
efficiency of HDR148,149 
Consistent with this idea, there is a previous study in which the transient downregulation of a 
PCNA-interacting factor, called PCNA-associated recombination inhibitor (PARI) improves 
homologous recombination and genomic stability in BRCA2/FANCD1 deficient cells, where HR 
is impaired150. PARI is an anti-recombinase which suppresses inappropriate HR. This protein is 
recruited in S phase of the cell cycle in a PCNA-dependent manner to inhibit recombination 
events at replication forks. In healthy donor (HD) cells PARI removes RAD51 from DNA when is 
recruited preventing hyper-recombination events that leads to genomic instability (Figure 9). 
However, in cells with mutations in some HR critical factors such as BRCA2/FANCD1 deficient 
cells, in which the frequency of HR events is very low, the inhibition of this anti-recombinant 
factor increases HR to normal levels and results in protective effects, suppressing genomic 
instability. 
Figure 9: PARI model in cells from healthy donors. In S phase of the cell cycle RAD51 is recruited to the 
sites in which the DNA is been replicating. If PARI protein is present (left), it binds to PCNA and mediates 
the release of RAD51 from the replicating DNA controlling the level of HR. However, if PARI protein is not 
present (right), RAD51 is still bound to the DNA ends of replicating strands and the frequency of HR is 
increased. 
PCNA
BRCA2
RAD51
+ PARI - PARI
HR
HR
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Since the inhibition of PARI in BRCA2 deficient cells increases the efficiency of HR, one of the 
objectives of this thesis will be to study the role of PARI inhibition in gene targeting efficiency 
in cells from FA-A patients where HR is mildly affected in comparison with BRCA2 deficient 
cells151. 
3. Fanconi Anemia 
3.1. General characteristics of the disease 
Fanconi anemia (FA) is a genetic inherited disorder that was first described in 1927 by the 
Swiss pediatrician Guido Fanconi in a family with five children, three of them presenting 
physical abnormalities and hematological defects152. Posterior studies performed in the 
peripheral blood (PB) of these and other patients with similar characteristics allowed him to 
appreciate that the disorder affects all the hematopoietic lineages, being these alterations the 
main cause of death153. 
Fanconi anemia is a highly heterogeneous syndrome mainly characterized by congenital 
abnormalities, hematological defects and increased cancer predisposition. Among these 
symptoms, bone marrow failure (BMF) is the most frequent cause of death in FA pediatric 
patients (50% of the patients develop BMF during the first decade of their lives)154,155.  
The disease is caused by mutations in any of the 19 genes described so far (Table 2). 
Depending on the mutated gene, patients are assigned to different complementation groups 
(FA-A to FA-T). Fanconi anemia is an autosomal-recessive disorder with the exception of 
patients with mutations in FANCB which is X-linked. All these genes are members of a DNA 
repair pathway known as the FA/BRCA pathway, involved in the resolution of DNA interstrand-
crosslinks (ICLs)156-158. Mutations in any of these genes increase the genetic instability of cells 
and compromise their survival upon exposure to ICL agents. These compounds include 
metabolic products such as aldehydes, which come from alcohol detoxification or lipid 
peroxidation; or exogenous agents such as cysplatin, mitomycin C (MMC) or diepoxybutane 
(DEB)159,160. The hypersensitivity of FA cells to ICL agents has been used as a diagnostic marker 
for the disease161.  
Although mutatins in 19 genes have been described to cause the disease, only 15 of them 
(FANCA, B, C, D1, D2, E, F, G, I, J, L, N, P, Q and T) fit all the criteria to be considered bona fide 
FA genes: mutations in these genes have been found in at least two patients who present BMF, 
and their cells are characterized by chromosomal instability measured by a positive 
chromosome fragility test. Mutations in FANCO, FANCR and FANCS genes results in a 
chromosome fragility syndrome without BMF, and are considered FA-like genes. Moreover, 
some recent publications claim that FANCM should not be considered a FA gene154 since there 
is only one patient reported with mutations in this gene that interestingly also harbored 
biallelic mutations in FANCA162. Additionally, the ectopic expression of FANCM in this patient 
did not rescue the FA phenotype. Finally, it has been described that two individuals with loss of 
function of FANCM are healthy and exhibit normal hematology162,163.  The FA/BRCA pathway 
also involves other associated proteins: FAAP10, FAAP16, FAAP20, FAAP24, FAAP100 and 
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FAN1; that although cooperate in the FA pathway, their mutations have not been found in any 
FA patients and therefore are not considered FA proteins157.  
FA gene Prevalence Chromosomal 
location 
Protein 
size 
(kDa) 
Protein characteristics 
FANCA
164,165
 60-70% 16q24.3 163 Member of the core complex  
FANCB
166
 2% Xp22.2 95 Member of the core complex 
FANCC
167
 14% 9q22.3 63 Member of the core complex 
FANCD1/BRCA2
168,169
 3% 13q12-13 380 Involved in HR. Cancer 
susceptibility gene 
FANCD2
170
 3% 3p25.3 155 Member of the FA ID2 complex. 
Monoubiquitinated by FANCL 
(core complex). Directs 
downstream events 
FANCE
171
 3% 6p21.3 60 Member of the core complex 
FANCF
172
 2% 11p15 42 Member of the core complex 
FANCG/XRCC9
173,174
 10% 9p13 68 Member of the core complex 
FANCI
175-179
 1% 15q26.1 149 Member of the FA ID2 complex. 
Monoubiquitinated by FANCL 
(core complex) in a FANCD2 
dependent manner. Directs 
downstream events 
FANCJ/ BRIP1/ 
BACH1
24,29-31
 
2% 17q23.1 140 Involved in HR: 5’-3’ DNA 
helicase. Cancer susceptibility 
gene 
FANCL
180
 0.2% 2p16.1 43 FA core complex. E3 ubiquitin 
ligase 
FANCM
181
 0.2% 14q21.3 250 Member of the core complex. 
DNA translocase. Important for 
ATR activation during ICL repair. 
Cancer susceptibility gene 
FANCN/PALB2
182-185
 0.7% 16p12.1 140 Involved in HR. Cancer 
susceptibility gene 
FANCO/RAD51C
186
 0.2% 17q22 43 Involved in HR. Cancer 
susceptibility gene 
FANCP/ SLX4/ 
BTBD12
187,188
 
0.2% 16p13.3 200 Scaffold/regulator of XPF-ERCC1, 
MUS81-EME1 and SLX1 nucleases 
FANCQ/ERCC4/ XPF
189
 NR 16p13.12 104 Associates with ERCC1 to form a 
FANCP-dependent ICL unhooking 
nuclease. Participates in NER 
independently of FANCP 
FANCR/RAD51
190
 NR 15q15.1 37 Involved in HR. Interacts with 
FANCS and FANCD1 
FANCS/ 
BRCA1
191
 
NR 17q21 208 Involved in HR. Inhibition of 
NHEJ. Removal of CMG (CDC45-
MCM-GINS) complex during ICL 
repair. Cancer susceptibility gene 
FANCT/UBE2T
192,193
  NR 1q32.1 22.5 FA core complex. E2 ubiquitin 
conjugating enzyme 
Table 2: FA genes described up to now. The table shows the prevalence in USA (NIH database)
194
 of the 
mutated genes (last review in 2013), chromosomal location, protein size and the main characteristics of 
each protein. NER: nucleotide excision repair. HR: homologous recombination. NHEJ: non-homologous 
end-joining. ICL: interstrand-cross link. NR: not reported. 
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3.2. Fanconi Anemia/BRCA pathway and the repair of 
interstrand-crosslink lesions 
Interstrand-crosslink lesions impede the normal progression of DNA replication or 
transcription because the DNA strands cannot be separated owing to the covalent linkage 
between the two strands. These processes are essential for correct cell function, so ICLs should 
be repaired during all phases of cell cycle. The FA/BRCA pathway is reported to be active 
following the stalled replication fork generated by an ICL or during S phase entry195. In the 
absence of active replication forks and a homologous template, ICL repair depends on 
nucleotide excision repair (NER), especially transcription-coupled NER (TC-NER) and 
translesion-synthesis (TLS) proteins196,197. Other DNA repair factors are also activated in 
response to this type of DNA damage, such as ATR, ATM or the effector kinase CHEK1. These 
proteins arrest the cell cycle198 in order to repair the DNA damage. 
The first protein that initiates the DNA repair process is FANCM. This protein presents 
translocase activity181 and, together with FAAP24 and MHF1/2199, moves across the DNA to 
detect stalled replication forks200, facilitating the translocation and anchoring of the rest of the 
FA core complex proteins (FANCA, B, C, E, F, G, L and T) to the damaged DNA. Moreover, 
FANCM also activates ATR, which phosphorylates some members of the core complex like 
FANCE and FANCG leading to the activation of FA/BCRA pathway201. 
Once the core complex is recruited to the ICL-induced stalled replication fork, FANCL, the 
catalytic E3 ligase subunit of the core complex, in concert with FANCT/UBE2T192, ubiquitinates 
the FANCD2-FANCI (ID2) complex. The mono-ubiquitination takes place on lysine 561 of the 
FANCD2 protein and on lysine 523 of the FANCI protein177,202. This process produces the 
heterodimerization of these two proteins. Mutations in any of the core proteins of the 
pathway - with the exception of FANCM, which present a redundant activity in other proteins 
such as the mismatch repair complex MutS203 - lead to a deficient mono-ubiquitination of 
FANCD2 and FANCI.  
The ubiquitinated ID2 complex is translocated to the DNA repair sites, forming nuclear repair 
foci with other downstream proteins. Once in the DNA repair foci it recruits FANCQ-ERCC1-
FANCP-SLX1 - where FANCP serves as a master scaffold - and 5’ and 3’ incisions on one 
parental strand are generated, allowing unhooking of DNA where the  ICL has occurred. Other 
nucleases, including the FAN1 and SNM1 family nucleases might act redundantly to make 
incisions at the ICL204. Unhooking converts the stalled replication fork in a double strand break 
(DSB) and allows translesion polymerases to repair one strand. Polymerase ζ and Rev1 are the 
key proteins in this step of ICL repair205,206. Rev1 acts as a scaffold, facilitates polymerase 
exchange207 and inserts a dCMP residue opposite to the ICL208; Pol ζ extends the DNA from the 
distorted primer-template termini (those formed by an insertion of a nucleotide at a lesion by 
another TLS polymerase). TLS polymerases need the monoubiquitination of PCNA - a 
polymerase processivity factor that encircles DNA and functions as a moving platform for DNA 
synthesis209 - to be recruited to the lesion210. 
The repaired strand can then be used for repairing the other strand using homologous 
recombination (HR). The activation of the ID2 complex also moves FANCD1 to chromatin, 
interacting with FANCJ, FANCN and FANCS, and thus facilitating the assembly of DNA damage-
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inducible FANCR nuclear foci. All these remaining FA proteins: FANCD1, J, N, O and S together 
with FANCR, are implicated in the resolution of DSBs by HR (see section 2.1.2. of the 
introduction). 
Finally the unhooked ICL, which no longer represents an obstacle for the completion of S-
phase, is removed by NER159 and the deubiquitinating enzyme, USP1 deubiquitinates the ID2 
complex to finish the process. Defects in this event have also been associated with ICL 
sensitivity211.  
Figure 10: FA/BRCA pathway. Proteins involved in the different steps of ICL repair are shown. In grey FA 
associated proteins are represented, and in different colors the FA proteins. During S-phase of cell cycle, 
if an ICL is found, the replication fork is stalled. FANCM, together with other FA associated proteins, 
detects the ICL, activates the DNA damage response mediated by ATR and facilitates the recruitment of 
the rest of FA core components to the lesion. Two of them, FANCL and FANCT monoubiquitinates the 
FANCD2-FANCI complex and is recruited to the lesion where recruits FANCQ, FANCP and other proteins to 
unhook the ICL. Then TLS polymerases repair one of the strands, which serves as DNA template to repair 
the other strand by HR. Finally when the DNA is repaired USP1 protein deubiquitinates the ID2 complex 
to finish the process. Modified from Wang and Smogorzewska
212
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3.2.1. Other important endogenous DNA repair pathways involved in 
the repair of interstrand-crosslinks 
Although FA/BRCA pathway mainly regulates the repair of an ICL in the DNA, other repair 
pathways are also activated during the ICL repair: nucleotide excision repair (NER) and 
translesion synthesis (TLS). The activation of these pathways generates a DSB in the DNA that 
can be finally repaired through HR. 
The interaction between the different pathways is highly regulated and is important to 
maintain the correct homeostasis of the cell. 
3.2.1.1. Nucleotide excision repair 
Nucleotide excision repair is the preferential via to solve lesions caused by ultraviolet 
radiation. The common denominator in NER repair is a significant distortion of DNA helix.  
The lesion is recognized by the heterodimer formed by XPC and RAD23B; which also acts as a 
repair-recruitment factor. Then, the transcription factor TFIIH, formed by XPB and XPD, is 
recruited. These proteins present helicase activity, and therefore mediate strand separation at 
the side of the lesion. After damage detection, XPA verifies the lesion in an open DNA 
conformation and RPA protein stabilizes the opened DNA and facilitates the location of the 
endonucleases XPG and ERCC1-XPF. These endonucleases remove a 27 to 29 base pairs (bp) 
oligonucleotide containing the lesion and finally the gap is filled by PCNA, δ polymerase and 
ligases using the complementary strand as a template. These repair is called global genome 
NER (GG-NER), which is the pathway in charge of repairing the lesion across the entire 
genome. However, there is another kind of NER repair, called transcription-coupled NER (TC-
NER) which repairs transcription-blocking lesions present in transcribed DNA strands and is 
involved in replication and recombination-independent ICL repair during G0/G1 phases of the 
cell cycle196,197. In TC-NER, DNA damage is detected by elongating RNA polymerase II complex, 
and the damage is much faster eliminated. CSA and CSB proteins are in this case needed for 
faster and more efficient repair of transcribed strands213,214 (Figure 11). 
Figure 11: Nucleotide excision repair (NER) pathway is involved in the removal of damaged bases in the 
genome. Red triangle represents the distorting base. In GG-NER: global genome NER, damage is 
GG-NER TC-NER
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detected by XPC together with RAD23B. Then XPB and XPD mediate strand separation. The damage is 
verified by XPA and RPA stabilizes the opened DNA. XPG and XPF endonucleases remove a DNA fragment 
that contains the lesion and the gap is filled by PCNA, δ polymerase and ligases using the complementary 
strand as template. In TC-NER: transcription-coupled NER the damage is detected by RNA polymerase II 
and the CS-factors are needed for faster and repair. Modified from de Laat et al
213
 and from Gillet and 
Schärer
215
. 
3.2.1.2. Translesion synthesis 
Translesion synthesis is a DNA damage tolerance (DDT) pathway that commonly allows 
replication in the cell across polymerase-blocking lesions. It specifically allows replication 
machinery to bypass DNA lesions using low-fidelity DNA polymerases. These low-fidelity 
polymerases are non-processive, lack any proofreading capability and contain larger active 
sites capable of accommodating distorted bases and base pair mismatches. This is an error-
prone pathway, as the lesion bypass occurs at the cost of replication fidelity216. 
Firstly RAD6 (E2 ubiquitin-conjugating enzyme) binds to RAD18 (E3 ubiquitin ligase) in 
response to DNA damage. These two enzymes induce monoubiquitination of PCNA to facilitate 
the switch between DNA replication and DDT processes. This monoubiquitination increases 
PCNA affinity for the low fidelity polymerases at the damaged site. The exchange of replicative 
DNA polymerase stalled for a TLS polymerase occurs in a multi-step process217. Firstly one TLS 
polymerase, called the insertion polymerase, is recruited by PCNA monoubiquitination.  The 
insertion polymerase incorporates one nucleotide opposite to the damaged site. The insertion 
polymerase is replaced by an extension TLS polymerase which extends the TLS patch by 
around 18 nucleotides, avoiding the detection of the lesion by the 3’-5’ exonuclease 
proofreading activity of a replicative DNA polymerase. Finally, there is a switched back to the 
high fidelity DNA polymerase (Figure 12). 
Figure 12: Translesion synthesis (TLS) pathway, a DNA damage tolerance mechanism involved in 
replication over modified or damaged DNA bases. Red triangle represents the distorting base. RAD6-
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RAD18 complex monoubiquitinates PCNA, which increments the affinity of this factor to low fidelity 
polymerases. Then the first polymerase switch occurs, the insertion polymerase is recruited and 
incorporates one nucleotide opposite to the damage site. This process enables to bypass the lesion. Then 
the insertion polymerase is replaced by extension polymerase, which extends the patch to avoid the 3’-5’ 
exonuclease proofreading activity of the replicative DNA polymerases. Finally, the third polymerase 
switch is produced, PCNA is deubiquitinated and the replicative polymerase continues replicating the 
DNA. Modified from Ghosal and Chen
218
. 
3.2.2. Interactions between FA/BRCA and other DNA repair 
pathways  
The FA/BRCA pathway is involved in the coordination of different repair mechanisms to solve 
ICL such as NER, TLS and HR. Moreover, FA/BRCA pathway is also involved in regulation of 
NHEJ. 
A clear example of the close interaction between these pathways is the case of mutations in 
XPF, a member of NER pathway. Mutations in this gene can provoke three different disorders: 
xeroderma pigmentosum219, progeroid syndrome220 or FA189. Moreover, RPA - involved in both 
HR and FA dependent ICL repair - can be associated to post-incision complexes, preventing 
further incision events and coupling effectively initiation of NER to completion of DNA repair 
synthesis221. 
There is also a clear link between TLS and FA/BRCA pathways. RAD6/RAD18 - an important 
complex in TLS - can directly impact in FA network activation via FANCD2 ubiquitination222-224. 
Moreover, monoubiquitinated PCNA is also able to recruit FANCL to the chromatin222. This and 
other studies suggest that PCNA acts as a scaffold protein for both FANCL and FANCD2 
recruitment to the chromatin by promoting FANCD2 ubiquitination. FANCD2 
monoubiquitination - with the subsequent activation of downstream proteins - also plays a 
role in recruiting polymerase η to the sites of damage, potentially facilitating TLS polymerase 
switching217. RAD18 protein is recruited to the ssDNA in a RPA dependent manner process that 
links TLS and HR225. FAAP20 - a FA-associated protein present in the core complex - binds to 
monoubiquitinated Rev1 (insertion polymerase) and promotes its interaction with the FA core 
complex226. Finally, it is known that monoubiquitinated PCNA is deubiquitinated by USP1 as 
well as ID2 complex of FA227, showing that regulation of both pathways should be very similar. 
FANCD2 affects all repair mechanisms of DSB when the replication fork is stalled. It is well 
known that its monoubiquitinated form has a role in DNA repair, promoting HR and single 
strand annealing (SSA)228-231. FA deficient cells present defects in HR when DNA damage is 
produced through ICLs232. On the other hand, monoubiquitinated FANCD2 inhibits non 
homologous end-joining (NHEJ) dependent on DNA-PKcs233,234. Human cell lines deficient in 
NHEJ proteins are not hypersensitive to ICL agents. However, some studies have shown that 
NHEJ inhibition in FA cell lines reduces the toxicity of ICL agents. These studies demonstrated 
that during the ICL repair, FA proteins prevent the inappropriate binding of NHEJ effectors in 
the DNA ends and suppress the imperfect ligation of DSB induced by ICL between non 
homologous chromosomes233,234. However, the inhibition of NHEJ in FA cells seems to be more 
deleterious in patient’s cells. For example the elimination of 53BP1 or Ku80 in FANCD2 
deficient cells increases its genetic instability235. FANCD2 has also been involved in the 
processing of DSBs promoting HR: monoubiquitinated FANCD2 carries CtlP protein to 
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chromatin to initiate resection of the DSB during the repair process of the ICL. Mutant cells 
deficient in CtlP domains that bind FANCD2 have increased NHEJ activity, resulting in 
hypersensitivity to ICL. Therefore, FANCD2 participates in the competition between NHEJ and 
HR pathways to repair during DSB processing236,237. It has been also described a model in which 
53BP1 inhibits initiation of DNA end-resection favoring the repair by NHEJ. This inhibition is 
negatively regulated by FANCS and thus, loss of FANCS results in persistent inhibition of end-
resection, which can be abolished by removal of 53BP153. This could at least in part explain the 
inhibition that FA/BRCA pathway exerts over NHEJ. 
FANCM also plays a role in HDR repair process independently of the FA network, as its 
depletion reduced RPA foci formation at ICL, while depletion of the rest of the FA core does 
not produce a similar response238. It has also been demonstrated that inactivation of FANCG 
decreases HR239. Finally, a link between B-NHEJ and FA has also been described, as depletion of 
FANCA protein reduces B-NHEJ240. 
3.3. Clinical aspects of the disease 
Fanconi anemia is a rare disease with an estimated frequency of 1-3 patients per 500,000 
births, and an estimated frequency of heterozygous mutation carriers of 1 per 300. This 
frequency is increased in highly consanguineous groups such as the Spanish gypsies, in which 
the frequency of carriers is estimated as 1 per 67 births241. 
Due to the heterogeneity of the disease, its presentation is very diverse. Around 70% of 
patients show physical abnormalities which can include: skeletal abnormalities of the hips, 
spine or ribs; radial ray anomalies including hand and arm anomalies, misshapen, missing or 
extra thumbs or an incompletely developed or missing radius; vertebral scoliosis; skin 
pigmentation anomalies such as café-au-lait spots, hyper- and hypopigmentation; short 
stature; small head or eyes; kidney and urinary tract problems, including missing or horseshoe 
kidney; mental retardation or learning disabilities; low birth weight; gastrointestinal 
difficulties; cardiac abnormalities; small reproductive organs and infertility in males and 
reduced fertility in females242. 
The most frequent feature of the disease is the bone marrow failure (BMF), which is 
manifested at a median age of 8 years, being the primary cause of morbidity and mortality in 
FA patients. Although some years ago the overall survival of these patients was situated 
around 25 years151, the more accurate diagnosis, better care and improvement in 
hematopoietic stem cell transplant (HSCT)  imply that the number of FA patients living into 
their third and fourth decade is increasing242. At birth, blood counts are usually normal, but not 
the number of hematopoietic stem and progenitor cells (HSPCs) which are reduced243-245. 
Macrocytosis is usually the first symptom of the BMF detected in these patients, followed by 
thrombocytopenia and neutropenia. 
In addition to the BMF, the incidence of cancer in FA patients is also increased compared to 
the normal population. The incidence of acute myeloid leukemia (AML) is 800-fold higher than 
in the general population, and patients are also prone to develop myelodysplasic syndrome 
(MDS). Moreover, FA patients have shown a higher risk of developing specific solid tumors, 
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such as head and neck squamous cell carcinomas (SCCs), esophagus SCCs and vulvar cancer in 
women (33% of FA patients develop a solid tumor in their fourth decade of life)246-248. 
An important aspect concerning the clinical symptoms of the disease is the observation that 
some FA patients can undergo somatic mosaicism by means of a spontaneous reversion of the 
pathogenic mutation, in particular somatic cells. If this reversion takes place in a HSPC, it may 
confer a proliferation advantage due to its increased genetic stability, leading to the recovery 
of the peripheral blood (PB) cell counts in patients5,249-251. 
Interestingly, in 2010, a singular phenotype in some FA patients was first described252. The 
blood cells of these patients did not show the FA characteristic G2/M cell cycle arrest after 
exposure to DNA cross-linkers. Strikingly and in contrast to mosaic FA patients, no reversion in 
the pathogenic mutations occurred. This phenomenon called attenuation was then associated 
with almost normal blood cell counts without the reversion of the FA mutation. However, the 
cost of this attenuated phenotype in patients is a higher risk of malignancy252. 
3.4. Phenotypic characteristics of Fanconi anemia cells 
The main characteristics of FA cells are: 
a) Hypersensitivity to ICL agents such as MMC or DEB: the treatment with these agents 
generates a high number of chromosomal aberrations. This characteristic is a hallmark 
of FA and it is used to diagnose the disease in PB lymphocytes253. 
b) G2/M cell cycle arrest after exposure to ICLs inducing agents: it is a consequence of the 
accumulation of blocked repair hairpins due to the incapability of these cells to repair 
the DNA lesions produced by ICL agents254. This technique has been very useful in the 
diagnosis of mosaic patients, since most of them do not present the typical MMC or 
DEB sensitivity in PB T lymphocytes. The treatment of fibroblasts with MMC or DEB 
and the G2/M arrest is usually used for the diagnosis255. 
c) Hypersensitivity to oxygen: this is a consequence of the deregulation of reactive 
oxygen species (ROS) metabolism256. This deregulation causes defects in the ex vivo 
growth of cells. Therefore, to facilitate FA cells growth, they must be cultured in 
hypoxic conditions (oxygen concentration lower than 5%), mimicking the low oxygen 
concentrations present in most tissues including the bone marrow niche257. 
d) Telomere abnormalities: FA cells present shorter telomeres than healthy related 
individuals258, but not as short as cells from dyskeratosis congenita patients (in which 
mutations in genes involved in maintenance of telomere’s structure occur)259. 
Although the telomeres are usually altered in FA patients; the telomerase activity is 
increased, probably to compensate this alteration260,261.  
e) Cytokine sensitivity: FA cells from patients produce higher levels of pro-apoptotic and 
pro-inflammatory cytokines such as interferon γ (IFN- γ)262, tumor necrosis factor α 
(TNF-α)263,264 or interleukin 1β (IL-1β)265. The overexpression of TNF-α and IFN-β in the 
bone marrow of FA patients is associated with the hyperactivity of two pathways 
involved in bone marrow failure and leukemogenesis266: p38MAPK267 and NF-κB268. The 
hematopoietic phenotype of FA patients is at least, in part, attributable to the 
overproduction of some cytokines to which FA cells are hypersensitive. Some attempts 
to ameliorate BMF have been developed with the objective of decreasing the levels of 
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cytokines such as TNF-α262. Although the in vitro culture of HSPCs from patients is 
increased in the presence of anti-TNF-α262,269, a clinical trial conducted in FA patients 
with an inhibitor of TNF-α did not improve the clinical status of the patients270. 
f) Adhesion and homing defects: they are linked to defects in CDC42 activity271 - a 
GTPase that is downregulated by over-expression of TNF-α. 
g) Defects in monoubiquitination and mobilization of FANCD2 to DNA repair foci: 
monoubiquitination of FANCD2 is essential for the recruitment of ICL repair proteins. 
Cells with mutations in the FA core complex present defects in the monoubiquitination 
of this protein and this can also be used as a diagnostic marker251,272. 
Monoubiquitination of FANCD2 could be observed in Western blots (WB) by the 
appearance of two bands. Since monoubiquitination of FANCD2 is essential for 
FANCD2 foci formation, the analysis of FANCD2 foci can also be an indicator of FANCD2 
monoubiquitination202. 
h) Defects in cytokinesis, due to the accumulation of monoubiquitinated ID2 complex 
during and after mitosis at fragile sites in which DNA replication is slower. Sister 
chromatids in which these foci are located are connected by ultra-fine bridges. This 
characteristic increases the number of binucleated or multinucleated cells that arise 
from cytokinesis failure273. 
i) Elevated levels of p53 protein and its effector p21 in patient cells is characteristic, and 
this could reflect the unresolved DNA damage of the cells, which might then lead to 
hematopoietic stem cell (HSC) depletion and hence, progressive BMF160. The strong 
induction of p53 gives rise to a new cell cycle arrest in G0/G1 phases, as a protective 
mechanism to keep the integrity of the genome, preventing damaged cells to progress 
through the cell cycle. Some in vitro studies have used small molecule inhibitors of 
p53, resulting in rescue of HSC apoptosis and improving hematopoiesis in FA patient´s 
cells, but this increases the risk of leukemia244. 
3.5. Diagnosis and identification of complementation 
groups in Fanconi anemia 
The diagnosis of FA patients is not an easy procedure. As it has been previously mentioned, 
one third of them do not present major malformations, so they are not identified until the 
first symptoms of the BMF appear161. Moreover, there are other diseases that reproduce 
some of the phenotypes of FA patients such as Nijmegen breakage syndrome (NBS), Bloom 
syndrome and Seckel syndrome. 
The differential test for FA is the chromosomal breakage test in the presence of ICL agents. 
This was first established by Schuler and colleagues in 1969, who observed that FA patient’s 
cells were positive for MMC chromosomal breakage induction, while healthy donors’ cells 
were negative274. The diagnosis of FA can also be done by a G2/M phase cell cycle arrest after 
treatment with ICL inducing agents255; and this can be very useful to confirm cases of 
mosaicism. 
The screening of FA complementation groups is performed to detect which is the mutated 
gene in a particular patient and assigned him/her to a complementation group. One widely 
method consists in the transduction of peripheral blood T cells using a battery of vectors with 
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either γ-retroviral (γ-RVs) or lentiviral vectors (LVs), each one encoding a different FA gene, 
followed by the analysis of the vector that corrects the hypersensitivity of these cells to 
interstrand cross-linking agents. The vector that reverts the phenotype determines the FA 
complementation group of the patient275. 
If the patient does not have mutations in the most common FA genes, WB of FANCD2 allows 
defining if the FA affected protein is located upstream or downstream of the ID-complex in 
the FA pathway, depending on the ubiquitinated status of the protein.  
Nowadays new approaches based on exome sequencing through the analysis of the 19 FA 
genes described so far, or the analysis of the entire genome, can allow the identification of 
new complementation groups, as in the studies that facilitate the of identification of FANCQ 
and FANCR as a FA genes189,190. In the near future this kind of analysis will substitute the 
subtyping carried out with γ-RVs and LVs. However, subtyping will continue to be essential to 
verify whether the insertion of the suspected FA gene restores the phenotype of the cell, 
confirming the pathogenicity of the mutations found by sequencing. 
3.6. Current treatments in Fanconi anemia 
Bone marrow failure (BMF) is the main cause of mortality in FA patients. Many of the 
treatments to avoid the BMF are palliative, and directed to maintain acceptable numbers of 
cells in PB. The standard therapies are based on the use of androgens, hematopoietic growth 
factors276, and if possible HSCT, that is the only curative treatment. Androgens stimulates 
erythropoiesis and are recommended when residual endogenous hematopoiesis remains277, 
however this treatment presents side effects such as masculinization278 or higher risk of 
hepatic tumors279. Recent results using danazol have shown that this androgen can be an 
effective and well-tolerated treatment option to delay the progressive marrow failure in FA 
patients and with less side effects than the previous androgens used280. Some hematopoietic 
growth factors that have been also used in FA treatment are granulocyte-colony stimulating 
factor (G-CSF), erythropoietin (EPO) or interleukin 3 (IL-3)281,282. However, the response to 
these factors was transient and they are no longer used.  
The only curative treatment capable of restoring the hematopoiesis of FA patients in the long-
term is allogenic HSCT. In 1984, Gluckman and coworkers283 developed the first successful 
preparative regimen for FA patients. However, there are many obstacles for HSCT for example 
the hypersensitivity of FA patients to conditioning regimens or the finding of a compatible 
donor. The ideal donor for a FA patient is an HLA-identical sibling donor, to limit the risks of 
graft rejection and graft versus host disease (GVHD). Nevertheless, recent advances including 
the depletion of alloreactive T cells, the use of reduced intensity conditioning and the addition 
of fludarabine (potent inmunosupressor which interferes with DNA synthesis) have also shown 
to improve the outcome of alternative (HLA-matched related or unrelated) donor transplants 
in FA patients284,285. However and although HSCT is the primary treatment of these patients, it 
does not solve the non-hematological complications of FA, particularly the increased incidence 
of solid tumors. 
The management of cancer in these patients is different than in other patients due to the 
toxicity of chemo- and radiotherapeutic regimens. Prevention is the critical element, so FA 
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patients should have annual analysis of bone marrow aspirates to rule out premalignant clonal 
expansion. Also frequent head and neck evaluations, and gynecologic exams in the case of 
women, are strongly recommended to prevent SCC. It is also recommended that all FA patients 
should receive human papillomavirus (HPV) vaccinations to prevent SCCs286. 
3.6.1. Gene therapy in Fanconi anemia 
Fanconi anemia is a monogenic disease and a good candidate for GT due to the proliferative 
advantage of corrected cells over non-corrected ones5. This phenomenon is naturally produced 
in mosaic patients, where the reversion of the pathogenic mutation in one cell leads to the 
correction of the hematological status of these patients. However, FA also presents some 
disadvantages in the field of GT; the main one is the difficulty to collect high numbers of HSCs 
from patients, as the pool of available HSPCs is already compromised at birth244. 
Despite all of this, three different gene therapy trials have been carried out using γ-RVs in 
patients with FA. The first one was carried out by Dr. Walsh in FA-A patients, but was not 
successful287. The second one was conducted by Liu and colleagues288 in FA-C patients. In this 
study the authors observed an increased number of BM cells in treated patients, but no clinical 
improvement was observed. The third study was developed by Kelly et al. to treat patients 
from FA-A complementation group. Neither, this study generated clinical improvements in the 
patients243. 
The lack of success observed in previous FA GT trials gather in 2011 worldwide experts in the 
field to create an International FA GT working group, in order to set up the conditions for 
future FA GT trials289. In 2012 a phase I clinical trial in patients of the complementation group A 
was opened at the Fred Hutchinson Center in Seattle, USA (NCT01331018). The first patient 
was recruited in 2014 and results have not been published yet. Our laboratory coordinates FA 
GT trial in Europe. This trial uses a SIN LV vector290 which was designated as an orphan drug in 
2010 by the European Commission (EMA/COMP/662962/2010) and was approved for phase 
I/II GT trial for FA-A patients (FANCOLEN: Eudra number CT: 2011-006100-12), the most 
frequent FA complementation group around world (>60%) and also in Spain (>80%)275. 
3.6.1.1. Gene targeting in Fanconi anemia 
Gene targeting will represent the safest gene therapy alternative to treat monogenic 
disorders, as extensively mentioned in section 2 of the introduction. Although nowadays there 
is no clinical trial in this respect to treat FA, some experimental studies have already addressed 
this topic in FA cells. The first work was reported by our laboratory. In this study, fibroblasts 
from FA-A patients were edited with AdVs which contained ZFNs that targeted the AAVS1 
locus and a donor IDLV which carried that FANCA gene. Corrected cells were then 
reprogramed to generate induced pluripotent stem cells (iPSCs) and finally differentiated to 
the hematopoietic lineage75. In the next study, fibroblasts from FA-A patients were directly 
reprogramed to iPSCs and iPSCs were then gene edited with helper-dependent AdVs in a 
knock-in strategy, to finally differentiate to the hematopoietic lineage291. The use of helper-
dependent AdVs without using nucleases markedly decreased the efficiency of gene targeting, 
compared to the previous work. The main limitation of using reprograming approaches is that 
the number of hematopoietic stem cells obtained after differentiation from iPSCs is very 
limited. The last work was based on the correction of FA-C fibroblasts using CRISPR/Cas9 
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system292. In this work CRISPR/Cas9 nucleases and nickases were used with the donor as 
plasmid DNA in a knock-in strategy. The main conclusion of this work was that although the 
nickase reduced of NHEJ events to repair the DSBs, it also decreases the efficiency of HDR with 
respect to the nuclease. 
So far, no gene editing studies have been performed in hematopoietic cells from FA patients, 
which constitute the main target in FA gene therapy. For this reason in the present work we 
have addressed this topic and we have investigated different options to target the 
hematopoietic cells, and thus to correct the hematopoietic phenotype of  FA-A patients. 
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The aim of this study was to investigate the feasibility of developing a targeted gene therapy 
approach in hematopoietic stem and progenitor cells from Fanconi anemia patients, subtype A 
(FA-A HSCs). In particular, our approach was focused on the specific insertion of the 
therapeutic FANCA gene into the AAVS1 safe harbor locus of FA-A HSCs. 
To achieve this objective, the following specific aims have been pursued: 
1.  
To construct a self-inactivating integrase-defective lentiviral vector harboring the FANCA 
therapeutic gene, as donor construct to be inserted into the AAVS1 locus, targeted with a 
specific engineered zinc-finger nuclease (ZFN). 
2.  
To investigate the feasibility, efficacy and specificity of a gene targeting approach aiming at the 
insertion of reporter and FA therapeutic genes into the AAVS1 safe harbor locus of 
lymphoblastic cell lines and hematopoietic stem cells from healthy donors. 
3.  
To improve the efficacy of gene targeting by increasing the transduction efficacy of integrase-
defective lentiviral vectors and enhancing the homologous recombination frequency in FA-A 
cells. 
4. 
To evaluate the efficacy of the proposed gene targeting approach to correct the phenotype of 
lymphoblastic cell lines and hematopoietic stem and progenitor cells from FA-A patients. 
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1. Cell lines and primary cells 
1.1. 293T cell line 
293T cells (ATCC: CRL-11268) are used to produce non replicative LVs. It is a human embryonic 
kidney epithelial cell line that was modified by the insertion of a temperature sensitive gene 
codified by the simian SV40 T antigen that is constitutively expressed to achieve higher 
transfection efficiency. The inserted sequence allows the episomal replication of plasmids that 
contain the replication origin in the early promoter region of the SV40. 
1.2. Lymphoblastic cell lines 
Healthy donor or FA patients’ B cells from peripheral blood were transformed with the 
Epstein-Barr virus (EBV) that activates the proliferation of these cells. These resulting 
lymphoblastic cells (LCLs) present a normal karyotype, are immortalized and are not 
tumorigenic293. Four different cell lines from healthy donors were used in this study CP1, CP2, 
C3 and C4, and four cell lines from Fanconi anemia A complementation group (FA-A) patients 
(FA-55, FA-56, FA-122, FA-378). 
1.3. Human fibroblasts 
Fibroblasts obtained from healthy donors and also from FA-A complementation group 
patients.  
1.4. CD34+ cells derived from umbilical cord blood 
Umbilical cord blood (UCB) samples from healthy donors were obtained from the Centro de 
Transfusiones de la Comunidad de Madrid. Mononuclear cells were purified by Ficoll-Paque 
PLUS (GE Healthcare, Fairfield, USA) density by gradient centrifugation. Then, CD34+ cells were 
selected using CD34 MicroBead Kit. Magnetic-labelled cells were selected with a LS column in 
QuadroMACSTM separator (MACS, Miltenyi Biotec, Bergisch Gladbach, Germany) following 
manufacturer’s instructions. Purified CD34+ were then evaluated for their purity by flow 
cytometry. Purities from 90-99% were routinely obtained. 
1.5. CD34+ from FA patients 
A very small proportion of mobilized peripheral blood (mPB) CD34+ cells that remained in cell 
collection bags and tubes from the CliniMACS® System (Miltenyi Biotec), was used.  This 
system is used to purify CD34+ cells from FA-A patients treated with plerixafor and G-CSF 
included in the FANCOSTEM mobilization trial. This procedure was performed after the 
informed consent of patients or their parents and with the approval of the ethic committee of 
the hospitals. 
1.6. Culture conditions 
The culture conditions of the different cell types used in this study are listed in Table 3: 
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293T Culture medium Iscove’s Modified Dulbecco’s Medium (IMDM, Gibco/Life 
Technologies/Thermo Fisher Scientific, Waltham, USA)) + 10% 
Hyclone (GE Healthcare) + 1% Penicillin/Streptomycin (P/S, Gibco) 
Growth Adherence 
Culture conditions Normoxia: 37°C, 21% O2, 5% CO2 and 95% relative humidity (RH) 
LCLs Culture medium Roswell Park Memorial Institute (RPMI, Invitrogen/Life 
Technologies/Thermo Fisher Scientific, Waltham, USA) + 20% 
Hyclone + 1%P/S + 0.005 mM β-Mercaptoethanol (Gibco) + 1mM 
sodium pyruvate (Sigma, Saint Louis, MO, USA) + non-essential 
aminoacids (NEEA, Lonza, Basel, Switzerland) 
Growth Suspension 
Culture conditions Normoxia: 37°C, 21% O2, 5% CO2 and 95% RH 
Human 
fibroblasts 
from 
healthy 
donors 
Culture medium Dulbecco's Modified Eagle's medium (DMEM, Invitrogen) + 20% 
Hyclone + 1% P/S 
Growth Adherence 
Culture conditions Normoxia: 37°C, 21% O2, 5% CO2 and 95% RH or Hypoxia: 37°C, 5% 
O2, 5% CO2 and 95% RH when these cells are used in experiments 
together with fibroblasts from FA-A patients 
Human 
fibroblasts 
from FA-A 
patients 
Culture medium DMEM + 20% Hyclone + 1% P/S 
Growth Adherence 
Culture conditions Hypoxia: 37°C, 5% O2, 5% CO2 and 95% RH 
UCB 
CD34
+
 
Culture medium StemSpam (StemCell Technologies, Vancouver, Canada) + 1% P/S + 
1% Glutamax (Gibco) + 100 ng/mL stem cell factor (SCF, 
EuroBiosciences, Friesoythe, Germany) + 100 ng/mL FMS-like 
tyrosine kinase 3 ligand (Flt3, EuroBiosciences) + 20 ng/mL 
thrombopoietin (TPO, EuroBiosciences)  + 20 ng/mL interleukin 6 
(IL6, EuroBiosciences)  
Growth Suspension 
Culture conditions Normoxia: 37°C, 21% O2, 5% CO2 and 95% RH 
CD34
+ 
from FA 
patients 
Culture medium StemSpam + 1% P/S + 1% Glutamax + 100 ng/mL SCF + 100 ng/mL 
Flt3 + 20 ng/mL TPO + 20 ng/mL IL6 + 10 µg/mL anti-TNFα (Enbrel-
Etanercept, Pfizer, New York, USA) + 1 mM N-acetylcysteine 
(Pharmazam, Spain) 
Growth Suspension 
Culture conditions Hypoxia: 37°C, 5% O2, 5% CO2 and 95% RH 
Table 3: Culture conditions of the different cell types used in this study. 
2. Lentiviral vectors and plasmids 
Bacterial plasmids containing the different constructs used for LV production were generated 
using typical procedures of molecular biology. All enzymes used during the cloning such as 
restriction enzymes, ligases, kinases and phosphatases were obtained from New England 
Biolabs (Ipswich, USA). After each ligation, the resulting products were transformed in TOP10 
bacteria (Invitrogen). Plasmid DNA was purified from selected colonies using NucleoBond® Xtra 
Midi EF kit (Macherey-Nagel, Duren, Germany) and analyzed by restriction enzymes. 
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2.1. Zinc-finger plasmids 
Specific ZFNs to target the AAVS1 locus are included in the pVAX plasmid (pVAX ZFN) or pUC 
vector (TEV ZFN). ZFNs were designed by Sangamo Bioscience (Richmond, California, USA) and 
kindly provided by Pr. Luigi Naldini (Hospital San Raffaelle, Milano, Italy). Both vectors contain 
the same sequence: the homology arm (HA) for intron 1 of PPP1R12C gene and a mutated 
version of FokI nuclease that increases the affinity by forced heterodimerization101,102, for this 
reason two different plasmids are required. One member of the pair presents the right 
homology arm (HA R) for the AAVS1 locus and FokI with EL mutation (Q486E and I499L) and 
the other member presents the left homology arm (HA L) for the AAVS1 locus and FokI with KK 
mutation (E490K and I538K). The difference between pVAX and pTEV is that TEV ZFNs pair 
presents regulatory sequences that enhances the stability of the in vitro produced mRNA 
whereas the pVAX ZFNs pair does not. 
These plasmids have been used in all the experiments performed with ZFNs as mRNA and this 
mRNA was synthesized in vitro (see section 3. Materials and methods). 
2.1.1. pVAX zinc-finger nucleases 
We used two different plasmids, one for the right ZFN and other for the left ZFN. In both 
plasmids there is a T7 promoter that drives the transcription of the ZFN from them followed by 
a nuclear localization signal (NLS), the HA right or left and finally, the mutated version of the 
nuclease FokI. The obligate heterodimer FokI domains generate an active nuclease only by 
heterodimerization and when incorporated into ZFNs induce DSBs with higher specificity. After 
the nuclease sequence a unique restriction enzyme site is included to allow linearization of the 
plasmid before the in vitro transcription. 
Figure 13: Schematic representation of pVAX ZFNs. T7 promoter: from which the mRNA is in vitro 
synthetized. NLS: nuclear localization signal. HA: homology arms (R: right or L: left) of PPP1R12C gene 
located in the AAVS1 locus. Obligated heterodimer FokI domain (FokI EL or FokI KK). XbaI indicates the 
unique restriction site present that allows linearization of the vector to improve the efficiency of the in 
vitro synthesis. 
2.1.2. TEV zinc-finger nucleases 
There are two different plasmids, one that encodes the right ZFN and the other that encodes 
the left one. The transcription of these two plasmids is also under the control of the T7 
promoter. The plasmid also carries a NLS, the homology arm for the PPP1R12C gene and the 
mutated version of the FokI endonuclease. In this case and in contrast with the pVAX vector, it 
also has two different regulatory elements that presumably confer more stability to the 
mRNA294. The 5’ untranslated region (UTR) comes from the tobacco etch virus (TEV) and the 3’ 
UTR comes from the human β-globin gene. 
HA R FokI ELT7
XbaI
HA L FokI KKT7
XbaI
NLS
NLS
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Figure 14: Schematic representation of TEV ZFNs. T7 promoter: from which the mRNA is in vitro 
synthetized. NLS: nuclear localization signal. HA: homology arms (R: right or L: left) of PPP1R12C gene in 
the AAVS1 locus. Regulatory sequences: TEV (tobacco etch virus) in 5’ UTR (untranslated region) and β-
Globin in 3’ UTR. Obligated heterodimer FokI domain (FokI EL or FokI KK). AflII indicates the unique 
restriction site present that allows linearization of the vector and consequently its in vitro synthesis. 
2.2. Donor constructs 
All the donor constructs used in this study are self-inactivating lentiviral vectors (SIN-LV) and 
were produced as integrase-defective lentiviral vectors (IDLV) to prevent their integration in 
the genome295. All of them present the same homology arms for the AAVS1 locus described 
previously65, but the recombination cassette between the homology arms differs. All the 
constructs were used as donor template as IDLV or plasmids for the homologous 
recombination during gene targeting experiments. 
2.2.1. GFP donor 
This plasmid has been kindly provided by Dr A. Lombardo65 (Hospital San Raffaelle) and 
includes the physiological human promoter: phosphoglycerate kinase (PGK) that drives the 
expression of a reporter gene: green fluorescent protein (GFP) flanked by the homology arms 
(HAs) for the AAVS1 locus. This construct was also produced as integrase-competent lentiviral 
vector (ICLV) in the experiments of improvement of gene targeting using gold nanoparticles 
(AuNPs). 
Figure 15: Schematic representation of GFP donor. The HDR cassette is included between both HAs. All 
the construct is flanked by the LTRs. 
2.2.2. GFP-FANCA donor 
This donor plasmid was previously developed in our laboratory75. The construct contains HA 
for AAVS1 locus and a promoterless reporter gen (GFP) whose expression is driven by the 
endogenous promoter of the PPP1R12C gene through the self-cleaving 2A peptide sequence296 
introduced before the reporter gene. It also contains PGK promoter that controls the 
expression of the human FANCA gene.  
PGK GFP
BGHpA
HA R HA L
3’ΔLTR
5’LTR
TEV 5’ UTR HA R FokI EL Globin 3’ UTRT7
TEV 5’ UTR HA L FokI KK Globin 3’ UTRT7
AflII
AflII
NLS
NLS
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Figure 16: Schematic representation of the GFP-FANCA donor. Between the 3’ and 5’ LTRs this plasmid 
includes two HA for the AAVS1 locus, a splicing acceptor site (SA), the reporter gene GFP, the human 
promoter PGK and the FANCA gene. 
2.2.3. FANCA-Puro donor 
We have designed this plasmid as an alternative donor for gene targeting experiments. It 
carries the HA for the PPP1R12C gene in the AAVS1 locus, the physiological promoter PGK 
driving the expression of FANCA gene, and the puromycin resistance gene, as a selectable 
marker. It also contains a 3xFlag signaling peptide before the FANCA gene. 
Figure 17: Schematic representation of the FANCA-Puro donor. Between the 5’ and 3’ LTRs this 
construct includes the two HA for the AAVS1 locus, the PGK promoter that drives the expression of the 
FANCA gene and the Puromycin resistance gene as a selectable marker. Finally, this plasmid also 
contains the 3X Flag signaling peptide at 5’ position of the FANCA gene. 
2.2.3.1. Cloning strategy 
The 3xFlag-FANCA-2A-Puro structure was chemically synthetized by GenScript (Piscataway 
Township, USA) in a pUC57 backbone. 3xFlag signaling peptide was added to the N-termini of 
the protein as it has been described that in this position it does not produce any alteration in 
the protein function or localization297. The cloning is summarized in the supplementary figure 1 
(appendix I). Firstly, a multicloning site was introduced in the plasmid: XbaI-NheI-AgeI-HpaI.  
Figure 18: Primer annealing of multicloning site designed to introduce the restriction enzyme sites for 
NheI and AgeI. In different colors are highlighted the different restriction sites for the different enzymes. 
Two different primers were designed (Figure 18); they were combined at equal concentrations 
and annealed by incubation 4 minutes at 95°C followed by 10 minutes at 70°C in the annealing 
buffer (100 mM potassium acetate, 30 mM HEPES pH 7.4 and 2 mM magnesium acetate). They 
were cooled down at room temperature (RT) and phosphorylated using a PNK kinase and T4 
ligase buffer 30 minutes at 37°C followed by 10 minutes at 70°C. At the same time the pUC57 
3xFlag-FANCA-2A-Puro plasmid (8,032 bp) was digested with XbaI and HpaI restriction 
enzymes and dephosphorylated with CIP enzyme during 1 hour at 37°C followed by 10 minutes 
SA
2A GFP PGK FANCA
HA R
BGHpA SV40pA
HA L
3’ΔLTR
5’LTR
SV40pA3xFlag
2APGK FANCA
HA R
Puro
HA L
3’ΔLTR
5’LTR
5’ CTAGAAGCGCTAGCGCCACCGGTCGCAGTT 3’
3’ TTCGCGATCGCGGTGGCCAGCGTCAA 5’
XbaI NheI AgeI HpaI
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at 70°C, in order to inactivate it. Annealed primers and the resulting fragment from pUC57 
3xFlag-FANCA-2A-Puro digestion were ligated with T4 DNA ligase and transformed in TOP10 
bacteria to obtain the first intermediate of the cloning (8,017 bp).  
This first intermediate plasmid (8,017 bp) was digested with NheI and AgeI restriction enzymes 
generating a fragment of 8,008 bp. On the other hand, the GFP donor plasmid (9,739 bp) was 
also digested with the same pair of restriction enzymes generating a fragment of 741 bp. 
These two resulting fragments were ligated with T4 DNA ligase and transformed in TOP10 
bacteria to obtain the second intermediate of the cloning (8,749 bp). 
Finally, this last intermediate was digested with NheI and BsaBI restriction enzymes and a 
fragment of 6,019 bp was purified. At the same time the GFP-FANCA donor plasmid (14,642 
bp) was digested with the same restriction enzymes leading to a fragment of 8,081 bp. These 
two resulting fragments were ligated with T4 DNA ligase and transformed in TOP10 bacteria to 
finally obtain the FANCA-Puro donor plasmid. 
3. mRNA synthesis  
ZFN plasmids were digested with the mentioned restriction enzymes in order to linearize the 
plasmids. This digestion was purified using phenol-chloroform and the amount of DNA was 
measured using a Nanodrop®. The in vitro synthesis of the mRNA was performed with the 5X 
MegaScript Kit T7 Kit (Ambion/Life Technologies/Thermo Fisher Scientific, Waltham, USA) and 
3´-0-Me-m7G(5')ppp(5')G RNA Cap Structure Analog (ARCA) (New England Biolabs). Firstly 6 µg 
of the digested DNA was mixed with 32 µL of dNTPs, 12 µL of ARCA, 8 µL of T7 Enzyme, 8 µL of 
T7 Buffer 10X and up to 80 µL with nuclease free water and incubated two hours at 37°C. Then 
4 µL of Turbo DNase were added to the reaction and incubated again for 30 minutes at 37°C. 
Then the polyadenylation reaction was performed in the synthetized RNA using the Poly(A) 
Tailing Kit (Ambion). 144 µL of nuclease free water, 80 µL EPAP buffer 5X, 40 µL MnCl2 25 mM, 
40 µL ATP 10 mM and 16 µL EPAP enzyme was added to the RNA reaction synthesis, mixed and 
incubated during one hour at 37°C. 
The resulting mRNA was purified using RNeasy Plus Mini (Qiagen, Venlo, Limburg, 
Netherlands) following the manufacturer’s protocol. 
Finally, the amount of mRNA was measured with Nanodrop®, aliquoted and stored at -80°C. 
An aliquot of the synthetized mRNA was run in an agarose gel in denaturing conditions (with 
formaldehyde) in order to confirm the integrity of the mRNA before and after the 
polyadenylation reaction (Figure 19). 
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Figure 19: A representative gel of in vitro synthetized mRNA from ZFN plasmids: pVAX or TEV. From 
each right (R) or left (L) ZFN the non-polyadenilated or polyadenilated mRNA from the L and R ZFN of 
both constructs is shown. 
Each in vitro ZFN mRNA production was tested using a control LCL (C4) in which 2x105 cells 
were nucleofected with serial dilutions of each ZFN pair using the SF Cell line 4D-Nucleofector® 
X Kit (Lonza). 24 hours after nucleofection, survival was tested in these cells and five days after 
nucleofection cells were harvested and the activity of the ZFN pair production was evaluated 
by Surveyor assay (see section 6. Materials and methods) to determine the optimal 
concentration of ZFNs to be used in the different productions. 
4. Production of integrase-defective 
lentiviral vectors and integration-
competent lentiviral vectors 
All self-inactivating (SIN) integrase-defective (IDLV) or integrase-competent (ICLV) vectors were 
generated by a third generation packaging system in which 293T cells were transiently 
transfected with the transfer, helpers (pRSV.REV and pMD.Lg/pRRE.D64Vint for IDLV or 
pMD.Lg/pRRE for ICLV) and envelope (pMD2.VGVg) plasmids (Table 4), obtaining VSV-G-
pseudotyped lentiviral particles. The pMD2.VSVg and the helper pRSV.REV plasmids used were 
obtained from PlasmidFactory (Bielefeld, Germany). 
Plasmid type Name Description 
Packaging plasmids pMD.Lg/pRRE.D64Vint Carries gag and pol genes. The integrase presents a 
deletion that impairs its expression 
295
 
pMD.Lg/pRRE Comprises gag and pol genes
298
 
pRSV.REV Contains rev gene
298
 
Envelope plasmid pMD2.VGVg Presents the glycoprotein G of Vesicular stomatitis 
virus (VSV)299,300 
Table 4: List of plasmids used in the third generation of IDLV and ICLV production. 
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Transfections were conducted in 293T cells at 50-70% confluence in 150 mm diameter plates 
following the CaCl2 DNA precipitation method. Culture medium was replaced with fresh media 
two hours before transfection. The amounts of plasmids used for a 150 mm plate of 293T cells 
were: 36 µg of the corresponding transfer plasmid, 9 µg of the pMD2.VSV.G envelope plasmid, 
12.5 µg of the pMD.Lg/pRRE.D64Vint or pMD.Lg/pRRE helper, 6.25 µg of the pRSV.REV plasmid 
and 15 µg of pAdVantage plasmid (Promega, Fitchburg, Wisconsin, United States). The 
pAdVantage plasmid is described that enhances transient protein expression by increasing 
translation initiation301. This mixture was prepared in a final volume of 1,100 µL of 0.1x Tris-
EDTA buffer/dH2O (2:1) per plate and then 150 µL of 2.5 M CaCl2 was added. After 15 minutes 
of incubation at room temperature (RT) in agitation in order to allow the correct 
homogenization of the mixture; 1,250 µL of 2X HBS buffer (100 mM HEPES, 281 mM NaCl, 1.5 
mM Na2HPO4, pH 7.15) were added dropwise while vortexing at full speed, allowing the 
formation of Ca2+/DNA- precipitates. Immediately, the total volume was added to 293T cells, 
which will subsequently phagocyte the precipitates. After 13 hours, culture medium was 
replaced by fresh medium. Lentiviral supernatants were collected 36 hours post-transfection, 
filtered through 0.2 µm pore-size filters (Milipore/Merck KGaA, Darmstadt, Germany) and 
concentrated by ultracentrifugation. Viral pellets were then resuspended in StemSpam 
medium to concentrate them 500 times, aliquoted and stored at -80°C. 
4.1. Titration of integrase-defective lentiviral vectors 
Viral titers were determined by transduction of 293T cells with serial dilutions of the 
supernatants. 7.5x104 cells/well were seeded in 6-well tissue culture plates the day before. The 
same day of the titration, the number of cells per well was determined. Serial dilutions of the 
IDLV supernatants were prepared in IMDM-based complete medium starting from 10-3 to 10-7 
and then used to transduce 293T cells. After 3 days, cells were collected. 
The titration was performed by quantitative PCR (Q-PCR). DNA was obtained from the 
transduced 293T cells using NucleoSpin® Tissue (Macherey-Nagel) and then vector copy 
number (VCN) was analyzed.  Q-PCR amplification was performed using specific primers (Table 
5) in a 7500 fast real-time PCR system (Applied Biosystems/Life Technologies/Thermo Fisher 
Scientific, Waltham, USA) using SYBRGreen FastStart Universal SYBR Green Master PCR master 
mix (Roche, Basel, Switzerland). After 95°C 20 seconds incubation, amplification was 
performed for 40 consecutive cycles at 95°C 3 seconds and 60°C 30 seconds. Primers were 
acquired from Grupo Taper (Alcobendas, Spain). 
Primer Sequence (5’ to 3’) Tm (°C) 
hAlb Fw GCTGTCATCTCTTGTGGGCTG 64 
hAlb Rv ACTCATGGGAGCTGCTGGTTC 63 
ΔU3 Fw TCACTCCCAACGAAGACAAGATC 63 
PBS Rv GAGTCCTGCGTCGAGAGAG 62 
Table 5: List of primers used for the Q-PCR for titration of IDLVs. 
The VCN is the parameter that indicates the number of infective proviral copies per transduced 
cell. Proviral genome and host cell genome were amplified and quantified using fast SYBR 
green based multiplex Q-PCR. In this reaction primers that bind the retrotrascribed DNA of the 
virus were used to quantify viral genome load and human albumin (hAlb) primers were used to 
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quantify human genome (Table 5). One of the primers that amplified the viral genome binds to 
ΔU3 and the other binds to the primer binding site (PBS) region. These regions are separated in 
the RNA viral genome however, once retrotranscription occurs in the cytoplasm of the 
transduced cell, and the LTRs are formed these two regions become together and the 
amplification can take place (Figure 20).  
Figure 20: Scheme of the RNA genome of a lentiviral vector and the retrotranscribed form of the 
vector. Only when the vector is retrotranscribed the ΔU3 and the PBS regions are close enough to allow 
the amplification by Q-PCR. 
Quantification of viral and cell genomes was performed by interpolating the cycle threshold 
values (Ct) from the gDNA samples to the Ct of a standard curve with five-fold dilutions of a 
known concentration of gDNA from a cell line that presents only one integration of a LV per 
cell which express GFP and Albumin (kindly provided by Dr. Anne Galy (Genethon, Evry, 
France))302. Cell number corresponding to the calculated number of hAlb copies was 
determined assuming that each cell contains two copies of hAlb. VCN was finally calculated as: 
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The viral titer was calculated for each dilution and then an average of them was used as the 
final titer expressed in viral particles (vp) per mL. The formula used for titer calculation is the 
following: 
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4.2. Titration of integration-competent lentiviral vectors 
Viral titers were determined by transduction of 293T cells with serial dilutions of the 
supernatants. 7.5x104 cells/well were seeded in 6-well tissue culture plates the day before. The 
same day of the titration, cell number in each well was determined. Serial dilutions of the IDLV 
supernatants were prepared in IMDM-based complete medium starting from 10-3 to 10-7 and 
then used to transduce 293T cells. After 10-15 days, cells were collected. 
The titration was performed as described with the IDLV vectors in the section 4.1. Materials 
and methods. 
Cap A(n)R U5 PBS L Transgene PPT ΔU3 R
R U5 PBS L Transgene PPT ΔU3 RΔU3 U5
5’ LTR 3’ LTR
5’ End 3’ End
Viral RNA genome
Integrated or episomal provirus
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5. Gene editing protocol 
5.1. Gene editing in lymphoblastic cell lines 
5.1.1. Using donor as plasmid 
2x105 LCLs cells from healthy donors or FA patients were nucleofected with 2 µg of each donor 
plasmid and half of the conditions also with 1.5 µg of total in vitro synthetized mRNA (0.75 µg 
of each ZFN pair) using the SF Cell Line 4D-Nucleofector® X Kit (Lonza). Ten days post 
nucleofection cells were harvested to conduct: flow cytometry, to analyze the percentage of 
GFP positive cells; integration analysis in the bulk population by PCR (see section 7.1. Materials 
and methods) and also the nuclease functional assay (see section 6. Materials and methods). 
5.1.2. Using donor as integrase-defective lentiviral vector 
Gene editing protocol for LCLs is shown in Figure 21. Briefly, 2x105 LCLs cells from healthy 
donors or FA patients were transduced with the corresponding IDLV at a MOI of 50 in a 96-well 
culture plate in a final volume of 100 µL. One day after transduction, cells were collected, 
washed in order to eliminate the viral particles and nucleofected with 1.5-6 µg of total in vitro 
synthetized mRNA (0.75-3 µg of each ZFN pair) depending on the ZFN production, using the SF 
Cell Line 4D-Nucleofector® X Kit (Lonza). Ten days post nucleofection (day 12 of the protocol) 
cells were harvested to conduct: flow cytometry to analyze the percentage of GFP positive 
cells; integration analysis in the bulk population by PCR (see section 7.1. Materials and 
methods) and also the nuclease functional assay (see section 6. Materials and methods). 
Figure 21: Schematic representation of the gene editing protocol in LCL cells. 
5.2. Gene editing in CD34+ cells from healthy donors and 
Fanconi anemia patients 
Gene editing protocol used in UCB CD34+ is shown in Figure 22. Briefly, purified CD34+ cells 
from healthy donor UCB or FA patients were prestimulated during 48 or 24 hours respectively, 
with corresponding hematopoietic cytokines at a density of 106 cells/mL. Then, 105 cells were 
transduced with the corresponding IDLV at a MOI of 100 in a 96-well culture plate in a final 
volume of 100 µL. One day after transduction cells were collected and washed in order to 
eliminate the viral particles and they were nucleofected with 6 µg of total in vitro synthetized 
mRNA (3 µg of each ZFN pair) using the P3 Primary Cell 4D-Nucleofector X Kit (Lonza). 24 hours 
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after nucleofection 900 cells from healthy donors or 10,000 cells from FA-A patients per M35 
plate were seeded in methylcellulose (StemMACSTM HSC-CFU complete with Epo, Miltenyi 
biotech) to perform the clonogenic assays (see section 5.2.2. Materials and methods). Three 
days post nucleofection (at day 7 of the protocol) the first flow cytometry analysis was 
performed as described in the section 5.2.1. Materials and methods. At day 11, 105 cells were 
harvested to perform the nuclease functional assay (see section 6. Materials and methods). 
Finally, at day 14 cells were harvested to conduct the second flow cytometry analysis and the 
integration analysis in the bulk population (see section 7.1. Materials and methods). 
Figure 22: Schematic representation of the gene editing protocol in CD34
+
 cells. 
5.2.1. Flow cytometry analysis in gene edited cells 
1-5x104 cells were collected and resuspended in flow cytometry buffer (PBS containing 0.5% 
BSA and 0.05% azide) to stain during 30 minutes at 4°C with CD34 PE-Cy7, CD133 PE and CD90 
APC (Table 6). Then, cells were washed and resuspended again in the flow cytometry buffer 
containing 1 µg/mL 4',6-diamidino-2-phenylindole (DAPI) as a viability marker. 
Antibody Clone Supplier 
CD34 PE-Cy7 4H11 eBioscience 
CD133 PE AC133 MACS 
CD90 APC 5E10 BD 
Table 6: List of antibodies used in flow cytometry for analysis of CD34
+
 gene targeted cells. 
Analysis was performed in the LSR Fortessa cell analyser (BD/Becton, Dickinson and Company, 
New Jersey, USA). Off-line analysis was conducted with the FlowJo Software v7.6.5 (Tree star, 
Ashland, USA). In this analysis the percentage of GFP+ cells was measured in the total 
population of cells and also in the different subpopulations of differentiated and progenitor 
cells. Gating strategy is shown in Figure 23: firstly, double positive CD34+ CD133+ cells were 
selected and, inside the double positive cells the percentage of CD90 positive and negative 
cells were selected. The most primitive compartment corresponds to the positive cells to the 
three markers (CD34+ CD133+ CD90+), followed by early progenitors (CD34+ CD133+ CD90-), 
committed progenitors (CD34+ CD133 – CD90-) and finally, differentiated cells (CD34-)113. 
1
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Figure 23: Gating strategy for the analysis of the different subpopulations of hematopoietic progenitor 
cells after gene editing. 
5.2.2. Clonogenic assays 
900 HD or 10,000 FA-A CD34+ cells depending on the experiment were resuspended in 3 mL of 
methylcellulose. Each mL of the triplicate was seeded in a M35 plate and cells were incubated 
as shown in Table 3. Fourteen days later the number of colonies was counted using an inverted 
microscope (Olympus IX70 WH10x/22, objective 4x). CFUs-GMs (granulocyte-macrophage 
colonies) and BFU-Es (erythroid colonies) were identified. 
Single colonies were picked to analyze the specific integration of the recombination cassette in 
the AAVS1 locus. 
6. Nuclease functional assay (Surveyor 
assay) 
This assay determines the percentage of NHEJ efficiency by Surveyor nuclease assay in samples 
that were treated with the ZFNs. Firstly DNA of these cells was extracted using NucleoSpin® 
Tissue kit. Then, a PCR was performed to amplify the homology region of the AAVS1 locus in 
which the ZFNs cut. The primers used in this PCR are NHEJ Fw (5’ CTTCAGGACAGCATGTTTGC 
3’) and NHEJ Rv (5’ ACAGGAGGENE TARGETINGGGGGTTAGAC 3’). The PCR was performed with 
2 ng/µL of DNA, 1 µM of each primer, 1x Taq Extender Buffer, 0.12 U/µL Taq Extender PCR 
Additive (both from Agilent Technologies, Santa Clara, CA, USA), 0.12 U/µL AmpliTaq Gold DNA 
polymerase (Applied Biosystems) and 0.24 mM dNTPs (Invitrogen) in a final volume of 50 µL. 
The cycling conditions are the following: 95°C 10 minutes, 40 cycles of 95°C 45 seconds, 62°C 
45 seconds and 72°C 45 seconds, and finally one cycle of 72°C 10 minutes. This PCR amplifies a 
224 bp product that is then dehybridize and rehybridaze in order to obtain heteroduplexes 
that can be formed with a WT DNA strand, coming from a cell in which the ZFNs do not cut, 
and a mutant DNA strand, coming from a cell in which the ZFNs cut and this cut was repaired 
Flow cytometry 
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by NHEJ, generating small insertions or deletions (INDELS). If an INDEL has occurred the 
heteroduplex presents a DNA hairpin that can be recognized by the Surveyor® nuclease 
(Surveyor® mutation detection kit (IDT, Coralville, Iowa, USA)) and cut, generating a band 
pattern that could be visualized on 10% TBE Gels 1.0 mm (Invitrogen) (Figure 24). Images from 
gels were analyzed in order to measure the cleavage fraction using Image J software (it 
measures the densitometry value of the different bands). The percentage of cleavage is 
determined by the next equation:  
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Figure 24: Representative image of Surveyor nuclease assay from one of the gene editing experiments 
in which a bulk population and also a pool of colony forming cells (CFCs) were assay. The parental 
band of 224 bp is shown and also the two cleavage bands formed after nuclease treatment (132 and 91 
bp). 
7. Analysis of the specific integration in 
the AAVS1 locus 
These assays allow us to confirm that the integration has occurred in the right place: the 
AAVS1 locus.  
7.1. PCRs 
After gene editing assay, genomic DNA from bulk populations was extracted using NucleoSpin® 
Tissue kit. Single colonies were pelleted and resuspended in 10 µl of PBS. Their gDNA was 
extracted using 20 µl of lysis buffer  (0.3 mM Tris HCl pH 7.5, 0.6 mM CaCl2, 1,5 % Glycerol , 
0.675 % Tween-20  and 0.3 mg/ml Proteinase K) and incubated at 65°C for 30 min, 90°C for 10 
min and  4°C. After lysis, 30 µl of water was added, as previously described302. 
Two PCRs were conducted both for the 5’ and 3’ ends of the target integration site. A different 
pair of primers was used depending on the vector that was used as a donor template, but in all 
cases one of them hybridizes in the AAVS1 locus, outside of the HA, and the other in the donor 
Nuclease functional assay 
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(Figure 25). Using this approach amplification can only be detected when donor template is 
integrated in the AAVS1 locus. 
Figure 25: Representative figure of PCRs to confirm the targeted integration. The arrows indicate the 
different primers used. 
PCR reactions were conducted using 100 ng of gDNA from bulk populations or 10 µL of gDNA 
from single colonies. PCRs from the 5’ and 3’ ends were performed with 1 µM of each primer 
(Table 7), 1x Taq Extender Buffer, 0.12 U/µL Taq Extender PCR Additive, 0.12 U/µL AmpliTaq 
Gold DNA polymerase and 0.24 mM dNTPs in a final volume of 25 µL. The conditions for the 
PCR were: 95°C 10 minutes, 40 cycles of 95°C 45 seconds, Tm 45 seconds and 72°C 2 minutes, 
and finally one cycle at 72°C 10 minutes. 
Primer Region  Sequence (5’ to 3’) Tm 
(°C) 
PCR product 
size (bp) 
GFP donor IDLV 5’ Fw AACTCTGCCCTCTAACGCTGC 59 1041 
Rv ACGTGAAGAATGTGCGAGACCCAG 59 
3’ Fw AACGGGGATGCAGGGGAACG 59 997 
Rv TTGCATCGCATTGTCTGAGTAGG 59 
FANCA-Puro 
donor IDLV 
5’ Fw AACTCTGCCCTCTAACGCTGC 59 1041 
Rv ACGTGAAGAATGTGCGAGACCCAG 59 
5’ Fw ACTTCCCCTCTTCCGATGTT 54 1230 
Rv GACGTGAAGAATGTGCGAGA 54 
GFP-FANCA 
donor IDLV 
5’ Fw AACTCTGCCCTCTAACGCTGC 59 1217 
Rv TGGTGCAGATGAACTTCAGGG 59 
3’ Fw AACGGGGATGCAGGGGAACG 59 997 
Rv TTGCATCGCATTGTCTGAGTAGG 59 
3’ Fw AAAGCTCGTCTTTTTCTGCTGCAGT 59 1332 
Rv TTGCATCGCATTGTCTGAGTAGG 59 
Table 7: PCR primers used to amplify the targeted integration in the AAVS1 locus of the different 
donor constructs. 
7.2. Vector copy number of donor construct in targeted 
cells 
Q-PCR was used to determine the VCN in gene targeted cells and also in samples from 
different organs from mouse engraftment experiments using gDNA as template. gDNA was 
extracted with NucleoSpin® Tissue kit. This template was amplified using specific primers listed 
in Table 8. Q-PCR amplification was performed in a 7500 fast real-time PCR system using 
TaqMan and fluorescent probes that were acquired from Sigma and are listed in the Table 8. 
 
AAVS1 locus
Promoter Exon 1 Exon 2PPP1R12C gene
Gene targeted PPP1R12C gene Promoter Exon 1 Donor Template Exon 2
5’ Fw
3’ Fw
5’ Rv
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Primer/Probe Sequence (5’ to 3’) Tm (°C) 
FANCA Fw GCTCAAGGGTCAGGGCAAC 58 
Rv TGTGAGAAGCTCTTTTTCGGG 60 
Probe [FAM]-CGTCTTTTTCTGCTGCAGTTAATACCTCGGT-[BHQ1] 70 
GFP Fw GTAAACGGCCACAAGTTCAGC 61 
Rv TGGTGCAGATGAACTTCAGGG 61 
Probe [FAM]-CTTGCCGTAGGTGGC-[BHQ1] 43.9 
Psi Fw TCCCCCGCTTAATACTGACG 59 
Rv CAGGACTCGGCTTGCTGAAG 63 
Probe [FAM]-CGCACGGCAAGAGGCGAGG-[BHQ1] 75.7 
hAlb Fw GCTGTCATCTCTTGTGGGCTG 64 
Rv ACTCATGGGAGCTGCTGGTTC 63 
Probe [TxRd]-CCTGTCATGCCCACACAAATCTCTCC-[BHQ2] 73.9 
Table 8: Q-PCR primers and probes used to determine VCN by Q-PCR. 
8. Functional assays in gene edited cells 
These assays were performed in order to determine the functionality of the FANCA gene in 
cells targeted by gene editing. 
8.1. Nuclear foci formation 
Cells were seeded in chamber slides (Nunc, Sigma) pre-coated with retronectin® (20 µg/cm2 
during 24 hours at 4°C (Takara bio inc., Japan)) at confluence. 24 hours later cells were treated 
with 40 nM MMC (Sigma) for 16 hours to induce DNA damage and foci formation. Then, cells 
were washed with PBS 1X and fixed with 3.7% paraformaldehyde (Sigma) 15 minutes at room 
temperature. Cells were washed 3 times with TBS 1X (20 mM Tris-HCl + 140 mM NaCl) and 
permeabilized using 0.5% Triton X100 (Sigma) during 10 minutes, washed again and blocked 
with blocking solution (0.1% Nonidet-P40 (Sigma) + 10% Hyclone) during 45 minutes.  Cells 
were incubated over night at 4°C in a humidity chamber with the primary antibody against 
human FANCD2 (ab2187-50, Abcam, Cambridge, UK) or human RAD51 (ab46981-100, Abcam) 
diluted 1:250 in blocking solution. Cells were washed 3 times with TBS 1X and then incubated 
during one hour with the secondary antibody IgG against rabbit, conjugated with TexasRed 
(711-075-152, Jackson ImmunoResearch, West Grove, PA, USA) 1:500 dilution and DAPI 
(Roche) 1:1,000 dilution in blocking buffer. Finally cells were washed 3 times in TBS 1X and 
slides were mounted with Moviol. 
Samples were visualized with a fluorescence microscope Axioplan 2 imaging (Carl Zeiss, Jena, 
Germany) with the objective 0.17 mm and 100x/1.45 magnification. Two hundred cells were 
counted and cells with more than 10 foci were analyzed in each sample. Images were captured 
with AxioCam MRm (Carl Zeiss) and processed with AxioVision 4.6.3 (Carl Zeiss) and Corel 
Photo-Paint 11 (Corel, Ottawa, Ontario, Canada). 
8.2. hFANCA expression by western blot 
Western blot analysis was performed to determine the expression of the human FANCA 
protein in LCLs samples transduced with the FANCA-Puro donor vector. Protein was extracted 
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from 107 cells per condition using: 20 mM Hepes-NaOH, 12.5% glycerol, 0.4 M NaCl, 1 mM 
EDTA, 1 mM EGTA, 1 mM PPiNa, 20 mM FNa, 1 mM orthovanadate and 1x protease inhibitors 
(Mini-complete, Roche). Samples diluted in the extraction buffer were frozen in liquid nitrogen 
and warmed in a thermoblock at 37°C five times, then 1% of Nonidet-P40 was added and 
samples were shaken at 4°C during 15 minutes. Finally, samples were centrifuged and the 
supernatant, in which the proteins are, was collected.  Protein quantification was carried out 
using Bradford method (BioRad, Hercules, CA, USA) in a spectrophotometer. 
Fifty µg of each sample was used in NUPAGE 4-12% Bis-Tris poliacrilamyde gels (Novex/Life 
Technologies/Thermo Fisher Scientific, Waltham, USA) in redox and denaturing conditions with 
MOPS buffer (NuPAGE, Novex). Electrophoresis was run for 7 hours at 4°C and 100 V. Then, 
samples were transferred to PDVF membrane during 2 hours at 90 V and 4°C in transfer buffer 
(NuPAGE). After the transference blocking of unspecific binding sites was performed with 5% 
powder milk diluted in TBS-T buffer (TBS 1X + 0.1% Tween) in agitation at RT during 1 hour. 
Then the membrane was stained with anti-hFANCA antibody produced in rabbit (ab5063, 
Abcam) (1:1,000 dilution in 0.5% milk TBS) or anti-β-actin antibody produced in mouse 
(ab6276, Abcam) (1:4,000 dilution in 0.5% milk TBS) over night at 4°C. The membrane was 
washed with TBS-T buffer three times and then was incubated with 1:5000 dilution in 0.5% 
milk TBS of the secondary antibody anti-rabbit (pAb to Rb IgG-HRP, ab6721-1, Abcam) anti-
mouse (Shp pAb to Ms IgG-HRT ab6808, Abcam) during 1 hour at RT. Finally, the membrane 
was washed three times with TBS-T. 
Membranes were developed by chemiluminiscence signal detection (SuperSignal West Pico 
Chemiluminescent Substrate, Thermo Scientific, Pierce, USA) through photography film 
(Amersham, UK) exposure in an automatic developer (Curix60, AGFA, Mortsel, Belgium). 
8.3. MMC resistance 
Gene targeted LCLs were evaluated in order to see the reversion of the phenotype. After the 
gene targeting protocol (see section 5.1. Materials and methods) 5x104 cells were seeded in 24 
well plates in a final volume of 1 mL and increasing concentrations of MMC were used (from 0 
to 1,000 nM). Cell viability was determined 5 to 15 days after by flow cytometry using DAPI 
vital marker in a LSRFortessa cell analyser and the off-line analysis was performed with the 
FlowJo Software v7.6.5. 
8.4. Transplant in immunodeficient mouse 
NOD.Cg-PrkdcscidTg (hSCF/hGM-CSF/hIL3) (NSG-SGM3) mice were used in these experiments. 
Mice were sublethally irradiated with 1.5 Gy the day before transplant. 4.5x105 CD34+ cells in 
which gene editing had been conducted (see section 5.2. Materials and methods) were 
transplanted through the tail vein at day 6 of the experiment (Figure 26). 30 and 60 days after 
transplant bone marrow (BM) aspiration was performed to analyze the human hematopoietic 
engraftment and the percentage of gene edited cells by flow cytometry analysis of hCD45 APC 
and hCD34 PE. 90 days post-transplant (dpt) mice were sacrificed and peripheral blood (PB), 
spleen and BM were collected. These organs were processed and stained to analyze human 
reconstitution, the percentage of gene targeted cells and also multilineage engraftment by 
flow cytometry using different antibodies (Table 9). The percentage of gene targeted cells and 
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the multilinage engraftment of the different subpopulations was analyzed in the hCD45+ 
fraction as it is shown in Figure 27. 
Figure 26: Protocol used to analyze the engraftment capacity of gene edited cells in immunodeficient 
mice. BM: bone marrow; dpt: days post-transplant. 
Antibody Clone Supplier 
hCD34 APC 581 BD 
hCD45 APC-Cy7 HI30 BioLegend 
hCD33 PE-Cy7 P67.6 BD 
hCD3 APC UCHT1 BioLegend 
hCD19 PE-Cy7 SL25C1 eBioscience 
hCD45 APC 2D1 eBioscience 
hCD34 PE 8G12 BD 
Table 9: Antibodies used to determine the multilineage human engraftment in immunodeficient mice 
transplanted with gene targeted cells.  
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Figure 27: Multilineage analysis in BM and spleen of NSG-SGM3 mice. hCD45
+
 cells were selected and 
hCD3
+
, hCD19
+
, hCD33
+
, hCD34
+
 and GFP were gated in this population. Finally, GFP positive cells were 
also analyzed in the different
 
subpopulations. 
Human CD45+ cells from BM of these animals were purified using immunomagnetic selection 
beads anti-hCD45+ (MACS). 105 cells were used in clonogenic assays (see section 5.2.2. 
Materials and methods). 
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9. Gene targeting improvement 
9.1. Improvement of homology directed repair efficiency by 
PARI inhibition 
9.1.1. Improvement of gene editing in lymphoblastic cell lines 
2x105 HD or FA LCLs were nucleofected with 25 pmol of a mix of three different PARI iRNAs (5’ 
GGCAGAGAUACUGUGAAAGCCUUAU 3’; 5’ CCAUCAUCAUGGAACGUCUAUUCUU 3’; 5’ 
CAGUGAUAAAGAUGCAACUGAUUAA 3’) (Stealth, Invitrogen) using SF Cell Line 4D-
Nucleofector® X Kit. As iRNA control we used Block-iT™ (Invitrogen).  
To verify that PARI inhibition correlates with inhibition of HR, RAD51 foci were stained as 
described in section 8.1 Materials and methods. 
Gene editing experiments were conducted 24 hours after the nucleofection using MOI 50 of 
GFP donor IDLV and 1.5 µg of pVAX ZFN pair as mRNA as described in section 5.1.2. Materials 
and methods. 
9.1.1.1. Analysis of PARI inhibition 
PARI interference was evaluated by Q-PCR two days after transfection. Cells were collected; 
RNA was extracted using High Pure RNA isolation kit (Roche) and RT-PCR was performed using 
RETROscript® First Strand Synthesis (Ambion). Finally, Q-PCR was conducted using SYBRGreen 
FastStart Universal SYBR Green Master PCR master mix (Roche) in Rotor Gene 6000 (Corbet, 
Australia) with specific primers (Table 10). 
Primer Sequence (5’to 3’) Tm (°C) 
PARI Fw TGTAGCTCTTAGCACCACTGACA 63 
Rv CCATGGTTTATGGCATGAGA 56 
β-Actin Fw ATTGGCAATGAGCGGTTCC 54.7 
Rv CACAGGACTCCATGCCCA 51.9 
Table 10: Primers to measure the inhibition of PARI by Q-PCR. 
9.1.1.2. Chromosomal stability analysis 
The possible increment in genomic instability produced by PARI inhibition was studied in 
metaphases of interfered cells. Briefly, interfered cells were treated or not during 72 hours 
with 0.1 µg/mL of diepoxybutane (DEB) (Sigma) to induce DNA damage. Then 0.1 µg/mL of 
colchemide (Gibco) was added to the culture media and cells were incubated for 4 hours to 
induce a block of cell division in metaphase. At that time cells were treated with 0.56% of KCl 
(0.075M) to provoke an osmotic shock. Finally, cells were fixed with methanol:acetic acid (4:1) 
solution and dropped onto clean slides. Metaphases were stained with 1% Giemsa stain, and in 
a total of 25-40 metaphases per sample, chromosomal aberrations were counted. 
9.1.2. Improvement of gene editing in fibroblasts 
Human fibroblasts immortalized with hTert were interfered with a single PARI iRNA (5’ 
GGCAGAGAUACUGUGAAAGCCUUAU 3’) (Stealth, Invitrogen) in order to increase the efficiency 
of HDR. As iRNA control Block-iTTM was used. Two rounds of transfection with 25 pmol of iRNA 
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were performed every 24 hours using Lipofectamine 2000 (Invitrogen), according to 
manufacturer instructions. PARI interference was evaluated by Q-PCR two days after the last 
transfection as it is described in section 9.1.1.1. Materials and methods. 
One day after the last transfection the gene targeting was performed, transduction was done 
with MOI 5 of GFP donor IDLV. The day after 5x105 cells were nucleofected with 3 µg of total 
pVAX ZFNs as mRNA (1.5 µg of each ZFN) using Amaxa® Human Dermal Fibroblast 
Nucleofector® Kit (NHDF) (Lonza). Finally the percentage of GFP positive cells was measured by 
flow cytometry 3 and 10 days after nucleofection. 
9.2. Gold nanoparticles to improve transduction efficiency 
CD34+ cells purified from UCB were prestimulated during 48 hours as previously described. The 
integrative competent and integrase-defective version of the GFP donor lentivirus were 
incubated one hour at room temperature with 4-8 nM of gold nanoparticles (AuNP) coated 
with positive charge and conjugated with TAMRA fluorescence protein. AuNPs were gently 
provided by Dr. Jesús M. de la Fuente (Instituto de nanociencia de Aragón, Zaragoza, Spain). 
Then 5x104 CD34+ prestimulated cells were transduced with different MOIs of these lentiviral 
vectors, previously incubated or not with the AuNPs. One day after transduction cells were 
washed. 
Cell viability was measured by DAPI exclusion in flow cytometry analysis performed one and 
two days after treatment, and also by trypan blue under microscope in which the proliferation 
rate was calculated by the number of living cells counted divided by the number of cells 
seeded the day before. 
Transduction efficiency was measured by flow cytometry analysis of TAMRA and GFP 
expression. In the case of cells transduced with IDLV vectors these parameters were measured 
1 and 2 days post transduction and in the case of the ICLV the transduction efficiency was 
measured 2 and 12 days post-transduction. 
9.2.1. Evaluation of human transduced cells engraftment in NSG 
mice 
One day after transduction, 250,000 cells that had been transduced with the GFP donor ICLV, 
either alone or with the AuNPs, were transplanted through the tail vein in NOD.Cg-Prkdcscid 
IL2rgtm1Wjl/SzJ (NSG) mice that had been sublethally irradiated the day before transplant 
with 1.5 Gy. Analysis of human engraftment was conducted as previously described in the 
section 8.4. Materials and methods. The thymus was also collected at the end point of the 
experiment, processed and analyzed using the antibodies listed in Table 11. In this organ the 
analysis of CD4+ and CD8+ subpopulations is done inside the CD3+ subpopulation as it is shown 
in Figure 28. 
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Figure 28: Multilineage analysis in the thymus of NSG mice. hCD3
+
 cells were analyzed in the hCD45
+
 
cells. GFP positive cells were gated in h CD45
+
 and hCD3
+
 populations. hCD4
-
 hCD8
-
, hCD4
+
 hCD8
+
, hCD4
+
 
hCD8
-
 and hCD4
-
 hCD8
+
 were gated inside hCD3
+
 population. Finally, the GFP population inside all this 
subpopulations was analyzed. 
Antibody Clone Supplier 
hCD3 PE-Cy7 UCHT1 BioLegend 
hCD4 APC MT466 Miltenyi Biotech 
hCD8 PE B9.11 Immunotech 
Table 11: List of antibodies used to determine multilineage engraftment in the thymus of 
immunodeficient mice transplanted with gene targeted cells. 
Secondary transplants were conducted using 80% of bone marrow from primary recipients. 
Animals were transplanted one to one into sublethally irradiated recipients (1.5 Gy dose the 
day before). 
Analysis of these secondary recipients was performed as previously described in section 8.4. 
Materials and methods. 
MATERIALS AND METHODS 
68 
 
10. Statistical analysis 
The statistical analysis was performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, USA). For the analyses of experiments in which n<5, a non-
parametric two-tailed Mann-Whitney test was performed when two variables were compared 
or Kruskal-Wallis with Dunn’s multiple comparison test when more than two variables were 
compared. In the experiments in which n≥5, a Kolmogorov-Smirnov test was done to test the 
normal distribution of the samples. If samples showed a normal distribution, a parametric two-
tailed paired T-test was performed when two variables were compared or an ANOVA with 
Bonferroni’s multiple comparison test when more than two variables were compared. If 
samples did not follow normal distribution, the previously mentioned non-parametric tests 
were used. The significances are indicated as p<0.05 (*), p<0.01 (**) and p<0.001 (***). 
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1. Gene targeting with a reporter and 
therapeutic FANCA genes in healthy 
donor hematopoietic cells 
1.1. Analysis of gene targeting efficiency in lymphoblastic 
cell lines 
1.1.1. Evaluation of ZFN efficiency in lymphoblastic cell lines 
The activity of two different in vitro synthetized mRNA constructs, TEV and pVAX, carrying the 
left and right ZFNs targeting the AAVS1 locus was tested in a healthy donor (HD) lymphoblastic 
cell line (LCL) (C4) (Figure 29). The principal difference between both constructs is that TEV 
presents two regulatory regions: 5’ UTR from the TEV and 3’ UTR from human β-globin; 
whereas the pVAX construct does not present any regulatory region. The indicated doses 
represent the total amount of left and right ZFNs for each construct. For example, the 3 µg 
dose means that cells were nucleofected with 1.5 µg of the right ZFN and 1.5 µg of the left 
ZFN. Nucleofected cells were harvested five days later to measure the activity of ZFNs using 
the Surveyor assay. In all instances, the efficacy of pVAX ZFN pair was higher, with more than 
50% of insertions/deletions (INDELs) representative of NHEJ repair.  
Figure 29: Surveyor assay of C4 LCL with different doses of pVAX and TEV ZFNs. a) Electrophoresis gel 
corresponding to the Surveyor assay. The parental band (224 bp) and two processed bands (132 and 91 
pb) are highlighted. b) Quantification of the percentage of INDELs calculated by measuring the ratio of 
the processed and parental bands using the ImageJ software. 
Thereafter, a gene targeting experiment using a GFP donor packaged in an IDLV was 
performed in this cell line to verify the efficiency of HDR using different doses of each ZFN pair. 
Consistent with the results of the Surveyor assay, higher percentages of gene targeting 
(measured as the percentage of GFP+ cells at day 12 of culture) were achieved when the pVAX 
ZFN pair was used (Figure 30 b). Only with the highest dose of the pVAX ZFN pair, gene 
targeting was low, most probably due to the toxicity associated to this dose (Figure 30 a). 
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Figure 30: Efficiency of different ZFN pairs in gene targeting experiments using a healthy donor LCL. 
Cells were nucleofected with different amounts of each ZFN pair. The viability and percentage of GFP
+
 
cells was measured. a) Percentage of alive cells 3 days after nucleofection measured by DAPI exclusion in 
flow cytometry analysis. b) Percentage of GFP positive cells evaluated by flow cytometry analysis in the 
different experimental conditions at day 12 of culture. 
The integration in the AAVS1 locus was analyzed by PCR in the samples with the highest 
percentage of GFP+ cells (3 µg in the case of TEV pair and 1.5 µg in the case of pVAX pair). The 
PCR was conducted in the bulk population using primers that hybridize in the endogenous 
locus of the AAVS1, outside of the homology arms (HAs), and inside the donor construct, both 
for the 5’ and the 3’ integration ends (Figure 31 a). As it was expected there was only 
amplification of the specific bands in the samples that were treated with the donor and the 
ZFNs (Figure 31 b). Although in the sample targeted with pVAX ZFNs only the band of the 3’ 
end was amplified, this could be due to the PCR reaction as in the rest of the experiments we 
were able to amplify this band. Taking into account the higher efficiency of gene targeting 
using pVAX construct, we selected this ZFN pair as the construct for the rest of the 
experiments conducted using LCLs. 
Figure 31: Representative PCR of integration in the AAVS1 locus using GFP donor IDLV in a HD LCL. a) 
Gene targeting of the GFP donor IDLV into the AAVS1 locus. The arrows represent different primers used 
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to detect the specific integration. b) Integration was confirmed in C4 LCL after gene editing in both the 5’ 
and 3’ ends (except for the 5’ end of the pVAX sample). HA: homology arm. Fw: forward. Rv: reverse. N: 
negative control. 
The fact that mRNA transfection mediated a high and transient expression of the ZFNs, 
reducing the risk of random insertion, led us to select the pVAX mRNA to perform the rest of 
the experiments. 
1.1.2. Selection of the donor delivery system: plasmid DNA versus 
IDLV 
In order to test the efficacy of the donor construct delivered as plasmid DNA in HD LCLs (C4), 
we nucleofected these cells with our GFP donor plasmid and the ZFN mRNA. When the donor 
was delivered as plasmid DNA, flow cytometry analysis conducted at day 12 of culture revealed 
that 2.99±0.22% of the population was GFP+. Very small population of cells (0.18±0.01%) were 
GFP+ when only the donor plasmid was used, suggesting that random integration was 
occurring in a low proportion of cells (Figure 32 a). The mean percentage of INDELs measured 
by Surveyor assay in samples nucleofected with the plasmid GFP donor and the ZFNs was 
51.43±1.97%. 
The PCR integration analysis of cells nucleofected with the donor plasmid confirmed the 
specific integration in the AAVS1 locus only when the samples were nucleofected with the 
donor and the ZFNs (see PCRs for both integration ends. Figure 32 b). 
Figure 32: Gene targeted HD LCL (C4) using the donor as plasmid DNA. a) The percentage of GFP
+
 cells 
was analyzed by flow cytometry at day 12 of cell culture. Bars represent the mean and standard 
deviation (SD). n=2. b) PCR of the integration in the AAVS1 locus for the 5’ and 3’ ends. 
Trying to improve the gene editing efficiency and also to minimize the random integration, we 
also tested the donor as an IDLV. Several independent experiments were performed in LCLs 
from two HDs (CP1 (n=5) and C4 (n=6)). The percentage of GFP+ cells was measured at day 12 
of cell culture after transduction only with the GFP donor IDLV, or also nucleofected with the 
ZFNs mRNA. The combination of the GFP donor IDLV and the ZFNs mRNA led to higher 
percentages of GFP+ cells than when the donor plasmid was used, reaching a 5.13% of GFP+ 
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cells in CP1 and 9.22% in C4 LCLs. The use of GFP donor IDLV alone also generated a low 
random integration of the donor cassette, measured by the presence of GFP+ cells (0.1% in CP1 
and 0.24% in C4 LCLs) (Figure 33). Moreover, the efficiency of the gene targeting process was 
cell line dependent, as the percentage of CP1 GFP+ cells (5.13±2.18%) were significantly lower 
than the percentage of C4 GFP+ cells (9.22±4.1%). 
Figure 33: Gene targeting of GFP in HD LCLs using IDLVs. Two different HD LCLs were targeted using a 
GFP donor IDLV. The percentage of GFP
+
 cells was evaluated by flow cytometry at day 12 of culture. Bars 
represent the mean with SD. n=5 in CP1 and n=6 in C4. The significance of differences between groups is 
calculated using T-test, p<0.01 (**). 
To verify that the integration took place in the AAVS1 locus, a PCR in the 5’ and 3’ ends of 
nucleofected cells was performed. PCR products confirmed the integration in the specific locus 
in both cell lines (Figure 34). 
Figure 34: Representative PCR of the integration of the GFP transgene integrated in the AAVS1 locus in 
HD LCLs. Gene targeting was conducted in CP1 and C4 LCLs and the PCR for the targeted integration of 
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the GFP donor IDLV in the 5’ and 3’ ends was conducted in the bulk population at day 12 of cell culture. 
Top: CP1 PCR for AAVS1 specific integration. Bottom: C4 PCR for AAVS1 specific integration. 
As PCR is the main test to verify if the integration is site-specific, we analyzed the detection 
limit of this assay using the GFP donor IDLV. Serial dilutions of the DNA from gene targeted C4 
LCL, in which the percentage of gene targeting measured by flow cytometry was 11%, were 
analyzed by PCR. As shown in Figure 35, a detection limit of 2.25% gene targeting (GFP+ cells) 
was observed in this PCR assay, indicating that levels of gene targeting lower than this 
percentage will not be detectable in bulk populations by this technique. 
Figure 35: Detection limit analysis of PCRs used to evaluate the specific integration of GFP donor IDLV 
in the AAVS1 locus. C4 LCL was gene targeted using GFP donor IDLV and the percentage of gene 
targeting was evaluated by flow cytometry at day 12 of culture. Cells were harvested and DNA from the 
bulk population was extracted. Serial dilutions of this DNA were used to conduct the PCR from the 5’ end 
to determine the limit of detection of the assay. N: negative control. 
1.1.3. Gene targeting efficiency of a GFP-FANCA donor IDLV in LCLs 
Aiming to evaluate the integration efficacy of the therapeutic GFP-FANCA donor, previously 
used to correct the phenotype of fibroblasts from FA-A patients75, C4 LCLs were targeted using 
this donor IDLV vector and two different ZFN constructs (pVAX and TEV). Once integrated in 
the AAVS1 locus the GFP expression is driven by the endogenous promoter of the AAVS1 locus, 
while FANCA expression is driven by PGK promoter. Surprisingly, when these cells were 
analyzed by flow cytometry at day 12 of culture, GFP+ cells could not be easily detected (Figure 
36). Nevertheless, cells targeted with PGK-GFP construct showed evident GFP expression, 
suggesting a very weak activity of the AAVS1 endogenous promoter in LCLs, in comparison 
with the exogenous PGK promoter used in the GFP donor vector.  
Figure 36: Representative dot plot of C4 LCLs gene edited with GFP-FANCA or GFP donor IDLVs using 
the pVAX or TEV ZFN constructs. HD LCLs were targeted using GFP-FANCA and GFP donor IDLVs 
RESULTS 
76 
 
respectively with the two different ZFN pairs. The percentage of GFP positive cells was evaluated at day 
12 of culture by flow cytometry. Images were obtained using FlowJo Software. 
Despite the difficulty to detect GFP+ cells when the GFP-FANCA donor IDLV was used, we 
investigated the integration of this construct in the AAVS1 site (Figure 37 a). All the PCRs 
showed the integration of the donor cassette in the AAVS1 site (Figure 37 b), indicating that 
the almost complete absence of GFP expression should be a consequence of the low 
expression driven by the AAVS1 promoter. 
Figure 37: Representative PCR of the integration in the AAVS1 locus of GFP-FANCA donor used as IDLV. 
a) Schematic representation of the GFP-FANCA donor specifically integrated in the AAVS1 locus. The 
arrows represent the primers used to evaluate if integration was site-specific. b) C4 LCLs were targeted 
and the PCR for the targeted integration of the GFP-FANCA donor IDLV in the 5’ and 3’ ends was 
conducted in the bulk population. 
1.2. Gene targeting in primary human hematopoietic 
progenitor cells 
1.2.1. Optimization of the gene editing conditions in umbilical cord 
blood CD34+ cells 
1.2.1.1. Evaluation of the activity of two ZFNs in umbilical cord blood CD34+ cells 
Once the conditions and reagents were tested in cell lines from HD, we moved to our main 
target population, the human hematopoietic stem and progenitors cells (HSPCs), characterized 
by the expression of the CD34+ antigen in their membrane. Firstly, and as we did with LCLs, 
two different doses of both ZFNs pair constructs, used as mRNA, were evaluated in CD34+ cells 
from umbilical cord blood (UCB) using a multiplicity of infection (MOI) of 100 LVs/cell of the 
GFP donor IDLV. Analysis of GFP positive cells at day 14 of cell culture showed gene targeting 
only when the pVAX construct was used (Figure 38 a). This study also demonstrated that the 
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higher concentration of the ZFNs used in the experiments allowed us to obtain levels of GFP+ 
cells of 15.7%. The surveyor analysis of these cells confirmed that only the pVAX pair 
generated INDELs in human progenitors (Figure 38 b). Higher doses of pVAX ZFNs (up to 12 µg) 
were also tested in these cells but low percentage of GFP+ cells was observed, probably due to 
an increment in cell toxicity (Figure 38 c). 
Figure 38: Evaluation of the efficiency of ZFNs mRNA to target CD34
+
 cells. a) Percentage of GFP
+
 CD34
+
 
cells measured by flow cytometry at day 14 of cell culture, using two different doses of each ZFN pair: 
pVAX and TEV. b) Surveyor assay in gene targeting experiment showed in panel a. Size of the Surveyor 
bands and the percentage of INDELs induced by selected ZFNs are also indicated. c) Surveyor assay 
evaluating increased doses of pVAX ZFNs. Surveyor bands and percentage of INDELs are shown. 
To confirm that the GFP expression observed in CD34+ cells was due to the specific integration 
in the AAVS1 locus, integration analyses were performed by PCR in cultured cells transduced 
with the GFP donor IDLV and nucleofected with both types of ZFN pairs. As shown in Figure 39 
b; gene targeting in the AAVS1 locus only occurred when pVAX ZFNs were used. Based on 
these results we also selected the pVAX ZFN pair as the best alternative for our gene targeting 
experiments in CD34+ cells. 
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Figure 39: Integration analysis by PCR in gene targeted CD34
+
 cells using different doses of two ZFN 
constructs. a) Schematic representation of gene targeted AAVS1 locus with the GFP donor. The arrows 
represent the primers used to evaluate if integration was site-specific. b) On the left the PCR for the 5’ 
end is shown and on the right the PCR for the 3’ end. 
1.2.1.2. Influence of the donor IDLV multiplicity of infection in the gene targeting 
efficiency in CD34+ cells 
We also tested if the increment in the MOI of the vector led to an increased efficiency of gene 
targeting. UCB CD34+ cells were transduced with a GFP donor IDLV at two different MOIs (100 
and 200 LVs/cell) and nucleofected with 6 µg of the ZFNs mRNA. The gene targeting efficiency 
was evaluated at day 14 of culture, measuring the percentage of GFP+ cells by flow cytometry. 
The results showed that the increase in the donor MOI did not improve the efficiency of gene 
targeting (Figure 40 a), suggesting that the maximum level of transduction with the IDLV vector 
was reached. It was also noticeable that the increment in the vector MOI did not increase the 
random integration in CD34+ cells, as we were not able to detect GFP+ cells when the donor 
was used alone. 
Targeted integration was also evaluated in the bulk population of these samples by PCR. The 
results showed that gene targeting occurred at both MOIs (Figure 40 b). Taking into account 
these results we selected an MOI of 100 LVs/cell for the subsequent gene targeting 
experiments in CD34+ cells. 
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Figure 40: Evaluation of the donor IDLV MOI for gene targeting in CD34
+
 cells. a) Gene targeting 
efficiency was evaluated as the percentage of GFP positive cells by flow cytometry in samples targeted 
with two doses of GFP donor IDLV at day 14 of the protocol. b) On the left the PCR for the 5’ end is shown 
and on the right the PCR for the 3’ end. N: negative control. 
1.2.2. Analysis of the gene targeting efficiency with a reporter GFP 
donor IDLV in CD34+ cells 
Once all the gene targeting conditions were stablished for human hematopoietic progenitors, 
eight independent gene targeting experiments were performed in UCB CD34+ cells using a GFP 
donor IDLV together with ZFNs mRNA to evaluate the feasibility and reproducibility of the 
technique. Gene targeting efficiency was evaluated by the percentage of GFP+ cells measured 
by flow cytometry in cells cultured for 7 and 14 days. As shown in Figure 41, GFP+ cells were 
only detected when the donor and the ZFNs were combined. Mean values of 9.99±4.3% and 
10.42±4.92% of gene edited cells were observed in samples cultured for 7 and 14 days 
respectively, confirming the efficacy of the gene targeting approach. 
Figure 41: Gene targeting efficiency in HD CD34
+
 cells measured by flow cytometry. The percentage of 
GFP
+
 cells is shown. Bars represent the mean with SD. n=8. The significance of differences between 
groups is calculated using the T-test, p<0.001 (***). 
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Gene targeting efficiency was also measured in different hematopoietic subpopulations 
analyzed at day 7 and 14 of culture (see section 5.2.1. Materials and methods) (Figure 42 a, b). 
Although the highest percentage of GFP+ cells was obtained in the most differentiated 
population (CD34-) (12.62±4.19% of GFP+ cells at day 7 of culture); 6.2±4.74% of the primitive 
progenitors (CD34+, CD133+, CD90+) at day 14 were also GFP+ cells. Results obtained at day 7 
(Figure 42 a) and day 14 (Figure 42 b) of culture showed the same tendency. Notably, no GFP+ 
cells were obtained when only the donor IDLV was used, suggesting that random integration 
did not occur in the different hematopoietic subpopulations. 
Figure 42: Gene targeting efficiency in different subpopulations of hematopoietic progenitors 
(differentiated: CD34
-
, committed progenitors: CD34
+
, early progenitors: CD34
+
 CD133
+
 and primitive 
cells: CD34
+
 CD133
+
 CD90
+
). The percentage of GFP
+
 cells was measured by flow cytometry after gene 
targeting. Panel a) represents the analysis at day 7 and panel b) at day 14 of cell culture. Bars represents 
the mean with SD. n=8. The significance of differences between groups is calculated using ANOVA and T-
test and is expressed as p<0.01 (**) and p<0.001 (***). 
Clonogenic assays were conducted with these gene edited cells. Thereafter, GFP positive single 
colonies were picked when the GFP donor IDLV together with ZFNs were used. When only the 
GFP donor was used, colonies were picked randomly, since in this case no GFP+ colonies were 
detected, and none of these colonies showed the band corresponding to specific integration in 
the AAVS1 locus. PCRs both for the 5’ and 3’ ends were conducted and in 90.48% of the cases 
the amplification of both ends was confirmed (Figure 43 b and c). In some single colonies the 
integration was only detected when one of the primers was used, but not the other one, 
probably due to the different efficiency of the PCR reaction or due to the different mechanisms 
mediating the repair of each end (HDR or NHEJ)112,113. 
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Figure 43: Representative example of the PCR integration analysis in the colonies generated after 
treatment of CD34
+
 cells with the GFP donor IDLV together with ZFNs or with the GFP donor IDLV 
alone. a) Schematic representation of gene targeted AAVS1 locus with GFP donor. The arrows represent 
the primers used to evaluate the specific integration of the GFP donor in the AAVS1 site. b) PCR for the 5’ 
end. c) PCR for the 3’ end. d) Representative images of two different green colonies obtained in the 
clonogenic assays when the GFP donor IDLV together with the ZFNs was used. Left colonies showed in 
bright field and right in fluorescence microscopy. 
The summary of all the experiments performed in HD CD34+ cells is presented in Table 12. The 
percentage of INDELs quantified in the Surveyor assay varied between 21.36 and 52.85%. The 
percentage of GFP+ cells measured by flow cytometry at day 14 of cell culture, reached a mean 
of 10.42%. Since the efficiency of gene targeting analyzed by PCR in GFP+ colonies was 90.48% 
(confirmed in both 5’ and 3’ ends), the estimated HDR frequency corresponding to the 
hematopoietic stem and progenitor cells is 9.43%. 
 % INDELs % GFP
+
 cells in 
liquid cultures 
% GFP
+
 in 
colonies 
% HDR in GFP
+
 
colonies 
E8 51.65 15.7 24.5 85.7 
E9 49.82 9.68 18.06 79.2 
E10 42.96 8.23 NA NA 
E11 52.85 18 NA 87.5 
E12 48.1 4.87 NA 100 
E16 NA 13.5 14.02 NA 
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 % INDELs % GFP
+
 cells in 
liquid cultures 
% GFP
+
 in 
colonies 
% HDR in GFP
+
 
colonies 
E17 21.36 4.4 5.26 100 
E19 NA 9 8.82 NA 
Mean 44.46 10.42 14.13 90.48 
SD 11.83 4.91 7.58 9.22 
Table 12: Summary of the gene targeting experiments in HD CD34
+
 cells from different donors. The 
table shows the percentage of INDELs; proportion of GFP positive cells (liquid culture) measured by flow 
cytometry at day 14 of cell culture; percentage of GFP
+
 colonies in the CFC assays in the different 
experiments; and finally, percentage of HDR in GFP
+
 colonies, measured by integration analysis of 5’ and 
3’ ends by PCR. E: experiment. NA: not analyzed. 
1.2.2.1. Analysis of the in vivo repopulating ability of gene targeted CD34+ cells in 
immunodeficient mice 
As a next step, we evaluated the ability of gene targeted cells to reconstitute the bone marrow 
(BM) of immunodeficient mice. Cells corresponding to two independent experiments (E10 and 
12 shown in Table 12) were used to perform these studies. The efficiency of gene targeting, 
evaluated as the percentage of GFP+ cells at day 14 of culture, was 8.23% in E10 and 4.87% in 
E12. The integration analysis performed by PCR in single colonies corresponding to experiment 
12 confirmed the specific integration in the AAVS1 locus for both extremes (Figure 44). 
Figure 44: Site-specific integration of the GFP
 
transgene in the AAVS1 site determined in single 
colonies corresponding to the in vivo experiments. PCR for the 5’ end and PCR for the 3’ end in GFP
+
 
colonies assays. 
Aliquots of 4.5x105 gene targeted CD34+ cells were transplanted per NSG-SGM3 mouse, 
pretreated with sublethal irradiation. Flow cytometry analysis of bone marrow (BM) aspirates 
from transplanted mice revealed both, a high level of human engraftment and also the 
presence of gene edited cells (represented by hCD45+ cells that express GFP fluorescence (see 
representative analysis in Figure 45)). 
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Figure 45: Representative dot plot analysis of the bone marrow cells from a NSG-SGM3 mouse 
transplanted with gene targeted cells. From left to right: total BM, hCD45
+
 cells and finally GFP
+
 cells 
are shown. 
Significantly all mice where engrafted with human hematopoietic cells, a median of 17.07% of 
hCD45+ cells at 90 days post transplantation (dpt Figure 46 a). Moreover the analysis of GFP 
fluorescence showed that gene edited cells can efficiently engraft in immunodeficient mice, 
even at 90 days post-transplantation. At this time a median efficiency of 11.93% human CD45+ 
cells were GFP+, fluctuating between 0.2 and 28.3% of GFP positive cells depending on the 
mouse (Figure 46 b). Notably, in most cases the percentage of gene edited cells was 
maintained or increased at 90 dpt, suggesting that gene targeting has occurred at the level of 
hematopoietic repopulating cells. 
Figure 46: Analysis of the engraftment of gene targeted cells in NSG-SGM3 mice. a) Human 
engraftment (% hCD45
+
 cells) 30, 60 and 90 days post-transplantation (dpt). b) GFP
+
 population in 
human hematopoietic cells at 30, 60 and 90 dpt. Horizontal lines represent the median. n=6.  
Multilineage analysis performed in the BM and spleen of these animals at 90 dpt showed that 
there was human engraftment in all hematopoietic subpopulations in different hematopoietic 
organs (34.65 - 64.35% human engraftment in spleen) (Figure 47 a and c). We were also able 
to detect GFP positive cells in all hematopoietic lineages in BM and spleen of recipients 
transplanted with gene edited cells, reaching values of 8.95% GFP positive cells in spleen 
(median of 4.47%). The multilineage engraftment of GFP+ cells confirmed that gene editing 
occurred in HSPCs and did not affect the differentiation capacity of these hematopoietic 
precursors (Figure 47 b and d). 
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Figure 47: Multilineage engraftment of gene edited cells in different hematopoietic organs. 
Multilineage reconstitution was evaluated by flow cytometry using antibodies anti- hCD3
+
 for T cells, 
hCD19
+
 for B cells, hCD33
+
 for myeloid cells and hCD34
+
 for progenitor cells. a) Multilineage engraftment 
in the BM. b) Percentage of GFP
+
 edited cells in the different subpopulations in the BM. c) Multilineage 
engraftment in spleen. The first column represents the total human engraftment in this organ. d) 
Percentage of GFP
+
 cells in the different subpopulations in the spleen. The first column represents the 
total content of GFP
+
 cells in hCD45
+ 
in this organ. Horizontal lines represent the median. n=6.  
1.2.2.1.1. Analysis of the long-term repopulating capacity of gene targeted CD34+ cells 
To evaluate if gene targeting was occurring at the level of hematopoietic stem cells, bone 
marrow from primary recipients was harvested. Human CD45+ cells purified by 
immunoselection were seeded in methylcellulose to evaluate their clonogenic capacity.  
Analysis of the specific integration by PCR was conducted in GFP positive colonies detected by 
fluorescence microscopy in the clonogenic assays conducted with cells from primary mice 
(Figure 48 a). The integration analysis of these colonies by PCR showed the site-specific 
integration of the GFP transgene (Figure 48 b), confirming that gene edited cells were stably 
maintained in primary recipients. 
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Figure 48: Analysis of the site-specific integration in CFCs obtained from primary mice transplanted 
with gene edited cells. a) Representative image of a GFP
+
 colony. Left panel shows a colony under 
bright-field microscopy and left panel the same colony under fluorescence microscopy. b) PCR analysis of 
two different GFP
+
 colonies obtained from primary recipients to detect targeted integration in the AAVS1 
locus. 
1.2.3. Analysis of the gene targeting efficiency using the GFP-FANCA 
donor IDLV in CD34+ cells from healthy donors 
To test the efficiency of a therapeutic vector to specifically integrate in the AAVS1 locus of 
HSPCs and engraft in immunodeficient mice, we initially focused our efforts to verify 
integration of the GFP-FANCA donor in HD CD34+ cells. As we previously observed in HD LCLs 
we could not detect GFP expression by flow cytometry (Figure 49 a). To estimate the gene 
targeting efficiency with this vector we picked randomly single colonies generated after the 
transfer of the GFP-FANCA donor IDLV and ZFNs in CD34+ cells. First we did a Q-PCR to detect 
the number of GFP copies in these single colonies. This analysis showed that 19.5% of these 
cells presented more than 0.5 copies of GFP. To verify that in these colonies the integration of 
the vector was site-specific we performed a PCR to detect the integration in a pull of colonies 
with more than 0.5 copies of the GFP vector per cell. Our results showed the specific 
integration of the donor in the AAVS1 locus by PCR analysis in the 5’ end (Figure 49 b), 
confirming that targeting HD CD34+ cells with this therapeutic donor is feasible. 
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Figure 49: Gene targeting of the GFP-FANCA donor in the AAVS1 locus of HD CD34
+
 cells. a) 
Representative flow cytometry dot plot of CD34
+
 cells targeted with the GFP donor or GFP-FANCA donor 
at day 14 of culture. b) Top: Schematic representation of gene targeted AAVS1 locus with GFP donor. The 
arrows represent the primers used to evaluate the specific integration of the donor in the AAVS1 site. 
Bottom: Integration analysis by PCR of different pools of individual colonies that presented more than 
0.5 copies of GFP/cell determined by Q-PCR analysis. N: negative control. 
Since gene targeting with GFP-FANCA donor was confirmed in CD34+ cells, cells transduced 
with this donor were transplanted in immunodeficient NSG-SGM3 mice. Once again, our 
results showed the engraftment of human hematopoietic cells in primary recipients (Figure 
50). Moreover, the analysis of GFP VCN in these samples by Q-PCR confirmed the engraftment 
of genetically modified cells. 
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Figure 50: Analysis of human engraftment of gene targeted cells using donor GFP-FANCA in primary 
NSG-SGM3 recipients. Human engraftment (% hCD45
+
 cells) 30, 60 and 90 dpt in primary recipients. 
Numbers represent VCN analyzed by Q-PCR in each sample. Horizontal lines represent the median. n=2.  
The multilineage analysis of primary recipients showed the repopulation of the lympho-
hematopoietic lineages in BM and spleen (Figure 51). Moreover, the GFP VCN analysis 
performed in the spleen of these mice also confirmed the engraftment of gene edited cells.  
Figure 51: Multilineage engraftment of primary recipients transplanted with human CD34
+
 cells after 
gene editing. Recipients transplanted with CD34
+
 cells targeted with the GFP-FANCA donor IDLV. The 
engraftment was evaluated with antibodies anti-hCD3
+
 for T cells, hCD19
+
 for B cells, hCD33
+
 for myeloid 
cells and hCD34
+
 for progenitor cells. a) Multilineage engraftment in BM. b) Multilineage engraftment in 
spleen. Numbers represents VCN analyzed by Q-PCR in each sample. Horizontal lines represent the 
median. n=2. 
1.3. Analysis of the efficiency of gold nanoparticles to 
improve lentiviral transduction and gene targeting in CD34+ 
cells 
One essential aspect to improve the efficiency of HDR is to improve the delivery of the donor 
constructs into the target cell. We investigated whether the transduction efficiency in CD34+ 
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cells from UCB could be improved using gold nanoparticles (AuNPs) conjugated with NH4
+ 
residues. These AuNPs have a positive charge, and therefore could be bound to negatively 
charged LVs. Our hypothesis was that the inhibition of the negative charge of LVs could 
improve their efficiency to transduce the target cell population, in particular the CD34+ cells, 
improving the delivery of the donor construct. 
First we tested the toxicity of these particles in CD34+ cells, and also if these cells were able to 
incorporate them efficiently. We analyzed the number of cells one and two days after 
treatment. As shown in Figure 52 a, although one day after treatment with AuNPs a decrease 
in the number of cells was obtained, this effect was not significant. Moreover, at two days 
after treatment no differences in CD34+ cell number, cultured with or without AuNPs, were 
observed. Strikingly, we demonstrated by fluorescence microcopy that CD34+ cells 
incorporated the AuNPs very efficiently (Figure 52 b). On average, more than 90% of the CD34+ 
cells contained AuNPs. 
Figure 52: Analysis of the proliferation and incorporation of gold nanoparticles into the CD34
+
 cells. a) 
Fold increase in the number of cells is represented. It is determined by the cell number observed one day 
over the number of cells counted the day before. Bars represent mean with SD. n=3. b) Image of CD34
+
 
cells in which the nanoparticles have been incorporated. Nucleus in blue (DAPI) and AuNPs in orange 
(TAMRA). 
In order to test if the transduction efficiency of LVs could be improved by the binding to 
AuNPs, CD34+ cells were transduced with LVs pre-incubated or not with AuNPs. Different MOIs 
of the GFP donor IDLVs or GFP donor ICLVs were used. The results showed that the pre-
incubation of either IDLVs or ICLVs with AuNPs markedly increased the transduction efficiency 
of these vectors. On average a two fold increase was observed (Figure 53). 
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Figure 53: Transduction efficiency in UCB CD34
+
 cells using a GFP donor ICLV or a GFP donor IDLV in the 
presence of AuNPs. a) The percentage of GFP positive cells transduced with a GFP donor ICLV was 
measured 12 days after transduction. b) Percentage of GFP positive cells transduced with a GFP donor 
IDLV measured at 2 days post-transduction. Bars represent mean with SD. n=4. The significance of 
differences between groups is calculated using Mann Whitney test and is expressed as p<0.05 (*). 
We also tested if the transduction improvement associated to the use of AuNPs in in vitro 
cultured CD34+ cells was correlated with similar improvements in NSG-repopulating cells. In 
these experiments, CD34+ cells were transduced with two doses of donor GFP ICLV (MOI 10 or 
100 LVs/cell) in the presence or the absence of AuNPs. Thereafter, cells were transplanted into 
sublethally irradiated NSG mice. We decided to use two different MOIs as MOI 100 LVs/cell 
could result in very high transduction of repopulating cells that may limit the detection of 
statistical differences. The human engraftment of these animals was evaluated monthly by BM 
aspiration until 90 dpt. Our results showed that the percentage of human engraftment did not 
change because of the use of AuNP-LVs at any time post-transplantation, indicating that AuNPs 
did not affect the capacity of HSPCs to repopulate the BM of immunodeficient mice, 
confirming the absence of toxicity of these AuNPs (Figure 54 a). When the percentage of GFP+ 
cells engrafting the animals was analyzed, we observed a slight increase in the percentage of 
transduced cells when AuNPs were used, although differences were only statistically significant 
in the short-term repopulating cells when MOI 100 was used (three-fold increase in GFP+ 
hCD45+ cells when AuNPs were used) (Figure 54 b). When the percentage of GFP+ cells was 
analyzed in the CD34+ subset we observed the same tendency, cells transduced in the 
presence of AuNPs presented an increment of this percentage, especially long term post-
transplantation (Figure 54 c). As expected, the higher MOIs led to a higher percentage of GFP+ 
cells in transplanted mice. This result indicated that although the efficiency of transduction 
was markedly improved in the liquid culture, this increase is mainly detected in the short-term 
in vivo, and only a mild increase is observed long term post-transplantation for both MOIs used 
(Figure 54 b and c).  
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Figure 54: Engraftment capacity of CD34
+ 
cells transduced in the presence of AuNPs in NSG mice. Cells 
were transduced with two different MOIs. Circles represent cells transduced with MOI 100 LVs/cell, while 
squares represent cells transduced with MOI 10 LVs/cell. a) Human engraftment (% hCD45
+
 cells) 30, 60 
and 90 dpt. b) GFP
+
 population in the human engraftment at 30, 60 and 90 dpt. c) GFP
+
 cells inside CD34
+
 
subpopulation at 30, 60 and 90 dpt. Horizontal lines represent the median. n=4 in MOI 100 and n=5 in 
MOI 10. The significance of differences between groups is calculated using Mann Whitney test and is 
expressed as p<0.05 (*). 
The multilineage analysis of the hematopoietic organs of these mice at 90 dpt showed that the 
distribution of human hematopoietic lineages in infused recipients was very similar between 
the different conditions. The lymphoid, myeloid and progenitor compartments were 
represented at the same levels in the different analyzed organs in the conditions treated or 
not with AuNPs (Figure 55 a, c and e). Moreover, the expression of GFP in all these different 
compartments was similar in animals transplanted with cells transduced with or without 
AuNPs; although there was a slight increment of GFP+ cells in all hematopoietic compartments 
of mice analyzed when AuNPs were used, especially in the thymus in which the human 
reconstitution was around 100% (Figure 55 f). As expected we observed that animals 
transplanted with cells transduced with higher MOIs show higher levels of GFP+ cells (Figure 55 
b, d and f). 
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Figure 55: Multilineage engraftment of transduced cells with or without AuNPs transplanted in NSG 
mice. Multilineage reconstitution was evaluated using antibodies against hCD3
+
 for T cells, hCD19
+
 for B 
cells, hCD33
+
 for myeloid cells, hCD34
+
 for progenitor cells and with hCD4
+
 and hCD8
+
 for different 
subpopulations of T cells in the thymus. Circles represent cells transduced with MOI 100 LVs/cell, while 
squares represent cells transduced with MOI 10 LVs/cell. a) Multilineage engraftment in the BM. b) 
Percentage of GFP edited cells in the different subpopulations in the BM. c) Multilineage engraftment in 
the spleen. d) Percentage of GFP
+
 cells in the different subpopulations inside the spleen. e) Analysis of T 
cell populations in the thymus. f) Percentage of GFP
+
 cells in the different subpopulations of T cells in the 
thymus. Horizontal lines represent the median. n=4 in MOI 100 and n=5 in MOI 10. The significance of 
differences between groups was calculated using Mann Whitney test and is expressed as p<0.05 (*). 
Finally, secondary transplants were performed using the BM of the primary recipients. The 
analysis of the secondary recipients showed that there is a moderate increment in the 
engraftment of GFP+ cells when nanoparticles are used at both MOIs, although these 
differences were not statistically significant (Figure 56).  
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Figure 56: Analysis of the engraftment of CD34
+
 cells transduced in the absence/presence of AuNPs in 
secondary recipients. Cells were transduced with two different MOIs. Circles represent cells transduced 
with MOI 100 LVs/cell, while squares represent cells transduced with MOI 10 LVs/cell. a) Human 
engraftment (% CD45
+
 cells) 30, 60 and 90 dpt. b) GFP
+
 population inside of human engraftment at 30, 
60 and 90 dpt. c) GFP
+
 cells inside CD34
+
 subpopulation at 30, 60 and 90 dpt. Horizontal lines represent 
the median. n=4 in MOI 100 and n=5 in MOI 10. 
The multilineage analysis of all hematopoietic organs of these mice at 90 dpt showed that 
there were no differences in the lineage reconstitution, since the lymphoid, myeloid and 
progenitor compartments were represented at the same levels in the different organs (Figure 
57 a, c and e). Moreover, the expression of GFP in all these different compartments was similar 
in the animals transplanted with cells transduced with or without AuNPs. As expected, we also 
observed that animals with higher percentages of GFP positive cells were the ones 
transplanted with cells transduced with higher MOIs (Figure 57 b, d and f). 
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Figure 57: Multilineage engraftment of transduced cells with or without AuNPs transplanted in NSG 
mice. Multilineage reconstitution was evaluated using antibodies against hCD3
+
 for T cells, hCD19
+
 for B 
cells, hCD33
+
 for myeloid cells, hCD34
+
 for progenitor cells and wit hCD4
+
 and hCD8
+
 for different 
subpopulations of T cells in the thymus. Circles represent cells transduced with MOI 100 LVs/cell, while 
squares represent cells transduced with MOI 10 LVs/cell. a) Multilineage engraftment in the BM. b) 
Percentage of GFP edited cells in the different subpopulations in the BM. c) Multilineage engraftment in 
the spleen. d) Percentage of GFP
+
 cells in the different subpopulations inside the spleen. e) Analysis of T 
cell populations in the thymus. f) Percentage of GFP
+
 cells in the different subpopulations of T cells in the 
thymus. Horizontal lines represent the median. n=4 in MOI 100 and n=5 in MOI 10. 
Finally the vector copy number was analysed in the BM from primary and secondary recipients 
at 90 dpt (Figure 58). Although the treatment with AuNPs did not increase the number of 
copies found in primary recipients (Figure 58 a); in the secondary recipients the treatment with 
gold nanoparticles increased the number of copies in the group transduced with MOI 100 LVs/ 
cells (from 1.47 to 3.26 copies/cell). Moreover, while we did not detect copies of the transgene 
in animals corresponding to the MOI 10 group, we could detect copies of the LV when cells 
were treated with AuNPs (0.089 copies/cell) (Figure 58 b). 
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Figure 58: Vector copy number analysis in human cells obtained from the BM of primary and 
secondary recipients at 90 dpt. a) VCN analysis in primary recipients. b) VCN analysis in secondary 
recipients. Horizontal lines represent the median. n=4 in MOI 100 and n=5 in MOI 10. 
Finally, and considering the significant increase obtained in the percentage of transduction 
when IDLVs were used (Figure 53 b), we tested the efficiency of gene targeting when AuNPs 
were combined with IDLVs in CD34+ using the GFP donor IDLV. Our results showed that the 
combination of AuNPs in cells after transduction with IDLVs and the nucleofection led to a high 
toxicity in CD34+ cells, preventing the evaluation of the effect of AuNPs in gene targeting 
experiments (data not shown). 
2. Gene targeting with a therapeutic 
donor IDLV in FA-A hematopoietic cells 
2.1. Evaluation of gene targeting efficiency in FA-A LCLs 
Although our previous studies demonstrated that gene targeting of hFANCA can be conducted 
in FA-A fibroblasts75, the efficiency of this approach in FA-A hematopoietic cells, such as LCLs, 
in comparison to HD LCLs has not been tested. Since the FA/BRCA pathway is involved in HR228, 
we wanted to examine if FA-A hematopoietic cells show a reduction in the gene targeting 
efficiency as compared to HD LCLs. To roll out any potential effect mediated by the transient 
expression of FANCA, a GFP donor IDLV was used in these experiments. Cell lines from four 
different FA-A patients, both uncorrected and corrected with a therapeutic lentiviral vector290, 
were used (Figure 59 b). Additionally, four HD LCLs were also included (Figure 59 a). Our 
results showed that gene targeting was feasible in FA-A hematopoietic cells and the efficiency 
of gene targeting was dependent on the specific cell line. Re-expression of hFANCA gene in FA-
A LCLs from patients mildly increased the gene targeting efficiency in three out of four 
analyzed cell lines. However, there were not significant differences between HD and FA-A cells 
corrected or not. We also corroborated that the integration was site-specific by PCR analysis of 
both 5’ and 3’ ends of AAVS1 locus in GFP+ cells obtained from these experiments by cell 
sorting (Figure 59 c). 
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Figure 59: Analysis of the gene targeting efficiency in different LCLs. The percentage of GFP
+
 cells 
measured by flow cytometry at day 12 of culture from gene targeting experiments using GFP donor IDLV 
is represented. a) Percentage of GFP
+
 cells from four different HD LCLs after gene targeting. b) 
Percentage of GFP
+
 cells obtained in gene targeting experiments from four different FANCA deficient LCLs 
and their gene therapy corrected counterparts. Bars represent mean with SD. n=3. c) Representative PCR 
of the 5’ end (top) and 3’ end (bottom) of the sorted bulk population of gene targeted HD, uncorrected 
and corrected FA-A LCLs using GFP donor IDLV and ZFNs. N: negative control. 
2.2. Gene targeting of FANCA in the AAVS1 locus of FA-A 
lymphoblastic cell lines 
2.2.1. Design of a new therapeutic vector to correct FA-A 
hematopoietic cells 
Due to the difficulties to detect the GFP expression conferred by the integration of the GFP-
FANCA donor in the AAVS1 locus, we designed a new IDLV carrying the hFANCA gene and the 
puromycin (Puro) resistant gene, both of them under the control of the PGK promoter. To test 
the functionality of this vector we initially produced it as an integrase-competent lentiviral 
vector (ICLV) and analyzed its efficiency to revert the phenotype of FA-A LCLs. In all these 
experiments the GFP donor vector, also produced as ICLV, was used as a control. 
A lymphoblastic cell line from a FA-A patient (FA-55) was transduced with a MOI 10 LVs/cell in 
two rounds of 12 hours of transduction with both vectors. The percentage of GFP positive cells 
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was evaluated by flow cytometry when the GFP donor ICLV was used, obtaining a 39.5% of 
GFP+ cells 15 days after transduction. To confirm the functionality of the therapeutic FANCA-
Puro vector four approaches were conducted in these cells: reversion of MMC sensitivity, 
western-blot analysis of FANCA and generation of FANCD2 foci formation after DNA damage. 
The resistance to puromycin was also tested. 
Fifteen days after transduction cells were plated with different concentrations of MMC or 
puromycin. The evaluation of MMC and puromycin sensitivity was performed by analyzing the 
percentage of DAPI negative cells at 15 days post-treatment by flow cytometry. The results 
showed that the transduction of the FA-A LCL with our FANCA-Puro therapeutic vector reverts 
the sensitivity of these cells to MMC (Figure 60 a), and also confers resistance to puromycin 
(Figure 60 b), confirming that both transgenes were functional in the vector. 
Figure 60: Survival curve of FA-55 LCL after transduction with the GFP or FANCA-Puro ICLVs. a) MMC 
survival curve of transduced cells. b) Puromycin survival curve of transduced cells. HD cell line CP1 and 
FA55 were used as controls. 
To confirm the expression of FANCA in these cells, western blot analysis of FANCA were 
conducted. As shown in Figure 61 FANCA expression was only detected in samples transduced 
with the FANCA-Puro vector, either unselected or after selection with MMC or puromycin, 
demonstrating the efficiency of the vector to promote the expression of the therapeutic 
transgene.  
Figure 61: Western blot analysis of FANCA in FA-55 edited LCLs. β-actin was used as a loading control. 
Since FANCA is necessary for FANCD2 monoubiquitination and mobilization to the DNA repair 
foci, we investigated the generation of FANCD2 foci after DNA damage in FANCA-Puro 
MMC (nM)
Su
rv
iv
al
 (
%
)
1 10 100 1000
1
10
100
1000
CP1 FA-55 FA-55 GFP donor ICLV FA-55 FANCA-Puro donor ICLV
Puromycin (µg/mL)
Su
rv
iv
al
 (
%
)
0.0 0.5 1.0 1.5 2.0
0
50
100
150
a) b)
  RESULTS 
 
97 
 
transduced cells. As shown in Figure 62 only in FA-A cells that had been transduced with the 
FANCA-Puro vector the presence of FANCD2 foci was noted. 
Figure 62: Percentage of cells with FANCD2 foci in a FA-A LCL after gene targeting using a FANCA-Puro 
donor ICLV or GFP donor ICLV. Cells with more than 10 foci were counted. 
Taken together, all these studies showed the capacity of the FANCA-Puro vector to restore the 
phenotype of a FA-A LCL. In subsequent experiments we thus investigated the efficiency of this 
construct to specifically conduct gene targeting in the AAVS1 locus of FA-A hematopoietic cells. 
2.2.2. Gene targeting efficiency of the donor FANCA-Puro delivered 
as plasmid DNA in LCLs 
In these experiments a FA-A LCL (FA-55) was nucleofected either with the donor FANCA-Puro 
construct or a control GFP donor, both delivered as plasmid DNA. A HD LCL (C4) was used as a 
control. Flow cytometry analyses performed at day 12 of culture in samples targeted with GFP 
donor showed that there were GFP+ cells in samples only nucleofected with the donor as DNA 
in both HD and FA-A LCLs. Notably, the percentage of positive cells was markedly higher in FA-
A cells nucleofected only with the donor in comparison with the HD, pointing out the 
possibility that random integration could be favored in FA-A cells due to its intrinsic genetic 
instability (Figure 63).  
It is important to remark that the percentages of INDELs obtained in both LCLs and using both 
donor vectors (GFP and FANCA-Puro) were very similar: around 50% (49.19±3.18%). 
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Figure 63: Gene targeting in FA-55 LCLs using GFP donor as DNA. Percentage of GFP positive cells 
measured by flow cytometry in FA-55 LCL cell line and C4 HD at day 12 of culture. Bars represent mean 
with SD. n=2. 
The integration analysis in the 5’ end of the AAVS1 locus of FA-55 LCLs targeted using GFP or 
FANCA-Puro donor as plasmid DNA confirmed the specific integration of the donor FANCA-
Puro, but not the donor GFP (Figure 64 b). The absence of the PCR amplicon in cells targeted 
with the GFP donor could be due to the low percentage of GFP+ cells obtained in these 
experiments (2.59±2.84%), which were very close to the detection limit of this PCR (2.25% of 
GFP+ cells; see Figure 35). However, although the size of the FANCA-Puro donor was relatively 
large, we could detect the PCR amplicon in cells targeted with this therapeutic donor. One 
possible explanation is related to the proliferative advantage of FA-A gene targeted cells over 
the non-targeted ones. This selective advantage increments the percentage of corrected cells 
in culture, allowing their detection by PCR.  
Figure 64: Integration analysis in the 5’ end of the AAVS1 locus by PCR of gene targeted FA-55 LCL 
nucleofected with the FANCA-Puro or GFP donors as plasmid DNA. a) Schematic representation of gene 
targeted AAVS1 locus with GFP or FANCA-Puro donors. Arrows represent the primers used to evaluate if 
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the integration was site-specific. b) PCR of the bulk population of gene targeted FA-55 LCL cells 
nucleofected with the FANCA-Puro or GFP donors as plasmid DNA. N: negative control. 
The reversion of MMC sensitivity in these cells was also tested. The survival curve showed that 
cells nucleofected with both FANCA-Puro and ZFNs were resistant to MMC. Surprisingly, cells 
nucleofected only with the FANCA-Puro donor were also MMC resistant (Figure 65), suggesting 
that random integration of the donor construct took place in FA-A cells, probably due to the 
genetic instability of these cells. 
Figure 65: MMC survival curve of FA-55 LCL cell line after gene targeting experiment in which cells 
were nucleofected with the FANCA Puro or GFP donors as plasmid DNA. 
2.2.3. Gene targeting efficiency of the FANCA-Puro and GFP-FANCA 
donors delivered as IDLV in FA-A LCLs 
In subsequent experiments, we investigated whether the specificity of the targeted gene 
therapy in FA-A LCLs could be improved by the delivery of the donor construct as an IDLV. We 
used our two therapeutic vectors: FANCA-Puro donor IDLV and GFP-FANCA donor IDLV in the 
LCL FA-56. 
Representative PCR showing the integration of GFP-FANCA donor IDLV in the AAVS1 in the bulk 
population of gene targeted FA-56 cells is represented in Figure 66. Only when ZFNs were 
present the expected band appeared. 
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Figure 66: Integration analysis in the 5’ and 3’ end of the AAVS1 locus by PCR of gene targeted FA-56 
LCL nucleofected with the GFP-FANCA donor IDLV. 
2.2.3.1. Functional assays 
Different functional assays were conducted in these cells to test the phenotypic correction of 
these cells. 
Firstly, we tested the MMC sensitivity of uncorrected and gene edited FA-56 cells. Cells were 
then cultured with different concentrations of MMC and their survival analyzed at 5 days post 
treatment. These analyses revealed that there was a reversion in the sensitivity to MMC in FA-
56 cells either targeted with the ZFNs and the FANCA-Puro or GFP-FANCA donors IDLV (Figure 
67 a, b). In this case the correction of MMC hypersensitivity was only evident when the ZFNs 
were included. This suggested that the packaging of the FA-donor construct in IDLV facilitated 
the specific integration, and thus the phenotypic correction of FA-56 cells, with no random 
integration as it was deduced from the experiments where the donor was used as plasmid 
DNA (Figure 65).  
Figure 67: MMC survival curve of FA-56 LCL after gene targeting experiments. Cells were nucleofected 
with the FANCA-Puro donor IDLV in panel a, or GFP-FANCA donor IDLV in panel b. HD C3 and FA-56 LCLs 
were used as controls. MMC resistance was evaluated 5 days after the drug treatment. 
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Finally, immunofluorescence studies in FA-56 gene edited cells clearly showed that FANCD2 
foci are restored only when gene editing was conducted both with FANCA-Puro and GFP-
FANCA donors IDLV together with ZFNs (Figure 68). Even more, the absence of FANCD2 foci 
when only the donor was used suggest that random integration was not occurring. 
Figure 68: Nuclear FANCD2 foci formation in FA-56 LCLs after gene targeting. Gene targeted cells were 
treated or not with MMC and FANCD2 staining was performed (Texas-red). In all instances MMC was 
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used to induce DNA damage before FANCD2 immunofluorescence was performed. a) FA-56 LCL. b) HD 
LCL. c) FA-56 FANCA-Puro donor IDLV. d) FA-56 FANCA-Puro donor IDLV with ZFNs. e) FA-56 GFP-FANCA 
donor. f) FA-56 GFP-FANCA donor with ZFNs. g) Percentage of cells with FANCD2 foci. HD and FA-56 were 
used as positive and negative controls respectively and FANCD2 foci were analyzed. Cells with more than 
10 foci were counted as positive cells. 
2.3. Influence of the PARI inhibition upon the efficacy of 
gene targeting in healthy donor and FA-A cells 
Previous studies have shown that PARI inhibition in FA-D1 cells increases the efficiency of HR 
leading to a reduction in chromosomal instability150. Nevertheless, FA-D1 cells presents a 
marked defect in HR; while this defect is only mild in FA-A cells151. We wanted to test if the 
consequences of PARI inhibition upon HR were also extensive to FA-A cells and, therefore, if 
the transient inhibition of this protein could increase the efficiency of HDR-mediated gene 
targeting. We tested this hypothesis in two different types of FA-A cells: FA-A LCLs and FA-A 
fibroblasts. 
2.3.1. Efficiency of gene editing in lymphoblastic cell lines from FA-
A patients after PARI inhibition 
First we evaluated the effect of PARI inhibition in a FA-A cell line (FA-55) as compared to a HD 
LCL (CP1). FA-55 and CP1 were both interfered using PARI iRNAs. Thereafter, the level of PARI 
inhibition was analyzed by RT-Q-PCR. We showed a reduction in PARI expression of 
52.22±0.03% in CP1 and of 68.12±0.08% in FA-55. Since PARI favors the release of RAD51 from 
the nucleofilament formed during HR; we analyzed the number of cells with RAD51 foci in PARI 
interfered and in non-interfered cells. As shown in Figure 69 a, the presence of RAD51 foci in 
HD cells remained constant regardless of the inhibition of PARI or the treatment with MMC. 
However, the number of cells with RAD51 foci was clearly increased in FA-55 cells treated with 
the PARI iRNAs both in the absence or presence of MMC, suggesting that the rate of HR in 
these cells was increased by PARI inhibition (Figure 69 a). To evaluate if the increase in HR due 
to PARI inhibition induced an increase in the chromosomal stability in FA-A cells, metaphases 
of non-interfered and PARI interfered FA-A LCLs and HD LCLs were studied (Figure 69 b, c). Our 
results showed that the interference of PARI in FA-A cells decreased the intrinsic genetic 
instability of these cells in the absence of DNA damage (- DEB), while did not modify the very 
low spontaneous genetic instability of HD cells (Figure 69 b, c). After DNA damage with DEB, 
PARI inhibition did not mediate significant effects, either in HD (which did not show significant 
aberrant chromosomes) nor in FA-A cells, characterized by a very high number of aberrations 
(around 60% of cells showed chromosomal aberrations).  
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Figure 69: Effect of PARI inhibition in RAD51 foci formation and in the genetic stability of HD and FA-A 
LCLs. FA-A and HD LCLs were interfered with PARI iRNAs. a) Analysis of the percentage of cells with 
nuclear RAD51 foci. Interfered FA-A and HD cells were treated or not with MMC and then fixed and 
stained with RAD51 antibody. Cells with more than 10 foci per cell were counted as a positive cell. b) 
Percentage of aberrant cells analyzed in metaphases of interfered HD and FA-A LCLs treated or not with 
diepoxybutane (DEB). c) Image of different metaphases analyzed in FA-55 samples interfered or not with 
PARI iRNAs. Arrows indicate chromosomal breakages. 
Once we confirmed that PARI inhibition increased the number of cells with RAD51 foci, 
suggesting an increase in HR, gene targeting experiments were conducted in PARI-interfered 
FA-A and HD LCLs, to test if the transient inhibition of PARI correlates with an increased 
efficiency of gene targeting. Cells were PARI-interfered and one day later transduced with the 
GFP donor IDLV. Finally, these cells were nucleofected with the ZFNs and the efficiency of gene 
targeting was measured by flow cytometry. Additionally, the percentage of INDELs was 
measured by the Surveyor assay. As shown in Figure 70 a, the ratio of INDELs in interfered 
versus their no-interfered counterparts was comparable in HD and in FA-A cells. The efficiency 
of gene targeting in these conditions showed that PARI inhibition did not significantly increase 
the ratio of GFP positive cells either in FA-A or in HD LCLs (Figure 70 b). The high variability in 
the efficiency of gene targeting between experiments and the relative low number of 
experiments so far conducted (n=3) did not allow us to obtain significant differences, but only 
a tendency for increased gene targeting efficiency when PARI was inhibited in FA-A cells. 
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Figure 70: Gene targeting efficiency in PARI-interfered FA-A or HD LCLs. FA-55 and CP1 cell lines were 
interfered with PARI iRNAs and then gene targeting experiments were conducted using a GFP donor 
IDLV. a) Percentage of INDELs measured by Surveyor assay during the different experiments. b) Efficiency 
of gene targeting represented as the ratio between the percentage of GFP positive cells in cells 
transduced with the GFP donor IDLV and nucleofected with ZFNs and cells transduced only with the GFP 
donor IDLV. Bars represent mean and SD. n=3. 
Finally, to verify that the integration of the donor was taking place in a site-specific manner, 
integration analysis in these samples was carried out by PCR. Our results demonstrated a site-
specific integration in these cells only when cells were transduced with the GFP donor IDLV 
and nucleofected with ZFNs, in both HD and FA-A LCLs (Figure 71). 
Figure 71: Integration analysis by PCR of PARI-interfered LCLs from a FA-A patient or a HD after gene 
targeting with a GFP donor IDLV. Top: Schematic representation of gene targeted AAVS1 locus with the 
GFP donor. The arrows represent the primers used to evaluate if integration was site-specific. Bottom: 
Representative PCR of PARI-interfered LCLs from FA-A and HD LCLs. 
2.3.2. Efficiency of gene editing in fibroblasts from FA-A patients 
after PARI inhibition 
Due to the difficulty to transfect LCLs, we also conducted gene targeting experiments in FA-A 
fibroblasts, trying to clarify the results previously obtained. In these experiments we tested the 
efficiency of PARI inhibition in fibroblasts from a FA-A patient (FA-123) and from a HD (HFF), in 
both cases immortalized with hTert. The inhibition of PARI in both types of fibroblasts reached 
a level of 70% of PARI downregulation (Figure 72 a). One day after the second round of 
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transduction with the PARI iRNA, cells were transduced with the GFP donor IDLV and one day 
later nucleofected with ZFNs. As previously observed in LCLs, the gene targeting efficiency in 
FA-A fibroblasts was not significantly increased when PARI was inhibited, probably due to the 
high variability in the efficiency obtained in the three experiments that we have conducted so 
far (Figure 72 b). 
Figure 72: Gene targeting efficiency in PARI-interfered FA-A or HD fibroblasts. Fibroblasts were 
interfered with PARI iRNA and then gene targeted using GFP donor IDLV. a) Inhibition of PARI measured 
by Q-PCR. Bars represent mean with SD. n=6. b) Efficiency of gene targeting represented as ratio of the 
percentage of GFP positive cells in cells transduced with GFP donor IDLV and nucleofected with ZFNs over 
cells only transduced with the GFP donor IDLV. Bars represent mean and SD. n=3. 
2.4. Targeted gene therapy in CD34+ cells from FA-A 
patients 
To test the efficiency of our targeted gene therapy approach with the therapeutic FANCA-Puro 
donor IDLV in hematopoietic stem and progenitor cells from FA-A patients, a small proportion 
of mPB CD34+ cells that remained in cell collection bags and tubes from the CliniMACS® System 
used to purify CD34+ cells from FA-A patients included in the FANCOSTEM mobilization trial 
were used after permission consent of the patients or their parents and approval of the 
corresponding ethics committees. Cells remaining in the immunoselection bags were 
prestimulated for 24 hours and then transduced with the GFP donor or the FANCA-Puro donor 
IDLVs. One day after transduction, cells were washed and nucleofected with 6 µg of the ZFN 
mRNA. To test the phenotypic correction of the FA CD34+ cells after gene targeting, cells were 
plated in methylcellulose in the presence or absence of MMC. Numbers of colonies obtained 
after 14 days in culture were analyzed. In the first two cases (02002 and 01003); cells from 
patients were transduced with the therapeutic FANCA-Puro donor and the GFP donor IDLV as a 
control. In both patients an increase in the number of MMC resistant colonies was observed 
when cells where transduced with the FANCA-Puro donor and nucleofected with the ZFNs 
(Figure 73 a and b). Since these percentages were higher than the ones expected from our 
results in HD CD34+ (see data obtained in Figure 41); and to discard that this high efficiency 
was due to the random integration of the donor vector; in the next two patients (02003 and 
02004) the cells were also transduced with the FANCA-Puro donor IDLV in the absence of ZFNs. 
Cells from patient 02003 presented a percentage of resistant colonies of 4.69% in the 
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condition transduced with the donor FANCA-Puro and nucleofected with the ZFNs, while no 
MMC-resistant colonies were obtained in the absence of ZFNs (Figure 73 c). In the last patient, 
a 10% of MMC resistant colonies were obtained when cells were only transduced with the 
FANCA-Puro donor IDLV, pointing out that random integration of the donor or an incomplete 
MMC selection could occur. The percentage of MMC resistant colonies in the condition 
transduced with the therapeutic vector and nucleofected with ZFNs was 13.16%; suggesting an 
efficiency of gene targeting of about 3% (Figure 73 d). Overall, our data suggests an increase in 
the number of MMC resistant colonies when cells were treated with both the FANCA-Puro 
donor IDLV and the ZFNs, as compared with samples treated either with the GFP donor IDLV or 
with the FANCA-Puro donor IDLV in the absence of the ZFNs. This data suggests for the first 
time that gene targeting is occurring in HSPCs from FA-A patients.  
Figure 73: MMC resistance in HPCs from four different FA-A patients after gene editing. The number of 
CFCs per 10,000 cells plated is shown both in the presence or absence of MMC using the GFP-donor or 
FANCA-Puro donor IDLV vectors combined with ZFNs or not. Bars represent mean with SD. 
Integration analysis by PCR of pooled colonies grown in the absence or the presence of MMC 
was performed to analyze the targeted integration of the FANCA-Puro donor in the AAVS1 
locus. As shown in Figure 74, specific integration in the 5’ end of AAVS1 locus was only 
observed when cells were cultured in the presence of MMC, demonstrating for the first time 
that targeted gene therapy in FA-A CD34+ cells is feasible, although at lower efficiencies as 
compared with those obtained in HD CD34+ cells targeted with smaller non-therapeutic donors 
(see data from experiments shown in Figure 41). 
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Figure 74: Integration analysis by PCR of hematopoietic colonies obtained from patient 02002 CD34
+
 
cells after gene targeting using FANCA-Puro donor IDLV. a) Schematic representation of gene targeted 
AAVS1 locus with FANCA-Puro donor. Arrows represent the primers used to evaluate the specific 
integration of FANCA-Puro donor in the 5’ end of the AAVS1 site. b) PCR of a pool of colonies from gene 
edited FA-A CD34
+
 cells treated or not with MMC. 
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1. General aspects of gene editing applied 
to the therapy of inherited monogenic 
diseases 
Clinical trials conducted with gamma-retroviral vectors (γ-RVs) presented some adverse effects 
derived from the insertion of transgenes in transcription start sites and upregulation of 
neighboring genes. Some of these insertions mediated the upregulation of proto-oncogenes 
inducing leukemia in clinical trials of X-linked severe combined immunodeficiency (SCID-
X1)26,27, Wiskott-Aldrich syndrome (WAS)17 and chronic granulomatous disease (CGD)15 
patients. In order to increase the safety of hematopoietic stem cell (HSC) gene therapy (GT), 
self-inactivating (SIN) vectors, with a very limited trans-activation potential, due to inactivation 
of the viral LTRs, have been developed. Moreover, the use of SIN-lentiviral vectors (LVs), which 
additionally present a safer integration profile than γ-RVs, have also contributed to increase 
the safety of HSC GT. Significantly, current GT trials with SIN-LVs and SIN-γ-RVs have shown 
clinical efficacy in the absence of severe side effects in several monogenic diseases such as 
WAS18, metachromatic leukodystrophy (MLD)23, SCID-X112-14, adrenoleukodystrophy (ALD)22, β-
thalassemia21 and sickle cell anemia303,304. 
Very recently, gene editing has appeared as a new and even safer GT platform that facilitates 
specific integration of the transgenes in desired genomic loci. However, gene editing is still 
promising and should be improved in order to be extensively applied in the clinics. The three 
key parameters of gene editing are specificity, efficiency and fidelity; being the combination of 
all of them what would facilitate their use in the clinics based on the optimized development 
of designed nucleases and donors and also an efficient approach for the gene transfer.  
The specificity in the gene editing is defined by the probability of integrating the selected 
transgene in the certain site, without affecting any other sequence of the genome. It can vary 
depending on the selected reagents and experimental conditions. For example, there are 
evidences that the short-term exposure of cells to nucleases reduces their off-target activity 
and their related cytotoxicity127,130. Acute cytotoxic effects may possibly result from ATM or 
ATR-dependent protein kinase signaling pathway activation, leading to cell cycle arrest and 
apoptosis305. This fact, together with the involvement of off-target DSBs in the generation of 
either, unintended mutations, illegitimate recombination events or translocations, makes 
nuclease specificity an important parameter in gene editing. Therefore, the development of 
designed nucleases is often associated with considerable efforts directed towards maximizing 
their specificity; for example by the generation of obligate heterodimeric variants in ZFNs and 
TALENs102,103. Some genome-modifying events may affect the specificity of gene editing for 
example by the targeting of the donor DNA in breakage-prone fragile sites, or in sites with 
DSBs generated by DNA metabolites or environmental mutagens306.  
The second key parameter, the efficiency of gene targeting is mainly mediated by delivery of 
genome editing tools into the target cells, which highly depends on the target cell type. For 
example, in the case of the HSCs, difficulties related to their transfection imply that the 
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delivery of nucleases and donors rely on other approaches such as transduction with viral 
vectors or electroporation117. However, viral vectors are sometimes difficult to produce due to 
the size of the donor transgenes. On the other hand, electroporation although nowadays is not 
as toxic as it used to be, still induces apoptosis and cell death in many different cells types. Due 
to all these reasons, an improvement of these technologies is necessary in order to efficiently 
conduct gene targeting. 
Finally, the fidelity of gene editing is based on the efficiency of the process to restore the 
sequence of the edited locus, without generating not intentioned mutations on it. This will 
reduce collateral adverse genome-modifying events derived from the targeting process. In this 
regard, homology-directed repair (HDR) strategies mediated by nucleases are multifaceted 
because their ultimate efficacy depends not only on the nuclease specificity but also on the 
fidelity with which the exogenous DNA is inserted at the targeted site. Fidelity is also 
compromised by the insertion of concatemeric sequences generated through non-homologous 
recombination processes, such as NHEJ. Although targeted, sometimes the integrated 
sequences can introduce vehicle-derived backbone fragments, such as viral or bacterial 
sequences, into the cellular DNA. Moreover, in nuclease-exposed populations, a substantial 
fraction of targeted alleles will undergo gene disruption instead of homology-directed gene 
targeting. These stems from the fact that NHEJ occurs throughout the cell cycle and competes 
with HR for DSB repair307. The use of nickase variants of nucleases, which generate single 
strand breaks in the genome instead of DSB, has shown to trigger the repair of these lesions 
through HDR rather than NHEJ308,309. Finally, it has also been proven that, for the gene 
correction of recurrent point mutations, donor sequences consisting in single stranded 
oligonucleotides offer a simpler and faster alternative to plasmid and viral vector donor 
DNAs121. 
In the early stages of gene targeting, the main focus of the research was the efficiency of the 
process. However, once the efficiency is reached, improvements in the specificity of the 
nucleases and in the fidelity of the approach are also required. 
Gene editing is a growing and a trending topic field in gene therapy. Most of the leader gene 
therapy teams are working in therapeutic and applied aspects of gene editing, and just this 
year, more than 190 papers have been published about this topic. From the clinical point of 
view, the most advanced nucleases are the ZFNs, probably because they were the first 
developed nucleases and also due to their high efficiency in hematopoietic cells. In this 
respect, nowadays there are seven different clinical trials to treat HIV-1 patients using ZFNs 
that target CCR5, a co-receptor used by the virus to enter into T cells. These trials are based on 
the disruption of this gene using specific ZFNs in CD4+ cells and also in hematopoietic stem and 
progenitor cells (HSPCs)62,110,111. Furthermore, two preclinical studies to treat two different 
monogenic disorders (X-SCID113 and sickle cell anemia115) have been already published based 
on a ZFN-mediated knock-in strategy. There is also a very advance study in which adeno-
associated vectors (AAVs) were used to carry ZFNs and donors to treat in vivo hemophilic mice 
using a knock-in strategy134,310. 
The final aim of our study is to develop a targeted GT approach in CD34+ cells from Fanconi 
anemia A (FA-A) patients. In terms of specificity we have used ZFNs specifically targeting the 
  DISCUSSION 
 
113 
 
AAVS1 locus, whose safety and efficiency has been already demonstrated65,69. Moreover, we 
have used ZFNs in which the FokI nuclease presents mutations that obligate it to work as a 
heterodimer102,103. Aiming to increase the efficiency of gene targeting, we have investigated 
the use of gold nanoparticles (AuNPs) to increase the transduction efficiency of lentiviral 
vectors, including integrase-defective lentiviral vectors (IDLVs). Potential increments in 
transduction efficiency could be associated with increases in the percentage of targeted cells, 
since more cells would incorporate the donor construct. Finally, in terms of fidelity we have 
investigated the potential increment of homology directed repair (HDR) in FA-A by the 
inhibition of an antirecombinase protein called PARI. 
2. Gene targeting with control vectors in 
healthy donor hematopoietic cells 
As it has been mentioned, gene editing strategies represent the best alternative to 
conventional GT, since the insertion of the gene of interest in the cell genome is controlled, 
avoiding the potential risk of insertional mutagenesis2. The application of this approach in the 
clinics appeared really improbable only a few years ago, due to the extremely low frequency of 
HR. However, the development of different types of nucleases generating DSBs in a specific 
site of the genome, has increased the frequency of HR up to 10,000 times311, getting the 
application of gene targeting closer to the clinics. Therefore, genome editing technologies 
based on programmable nucleases are opening up the possibility of achieving therapeutic 
genome editing in diseased cells, resulting in the removal312 or correction of deleterious 
mutations, or the insertion of wild type genes. Designed nucleases enable the precise genome 
editing by introducing DNA DSBs at specific genomic loci. DSBs subsequently recruit the 
endogenous machinery of the cells to repair by NHEJ or HR the DSBs, facilitating in the case of 
HDR genome editing. The DNA repair mechanism selected by the cell depends on its cycling 
state, and also on the presence of a repair template: the donor. During the present thesis we 
have established a robust protocol of gene targeting for different types of hematopoietic cells, 
mainly lymphoblastic cell lines (LCLs) and hematopoietic stem and progenitor cells (HSPCs) 
(CD34+ cells) using ZFNs as a tool to facilitate the targeting in the AAVS1 safe harbor locus.   
In our case we selected the AAVS1 safe harbor strategy to accomplish our gene targeting 
experiments for several reasons: AAVS1 locus has been deeply characterized. It consistently 
allowed higher transgene expression as compared with another safe harbor locus, such as the 
CCR5, in several human cell types including CD34+ cells113, when different constructs were 
used. Additionally, the promoter of the PPP1R12C gene, located in the AAVS1 locus, facilitated 
in most instances the expression of the transgenes since this gene is constitutively transcribed 
in most cell types. Moreover, the chromatin in this locus presents an open conformation, 
which facilitates the incorporation of the transgenes and the expression driven from the 
exogenous promoters inserted together with the transgene. Even more, transgene insertion in 
AAVS1 locus do not upregulate the targeted and flanking genes65, and finally, and more 
importantly, the interruption of the AAVS1 locus does not produce any pathological effect68. 
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These observations let us to predict that transgene insertion should have no detrimental 
consequences in targeted HSPCs.  
Gene targeting mediated by HDR could be achieved in three different ways: gene correction, in 
which the mutated sequence is replaced by the original one; knock-in, in which a partial cDNA 
of the gene of interest is introduced in its endogenous locus; and safe harbor, in which the 
whole expression cassette is inserted in a safe site in the genome. We considered that safe 
harbor approaches may constitute an advantage in FA, since 19 different complementation 
groups have been described so far. This implies that other HDR-mediating gene targeting 
strategies, such as knock-in, would require the development and testing of 19 different 
nucleases and donors. Furthermore, gene correction, although it could be possible in FA-A 
patients from the intron 2 of the protein (the majority of mutations are allocated after the 
second intron of the gene59), it would require the generation and deeply characterization of 
new nucleases and donor substrates. Our selected safe harbor strategy presents the additional 
advantage that highly characterized ZFNs designed for the AAVS1 site have been already 
generated and used in different studies65,69,75. In contrast, the main disadvantage of the safe 
harbor strategy is the loss of the endogenous regulation of the inserted gene as it is not 
located in its original locus. However, this potential limitation could be solved, at least in part, 
using the endogenous promoter of the therapeutic gene if it is known, as is the case of 
FANCA
313. Using this kind of strategy and only changing the transgene and maybe the 
promoter, any monogenic disease could be in principle treated by this approach. Nevertheless, 
a deep study of the regulation of the gene of interest to evaluate potential problems derived 
from the down- or up-regulation of the therapeutic protein in the cell of interest are 
necessary. In the case of FA, a previous study from our laboratory has shown that FANCA 
expression mediated by ubiquitous PGK promoter allows the correction of the phenotype in 
hematopoietic cells from FA-A patients reaching FANCA expression levels similar to healthy 
donors (HD). Even more, this study also showed that levels of FANCA expression are not a 
critical point since both, low levels of expression directed by VAV promoter, and supra-
physiological levels directed by SFFV promoter corrected the FA phenotype in hematopoietic 
cells290. Moreover, experiments conducted in our laboratory overexpressing hFANCA in healthy 
donor cells, did not induce any toxicity290.  
Zinc finger nucleases are the only nucleases that have been approved so far in clinical trials to 
treat HIV-1 patients by knocking out the CCR5 receptor, which is a co-receptor used by the 
virus to enter into the cells110. In this respect, it has been demonstrated that the disruption of 
this gene in CD4+ cells did not mediate any deleterious effect62. It has also been demonstrated 
that the use of ZFNs to target the CCR5 in CD34+ cells is also feasible, and could be a long term 
treatment for patients infected with HIV-1. In that study the nucleofection of the ZFNs as 
plasmid DNA induced a 17% of disruption of CCR5, maintaining the differentiation potential of 
edited cells to any lineage and their repopulation capacity in immunodeficient animals111. 
However, considering that the AAVS1 locus supports higher transgene expression than CCR5, 
we selected ZFNs targeting the AAVS1 locus as the most appropriate tool to conduct our gene 
targeting studies. 
The target cell type is a major issue in gene targeting approaches. In most of the 
hematopoietic diseases the target cell of interest is the HSCs, since the correction of this 
  DISCUSSION 
 
115 
 
population of cells will lead to the generation of corrected cells in the different hematopoietic 
lineages. However, in contrast to other hematopoietic diseases in which a specific lineage is 
affected, in the case of FA the hematopoietic stem cell is also affected, leading to a defective 
generation of mature cells and finally to the BM failure. This complicates gene targeting 
approaches in FA compared with other hematopoietic diseases. 
Targeting of HSCs with nucleases is really challenging. There are different strategies to 
introduce the ZFNs in hematopoietic cells: the cells could be transduced with non-integrative 
viral vectors such as IDLVs112 or AdVs314 carrying the nucleases, or they could be nucleofected 
with the ZFNs as plasmid DNA111, mRNA113,115 or protein315. Although the transduction with 
these kind of viral vectors would not mediate their integration in the genome of the 
hematopoietic cell, their effects could remain for some time in these type of slowly 
proliferating cells leading to toxicity316. On the other hand, nucleofection has been associated 
with a relatively high toxicity for CD34+, leading to the loss of engraftment potential, although 
more recently less toxic approaches have been described113,115. IDLVs and nucleofection using 
plasmid DNA has the problem, although it is improbable, of random integration of the 
nuclease in the genome leading genomic instability. Moreover, the nucleofection of DNA is 
always more toxic than nucleofection of mRNA or proteins, due to the activation of cellular 
immunity mechanisms. The delivery of ZFNs as mRNA or protein ensures a rapid burst of 
expression and also avoids the possible insertional risk. However, the in vitro synthesis of 
proteins is more technically difficult than the in vitro synthesis of mRNA, so we decided to 
select the delivery of the ZFNs as mRNA in our experiments. Moreover, ZFNs used as mRNA 
showed to be a good method to conduct gene targeting in CD34+ cells113,115. We tested two 
different pairs of ZFNs: one of them without any regulatory region, and the other with the 
regulatory regions of the tobacco etch virus and human β-globin, based on previous studies 
shown that modifications in RNA during the synthesis of the nucleases increment its activity317. 
In our hands, the presence of these regulatory regions diminished the cutting efficiency of the 
ZFNs (Figure 29), and therefore reduced the gene targeting in LCLs (Figure 30 b), and also 
completely abolished the gene targeting in hematopoietic progenitors, (Figure 38). 
One of the most important parameters to analyze when a new nuclease is developed is its off-
target activity that can lead to the unspecific integration of the donor cassette, potentially 
inducing genetic instability. To minimize the off-target activity, we selected the AAVS1 ZFNs 
developed by Sangamo Bioscience which have been deeply characterized. Although one 
published report showed that AAVS1 TALENs were more specific than ZFNs, only very low off-
target effects were detected66. These ZFNs were firstly studied in the work of Hockemeyer and 
coworkers69, in which they demonstrated by Southern blot analysis that gene targeting in an 
embryonic stem cell line only presented the site-specific integration. Moreover, in the work of 
Rio et al75 we also demonstrated by Southern blot that the integration mediated by these ZFNs 
was also site-specific. In the study of Lombardo and coworkers65, the authors analyzed how the 
integration of a promoter and a transgene affected the expression and regulation of 
neighboring genes in different cell types, showing that the use of the PGK promoter together 
with a transgene did not alter the expression of neighboring genes. These ZFNs were also used 
in the study of Genovese and coworkers113, in which they efficiently targeted CD34+ cells using 
a GFP donor and they observed by Southern blot analysis of iPSCs derived from GFP+ sorted 
gene targeted cells, that the integration in this locus was site-specific. 
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We also tested different ways to deliver the donor to lymphoblastic cell lines. First we used the 
donor as plasmid DNA. This is easy to produce and also cheap, but presents a potential risk of 
random integration. Although plasmid donors have not been used in HSPCs, probably due to 
the toxicity and difficulty to deliver this molecule in this kind of cells, its efficiency has been 
proven in other set of cell types, such as K56270,97,118, CD4+ T cells118 and human embryonic 
stem cells (hESCs)69 accomplishing efficiencies between 7.7-18%, 5.3% and 50% of hESCs 
selected clones respectively.  
Then, we used the donor as IDLV. IDLVs have been already tested in LCLs65,112, reaching 
efficiencies between 5.4-12% and in CD34+ cells113,115 with efficiencies between 6-18%. The 
main limitation of IDLV is their production since IDLV vector production often results in lower 
titers as compared with ICLVs, limiting the transduction of primary cells, and therefore 
reducing the gene targeting efficiency. Moreover, the variability observed between IDLV 
productions is higher than in ICLV productions. Using donor as DNA we could achieve gene 
targeting in LCLs, but the frequencies that we obtained were lower than the ones obtained 
with IDLV (around 3% using DNA as donor compared with 10% using IDLVs) (Figure 32, Figure 
33). The levels of gene targeting that we obtained using IDLV as donor are comparable with 
the ones obtained by Lombardo and coworkers using the donor and the ZFN as IDLVs65. Taking 
this into account, we selected the donor as IDLV for our gene targeting experiments in CD34+ 
cells. Consistent with our studies, the only two papers published in gene editing in CD34+ cells 
also used IDLV as the method to deliver the donor construct113,115.  
When gene targeting is performed, it is important to verify that the integration is site-specific. 
In order to do that, different approaches can be performed. Sequencing of the entire genome 
of single clones is time consuming and expensive, but is the most accurate technique to detect 
the overall targeting events that are occurring in each cell. Another possibility is to conduct 
only the sequencing of the targeted sequence. An alternative strategy that can be used and 
that gives information of the targeting events in the entire genome is the Southern blot 
analysis. However, the amount of sample required to perform this technique is not always 
possible to collect, especially when the target population consist on primary cells in which the 
expansion is limited as it is the case of HSPCs. Finally, the most frequently used approach to 
verify if the integration is site-specific is the PCR, using primers that hybridize outside and 
inside of the donor cassette using both integration ends, the 5’ and the 3’. Using this technique 
we have only detected on-target events in the desired locus. However, we cannot be sure if 
some concatemeric insertions were generated, or if there are a few off target events. Although 
PCRs interrogating both sides of the targeted locus constitute a routine widely used analysis, it 
presents a limit of detection when bulk populations are used. We investigated the PCR 
detection limit in a sample in which gene targeting was confirmed both by flow cytometry and 
also by PCR (Figure 35). We estimated that percentages of integration below 2.25% in a bulk 
population induced with our GFP donor IDLV were not detected by PCR. One possibility to 
overcome this problem, in the case in which the gene targeting is performed with some 
reporter genes such as GFP, is to sort GFP positive cells in order to enrich the gene targeted 
cell population as it has been done in previous reports113. 
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In order to conduct gene targeting in CD34+ cells, we pre-stimulated the cells for two days to 
promote the cycling of the primitive HSCs, most of which are quiescent in bone marrow (BM), 
umbilical cord blood (UCB) or mobilized peripheral blood (mPB)318. Cycling is necessary to 
activate the HR in these cells. Otherwise DSBs generated by the ZFN would only be repaired by 
NHEJ, since HR is only active in the G2/S phases of cell cycle. The increased HDR-mediated 
targeting in pre-stimulated HSCs was also demonstrated in the study of Genovese and 
coworkers113 in which they observed a significant increase in the percentage of GFP+ cells when 
CD34+ cells were pre-stimulated for two days before conducting the gene targeting approach. 
Although these authors added some molecules to prevent the differentiation of the HSCs, such 
as aryl hydrocarbon receptor antagonist (SR1) and/or 16,16-dimethyl-prostaglandin E2, we 
saw that we could achieve slightly increased percentages of GFP+ cells in the primitive HSCs 
(CD34+ CD133+ CD90+) in the absence of these compounds (4.5% of GFP+ cells compared with 
3% measured at day 7 of culture113) (Figure 42 a) without affecting its engraftment and 
repopulating capacity (Figure 46). In agreement with the study of Genovese et al113, the lowest 
gene target efficiency is observed in the most primitive subset (Figure 42). Eight different 
experiments were carried out in CD34+ cells using different samples of thawed UCB, which 
revealed the reproducibility of the targeted GT (Table 12). On average we obtained 10.42% 
GFP positive cells (Figure 41), which reflected a gene targeting efficiency of 9.43%, considering 
that 90.48% of the GFP positive colonies had the specific integration of the donor in the AAVS1 
site. The efficacy of targeting achieved in our experiments could be enough to obtain a clinical 
benefit in FA patients, as it has been demonstrated that the spontaneous reversion of only one 
progenitor cell can reconstitute the hematopoiesis of the patient due to the proliferative 
advantage that corrected cells present over non-corrected ones5. However, our gene targeting 
efficiencies are lower than the ones obtained in a more recent study (18% in CD34+)115. 
Nevertheless, in this study they targeted the mutated locus using a therapeutic donor IDLV and 
following a knock-in strategy in comparison with our safe harbor strategy using GFP donor 
IDLV which was also investigated in the study of Genovese and coworkers113. Moreover, the 
efficiency of gene targeting in Hoban study is measured by Q-PCR assay, and we measured this 
efficiency by flow cytometry as Genovese et al113.  
Our results showed that the increment of gene targeting efficiency correlates with an increase 
in the efficiency of ZFN to generate DSBs (measured by %NHEJ), suggesting that the donor is 
not a limiting factor for gene editing in our approach. 
Since our final goal is to conduct gene editing in HSPCs from FA-A patients and to demonstrate 
their capacity to restore their hematopoiesis in the long term; we also evaluated if gene 
targeted HSPCs presents multilineage repopulating potential. To test their repopulating 
capacity, gene edited CD34+ cells were transplanted in sublethally irradiated immunodeficient 
mice. For this purpose we selected NSG-SGM3 mice strain, which constitutively express three 
different human cytokines: human interleukin-3 (IL-3), granulocyte/macrophage-stimulating 
factor (GM-CSF) and steel factor (SF). This mouse strain was developed to increase the 
engraftment potential of acute myeloid leukemia (AML) cells, a process which also depends on 
the continuous cytokine stimulation of these cells319. As shown in Figure 46 a, we obtained a 
stable engraftment of human cells in all transplanted mice at 90 dpt, with a median of human 
engraftment of 17.1%. Furthermore, 83.3% of the transplanted mice presented GFP positive 
engraftment with a median of 11.9% of GFP+ cells in the human engraftment (mean: 14±12%) 
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(Figure 46 b). This value is very similar to the gene targeting efficiency detected in CD34+ cells 
in vitro before the transplantation (10.42±4.91%) suggesting the efficient targeting of the 
HSPCs and that targeted HSPCs do not present any engraftment disadvantage in comparison 
with non-targeted ones. These results are in contrast to previous studies, in which the 
percentage of GFP+ cells decreased after transplant113,115. This could be due to differences in 
the strains of immunodeficient animals used, as in these studies the authors used the NSG 
mouse strain, while we used the NSG-SGM3 strain. Since we are directing our gene targeting 
strategy to the HSPCs, capable to differentiate towards the different hematopoietic lineages, 
we also confirmed the presence of GFP positive cells in all different subpopulations present in 
the BM (Figure 47), pointing out that we have targeted HSPCs and that gene editing did not 
interfere with the multilineage potential of these cells. Moreover, the PCR analysis of the site-
specific integration in GFP positive colonies obtained from the BM of transplanted recipients 
showed that the integration was maintained over time in the HSPCs (Figure 48).  
Strikingly, when we used the donor in which the FANCA gene expression is driven by the PGK 
promoter and the GFP by the endogenous promoter of the PPP1R12C75 (Figure 16), we did not 
observe GFP expression in gene-edited LCLs (Figure 36) or in CD34+ cells (Figure 49 a). 
However, we were able to confirm the targeted integration of this cassette in the AAVS1 locus 
by PCR analyses in both cell types (Figure 37, Figure 49 b). In contrast, in a previously published 
study, GFP expression from PPP1R12C promoter was detected in a B lymphoblastic cell line 
after gene targeting65, and we were also able to detect GFP expression of this donor cassette in 
fibroblasts from healthy donors and FA patients75. It has been proven that viral titers 
decreased semi-logarithmically with increasing vector lengths320 and therefore the 
transduction efficiency reached with bigger vectors such as our GFP-FANCA donor (14.6 kb) 
was lower compared to the one obtained using smaller vectors such as GFP donor (9.7 kb). 
This lower transduction efficiency reduces therefore the gene targeting and this could impede 
us to detect any GFP signal by flow cytometry in hematopoietic cells, which are cells more 
difficult to target than fibroblasts. 
However, as we were able to detect specific integration of this GFP-FANCA donor in pools of 
colonies positive for GFP presence by Q-PCR (Figure 49 b), NSG-SGM3 mice were transplanted 
to evaluate the engraftment and multilineage reconstitution capacity of gene edited cells 
targeted using GFP-FANCA donor. Our results demonstrated that integration of hFANCA 
cassette in the AAVS1 locus did not affect the engraftment capacity of these cells (Figure 50). 
Moreover, we still detected GFP engraftment by Q-PCR and this engraftment could also lead to 
all the different hematopoietic subpopulations (Figure 51). Additionally, the human 
engraftment of these cells was similar to the one obtained using the GFP donor (Figure 46 a). 
Therefore, despite the big size of the donor therapeutic construct, in comparison with 
previously used donors113,115, we were able to target CD34+ cells, and this population of 
targeted cells showed in vivo reconstitution capacity in immunodeficient mice.  
Since one possible approach to increase the efficiency of gene targeting rely on the 
improvement in the delivery of the donor and the nuclease, we investigated the efficiency of 
combining AuNPs with the IDLVs as a potential approach to improve the efficiency of gene 
targeting. Gold nanoparticles (AuNPs) have been used as carriers to introduce different 
molecules in many cell types and organisms, both in vitro and also in vivo. These particles have 
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been combined with siRNAs by electrostatic charges (AuNP is positively charged and the 
siRNAs present negative charge)145 or covalently conjugated with them obtaining good results 
of gene silencing in different models, from cells to complex organisms such as mice143,144. Here, 
we have demonstrated for the first time that the combination of AuNPs with ICLVs and IDLVs 
doubles the transduction efficiency of both types of vectors in HSPCs in vitro (Figure 53). 
Moreover, we have proven that AuNP-mediated transduction of LVs in CD34+ increases its 
transduction efficacy as revealed by in vitro assays (Figure 53) and also in short-term 
repopulating experiments (Figure 54 b). This effect was even more pronounced when lower 
MOIs were used, probably because with higher MOIs maximum transduction efficiency is 
reached in all circumstances. In spite of these data, the application of AuNPs to our gene 
targeting protocol resulted in high toxicity. This is probably due to the nucleofection step used 
to introduce the ZFN mRNAs in the cells to counteract this effect. One possibility would be to 
deliver the nucleases and also the donor as IDLV, in combination with the nanoparticles. The 
delivery of both as IDLV has been already proven in CD34+ cells with very modest efficiency112, 
but the use of gold nanoparticles could increase their efficiency maintaining a low toxicity. 
Recent studies have also demonstrated that the addition of some drugs such as 
rapamycin139,140 increases the transduction efficiency of ICLVs and IDLVs in human and mouse 
HSCs without disturbing the main characteristics of these cells and decreasing the timing of 
culture of these stem cells. However, when we tested the effect of rapamycin in gene targeting  
experiments, although we detected an increment in the transduction efficiency, a negative 
effect in the gene targeting efficiency was observed (data not shown); probably related with 
other effects induced by rapamycin on the cell, such as inhibition of cell cycle progression321. 
3. Gene targeting in Fanconi anemia 
hematopoietic cells 
Monogenic disorders that affect the hematopoietic system are one of the main targets of 
conventional gene therapy due to the accessibility of the hematopoietic stem and progenitor 
cells (HSPCs) and the improvements in hematopoietic stem cell manipulation and 
transplantation (HSCT). Advances in the development of integrative vectors such as lentiviral 
vectors (LVs) with a safer integration profile than RVs24, the development of self-inactivating 
(SIN) vectors lacking the strong promoter activity of the LTRs, and the use of weaker or cell 
lineage promoters, has increased the safety of gene therapy (GT), as it has been proved in 
different successful clinical trials, such as the SCID-X1 clinical trial with SIN-γ-RV13 or WAS 
clinical trial with SIN-LVs18. 
In spite of the advances of conventional GT, the site of insertion of the transgene in these 
conventional GT approaches is not controlled. Gene editing could overcome this limitation, 
and for that reason many efforts are nowadays focused on the treatment of monogenic 
disorders, such as FA, using gene editing approaches. 
Fanconi anemia cells present a clear advantage to perform gene targeting, which derive from 
the proliferative advantage of corrected cells over the non-corrected ones. However, the main 
disadvantage of FA-GT is that the main affected cells are the HSCs, which limits the number of 
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cells to conduct gene editing. Additionally, the frequency of homologous recombination in FA 
cells could be low due to their DNA repair defects. In this study, we first tested if gene 
targeting is feasible in FA-A hematopoietic cells. It has been described that mutations in 
proteins of the FA core complex result in only mild HR defects in mammalian cells228 except for 
HR repair of cross links coupled to replication232. Although some FA proteins such as 
FANCD1/BRCA2 clearly promote HR, members of the core complex are not essential 
components of the HR machinery151. On the other hand, FA cells have levels of NHEJ that are 
comparable with those of complemented cells228. A previous study from our laboratory has 
also shown the feasibility to conduct gene editing in fibroblast from FA-A patients75. However, 
there is no study showing the efficiency of gene editing in hematopoietic cells from FA 
patients, which are the preferential target to conduct gene editing, as defects in these cells are 
responsible of one of the main cause of death in these patients, the bone marrow failure. To 
clarify if HDR-mediated GT can be conducted in hematopoietic cells from FA patients we 
performed three independent experiments in four different LCLs from FA-A patients, either 
uncorrected or corrected with a therapeutic LV, to compare the respective gene targeting 
efficiency (Figure 59). Our results showed that the correction of the FA pathway in FA-A LCLs 
mildly increased the efficiency but was not essential for HDR, confirming for the first time the 
feasibility to conduct gene editing in hematopoietic cells from FA-A patients.  
Working with a plasmid donor we have observed that the off-target integrations in FA-A LCLs 
are more frequent when compared with healthy donor cells (Figure 63). This observation can 
be explained by the fact that increasing spontaneous DSBs in FA cells can lead to higher 
increase in random integration. This, together with the fact that cells which incorporate the 
FANCA transgene, either in the AAVS1 site or randomly, present a proliferative advantage 
could lead to a population of selected cells with a high proportion of cells harboring the FANCA 
gene in off-target sites. However, in contrast with the high percentage of off-targets observed 
with plasmid DNA, the use of IDLV vectors markedly improved the targeted integration, and 
thus the safety of this process. In this case the proliferation advantage of cells that incorporate 
randomly the donor is an adverse event, as the donor cassette incorporates an ubiquitous 
promoter and therefore is expressed in any place in which it integrates. One possible solution 
could be the use of a donor construct with a splicing acceptor site such as E2A without 
promoter. This direct the expression of the transgene from the endogenous promoter of the 
AAVS1 locus, but in this case the level of the protein expression should be evaluated, as we do 
not know if it could be high enough to correct the FA phenotype. 
During the present thesis we have developed a new therapeutic vector (FANCA-Puro donor) 
because of the difficulties to detect the reporter gene after targeting of the GFP-FANCA 
donor75 in the AAVS1 site of hematopoietic cells (Figure 36 and Figure 49). This new 
therapeutic donor vector contains the puromycin resistance gene, instead of a fluorescence 
reporter gene, that would allow us to select targeted HSCs in short periods of time (24 
hours)69, to prevent the in vitro differentiation of HSCs. This antibiotic resistance gene is also 
under the control of the PGK promoter, as it is placed downstream the FANCA gene and 
preceded by an E2A splicing acceptor site. This is in contrast to the GFP gene in the GFP-FANCA 
donor, which expression was driven by the endogenous promoter of the PPP1R12C after HDR 
in the first intron of this locus. To assure the functionality of the new vector we tested it as an 
ICLV in FA-A LCLs, showing reversion of the classical FA phenotype: reversion of MMC hyper-
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sensitivity (Figure 60 a), as well as the re-expression of the FANCA protein (Figure 61) and 
finally the restoration of the FANCD2 nuclear foci formation after DNA damage (Figure 62). All 
this data constitutes a proof that the FA/BRCA pathway was reestablished after transduction 
with this therapeutic vector. In addition to these results we also noted that transduced cells 
became resistant to puromycin confirming that the selection gene was also working (Figure 60 
b). 
It is known that GT efficiency depends on transduction efficiency which also depends on the 
viral titer, a parameter that is related to the size of the transfer vector. Larger vectors lead to a 
reduction in the titer, and consequently in the transduction efficiency320. Taking this into 
account, the efficient transduction of hematopoietic cells with large vectors, such as the ones 
carrying the GFP and FANCA genes (GFP-FANCA vector: 10.7 kb) and the FANCA and puromycin 
resistant genes (FANCA-Puro vector: 10.1 kb), is challenging, since previous studies have used 
much smaller constructs113,115. Interestingly, our results show for the first time that gene 
targeting can occur with donor vectors such as GFP-FANCA and FANCA-Puro donors in 
hematopoietic cells from HD (Figure 49) and also from FA-A patients (Figure 64, Figure 66). 
As observed after transduction with the GFP-FANCA and FANCA-Puro ICLVs, our gene targeting 
experiments demonstrated the phenotypic correction of FA deficient hematopoietic cells using 
our therapeutic donor vectors (Figure 67, Figure 68). This correction restored the FA/BRCA 
pathway measured by the FANCD2 foci formation (Figure 68), a process that is essential for the 
repair the ICLs. Members of FA core complex are the ones that allow the monoubiquitation 
and recruitment of FANCD2-FANCI complex to the DNA repair foci, so FAND2 foci restoration 
constitutes therefore a hallmark in ICL repair. Moreover, the reversion of MMC hyper-
sensitivity in FA-A cells (Figure 67) confirms the correction of the FA phenotype. 
One possibility for enhancing the efficacy of gene targeting is based on the use of small 
molecules capable of enhancing the HR in the cell. Several groups have studied this possibility 
using small molecules such as L755507, which has been reported to increase the HDR 
efficiency in different cells types treated with CRISPR/Cas9 nucleases147. Moreover other 
groups has inhibited key components of NHEJ such as DNA ligase IV, during their gene 
targeting experiments in order to increase the efficiency of HDR148,149. In our experiments, the 
repair of nuclease derived-DSBs by NHEJ was, as expected, higher than that mediated by HDR 
in HSPCs (Table 12). HSPCs are more quiescent cells318, and the HR machinery is only turned on 
during the S-phase of the cell cycle. As it has been already mentioned, one possible approach 
to increase the efficiency of HDR is to use nickase variants instead of nucleases308,309. This 
approach was addressed in FA cells in the Osborn and coworkers’ study, in which they use a 
CRISPR/Cas9 nickase to promote HDR in FA-C cells292. However, in this study although the 
nickase reduces the percentage of NHEJ events to repair the DSBs, it also decreases the 
efficiency of HDR with respect to the nuclease. 
In 2012 Moldovan and coworkers published that the inhibition of the antirecombinase PARI in 
FANCD1/BRCA2 deficient fibroblasts increased the efficiency of HR150. In healthy cells, during S-
phase of cell cycle, PARI interacts with PCNA to release RAD51 from ssDNA, avoiding 
recombination events at replication forks. This prevents hyper-recombination events that lead 
to genomic instability. However, in FANCD1 deficient cells, where HR is impaired, PARI 
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inhibition leads to an increase in RAD51 levels and consequently an improvement in HR 
efficiency that finally leads to an increase in genomic stability. In our experiments, we 
demonstrated that siRNA inhibited PARI in both FA-A LCLs (68.12±0.08% of inhibition) and also 
in FA-A fibroblasts (68.51±0.12%). We also showed an increase in RAD51 foci formation, either 
in the presence or absence of DNA damage, in PARI interfered FA-A cells (Figure 69 a), 
suggesting that HR is increased by PARI inhibition not only in FA-D1 cells150, but also in FA-A 
cells. It is also important to consider that the inhibition of this gene in FA-A cells decreased the 
intrinsic genomic instability of these cells (Figure 69 b, c) confirming the protective effects of 
PARI inhibition in FA-A cells, as was also shown by Moldovan et al150 in FA-D1 cells. However, 
when gene targeting was tested in PARI interfered FA-A cells (but not in HD cells), only mild, 
non-significant, increases in gene editing efficiency were observed (Figure 70 b, Figure 72 b), 
probably due to the variability observed between experiments. Although we cannot 
demonstrate robustly that PARI inhibition increases gene targeting in FA-A cells, the use of 
PARI-inhibiting molecules may constitute less toxic a more reproducible approach to 
demonstrate the role of PARI inhibition in gene targeting in FA-A cells, and also could be 
translated easily to HSPCs.  
In our final experiments, we moved from LCLs to hematopoietic progenitor cells from FA-A 
patients. In these studies, we used a very small proportion of mPB CD34+ cells that remained in 
cell collection bags and tubes from the CliniMACS® system used to purify CD34+ cells from FA-A 
patients included in the FANCOSTEM mobilization trial. This procedure was performed after 
the informed consent of patients or their parents and with the approval of the ethic 
committee of the hospitals. Here, we have demonstrated for the first time that gene targeting 
is feasible in FA-A CD34+ cells from four different patients (Figure 73) using a safe harbor 
strategy. Additionally, we demonstrate this approach corrects the phenotype of these cells, as 
we were able to partially restore the MMC sensitivity of these cells after gene targeting with 
the therapeutic donor and also we confirmed the specific integration in the AAVS1 locus by 
PCR after MMC selection (Figure 74). Gene targeting efficiency has been also proven in CD34+ 
cells from patients with other hematological disorders such as SCID-X1, in which gene targeting 
was demonstrated in bone-marrow derived CD34+ cells from one patient113 and sickle cell 
disease, in which gene editing was also shown in BM CD34+ cell aspirates115. Ongoing 
experiments aim to demonstrate the feasibility of gene edited FA-A CD34+ cells to engraft in 
immunodeficient mice. 
Taking into account all our data, we propose that FA-A hematopoietic cells, can be corrected 
by gene editing. Our proposed strategy of gene targeting in a safe harbor locus should 
abrogate the eventual risk of insertional mutagenesis. Moreover, the proliferative advantage 
that FA corrected cells present over non-corrected ones250 suggest that gene editing 
efficiencies obtained in our study might ameliorate the BMF of FA patients. The somatic 
mosaicism observed in FA patients, in whom an in vivo spontaneous reversion of a single HSPC 
corrects the hematopoietic phenotype of the patients support this idea5. However, considering 
the low number of CD34+ cells usually obtained from FA patients, the improvement in gene 
targeting efficiencies will be essential to assure the transplant of a relatively high number of 
corrected cells in the patients and their future successful in the clinics.  
 
   
 
 
 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  CONCLUSIONS 
 
125 
 
 
1. 
Aiming at the development of new targeted gene therapy approaches in FA-A cells, we have 
constructed an IDLV harboring the FANCA gene under the regulation of the PGK promoter and 
flanked by the homology arms corresponding to the first intron of the AAVS1 locus. 
2. 
The combined use of zinc finger nucleases specific for the AAVS1 locus together with IDLV 
donors, either harboring the GFP reporter or the FANCA therapeutic genes, facilitated the 
targeted integration of these genes into LCLs and cord blood hematopoietic stem cells from 
healthy donors. 
3. 
The transplantation of targeted CD34+ cells into NSG-SGM3 immunodeficient mice allowed us 
to demonstrate the specific integration of the GFP reporter gene in the AAVS1 safe harbor 
locus in human long term hematopoietic repopulating cells at average efficacies of 11%. This 
value constitutes the highest level of gene targeting reported so far in human hematopoietic 
stem cells. 
4. 
The use of gold nanoparticles improved the transduction efficiency of lentiviral vectors in 
hematopoietic progenitors and short-term repopulating cells. However, the combination of 
gold nanoparticles with nucleofection was very toxic for CD34+ cells, preventing their 
application in our gene targeting approaches. 
5. 
The gene targeting efficiency observed in FA-A LCLs was only modestly reduced as compared 
with that observed in either their corrected counterparts or in healthy donor LCLs. This 
demonstrates for the first time that FANCA protein, a member of the core complex of the 
FA/BRCA pathway, is not essential to conduct gene targeting in the genome of hematopoietic 
cells. 
6. 
The targeted integration of FANCA in the AAVS1 locus of FA-A LCLs restores the formation of 
FANCD2 foci and the correction of the hyper-sensitivity of these cells to mitomycin C. 
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7. 
The inhibition of the antirecombinase PARI increased the proportion of FA-A cells with RAD51 
foci, but did not significantly improve the efficacy of gene targeting, either in LCLs or in 
fibroblasts from FA-A patients. 
8. 
Our gene targeting approach showed for the first time that gene editing is feasible in 
hematopoietic stem and progenitor cells from FA-A patients, leading to the partial reversion of 
their characteristic hyper-sensitivity to mitomycin C. 
 
Altogether the results presented in this study demonstrate for the first time the feasibility of 
conducting targeted gene therapy in hematopoietic progenitor cells from FA patients 
characterized by DNA repair defects. These results open new perspectives for the 
development of the safest gene therapy approach that nowadays can be envisaged for the 
treatment of monogenic diseases. Our data also reflects that further improvements in gene 
editing efficacy should be developed before these strategies could be applied for the 
treatment of patients affected by FA or similar devastating diseases. 
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1. 
Con el objetivo de desarrollar nuevas aproximaciones de terapia génica de edición en células 
AF-A, hemos construido un vector lentiviral defectivo en integración (VLDI) que porta el gen 
FANCA regulado por el promotor PGK y flanqueado por los brazos de homología 
correspondientes al primer intrón del locus AAVS1. 
2. 
La combinación de nucleasas de dedos de zinc específicas para el locus AAVS1 con VLDIs que 
portan el gen marcador GFP o el gen terapéutico FANCA, facilita la integración dirigida de estos 
genes en células linfoblastoides (LCLs), así como en células CD34+ de sangre de cordón 
umbilical de donantes sanos. 
3. 
El trasplante de células CD34+ editadas genéticamente en ratones inmunodeficientes NSG-
SGM3, nos permitió demostrar la integración específica del gen marcador GFP en el locus 
seguro AAVS1 en el 11% de las células hematopoyéticas con capacidad de reconstitución a 
largo plazo. Este es el nivel más alto de edición génica obtenido hasta el momento en células 
madre hematopoyéticas humanas. 
4. 
El uso de nanopartículas de oro mejoró la eficacia de transducción de los vectores lentivirales 
en progenitores hematopoyéticos y en células con capacidad de repoblación a corto plazo. Sin 
embargo, la combinación de nanopartículas de oro con nucleofección resultó muy tóxica para 
las células CD34+, lo que impidió su aplicación en nuestra aproximación de edición génica. 
5. 
La eficiencia de edición génica en LCLs de AF-A es sólo ligeramente inferior a la observada en 
las mismas células corregidas genéticamente o en LCLs de donantes sanos. Esto demuestra por 
primera vez que la proteína FANCA, un miembro del complejo core de la ruta AF/BRCA, no es 
esencial para llevar a cabo terapia génica de edición mediada por recombinación homóloga en 
células hematopoyéticas. 
6. 
La integración dirigida del gen FANCA en el locus AAVS1 en LCLs AF-A recuperó la formación de 
focos de reparación de FANCD2, así como la corrección de su hipersensibilidad a mitomicina C. 
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7. 
La inhibición de la proteína anti-recombinasa PARI aumentó la proporción de células AF-A con 
focos de reparación de RAD51, pero no aumentó la eficacia de edición génica en LCLs ni en 
fibroblastos de pacientes con AF-A. 
8. 
Nuestra aproximación experimental demuestra por primera vez que la edición génica es 
factible en células progenitoras hematopoyéticas obtenidas de pacientes con AF-A, 
conduciendo a la reversión parcial de su característica hipersensibilidad a mitomicina C. 
 
En conjunto, los resultados presentados en este estudio demuestran por primera vez la 
posibilidad de realizar terapia génica de edición en células progenitoras hematopoyéticas de 
pacientes con AF, caracterizados por defectos en la reparación del ADN. Estos resultados abren 
nuevas perspectivas para el desarrollo de aproximaciones de terapia génica más segura para el 
tratamiento de diferentes enfermedades monogénicas. Nuestros datos también reflejan que 
para la aplicación clínica de estas estrategias en pacientes con AF y otras enfermedades 
similares, será necesario continuar mejorando su eficacia en las células diana afectadas. 
 
 
   
 
 
 
Bibliography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  BIBLIOGRAPHY 
 
131 
 
 
1 Ghosh, S., Thrasher, A. J. & Gaspar, H. B. Gene therapy for monogenic disorders of the 
bone marrow. British journal of haematology, doi:10.1111/bjh.13520 (2015). 
2 Naldini, L. Ex vivo gene transfer and correction for cell-based therapies. Nature reviews. 
Genetics 12, 301-315, doi:10.1038/nrg2985 (2011). 
3 Kaufmann, K. B., Buning, H., Galy, A., Schambach, A. & Grez, M. Gene therapy on the move. 
EMBO molecular medicine 5, 1642-1661, doi:10.1002/emmm.201202287 (2013). 
4 Kay, M. A. State-of-the-art gene-based therapies: the road ahead. Nature reviews. Genetics 
12, 316-328, doi:10.1038/nrg2971 (2011). 
5 Gross, M. et al. Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular 
self-correction. Cytogenetic and genome research 98, 126-135, doi:69805 (2002). 
6 Aiuti, A. et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. 
The New England journal of medicine 360, 447-458, doi:10.1056/NEJMoa0805817 (2009). 
7 Gaspar, H. B. et al. Hematopoietic stem cell gene therapy for adenosine deaminase-
deficient severe combined immunodeficiency leads to long-term immunological recovery 
and metabolic correction. Science translational medicine 3, 97ra80, 
doi:10.1126/scitranslmed.3002716 (2011). 
8 Candotti, F. et al. Gene therapy for adenosine deaminase-deficient severe combined 
immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood 
120, 3635-3646, doi:10.1182/blood-2012-02-400937 (2012). 
9 Hacein-Bey-Abina, S. et al. Efficacy of gene therapy for X-linked severe combined 
immunodeficiency. The New England journal of medicine 363, 355-364, 
doi:10.1056/NEJMoa1000164 (2010). 
10 Fischer, A., Hacein-Bey-Abina, S. & Cavazzana-Calvo, M. 20 years of gene therapy for SCID. 
Nature immunology 11, 457-460, doi:10.1038/ni0610-457 (2010). 
11 Gaspar, H. B. et al. Long-term persistence of a polyclonal T cell repertoire after gene 
therapy for X-linked severe combined immunodeficiency. Science translational medicine 3, 
97ra79, doi:10.1126/scitranslmed.3002715 (2011). 
12 Mukherjee, S. & Thrasher, A. J. Gene therapy for PIDs: progress, pitfalls and prospects. 
Gene 525, 174-181, doi:10.1016/j.gene.2013.03.098 (2013). 
13 Hacein-Bey-Abina, S. et al. A modified gamma-retrovirus vector for X-linked severe 
combined immunodeficiency. The New England journal of medicine 371, 1407-1417, 
doi:10.1056/NEJMoa1404588 (2014). 
14 Touzot, F. et al. Faster T-cell development following gene therapy compared with 
haploidentical HSCT in the treatment of SCID-X1. Blood 125, 3563-3569, 
doi:10.1182/blood-2014-12-616003 (2015). 
15 Grez, M. et al. Gene therapy of chronic granulomatous disease: the engraftment dilemma. 
Molecular therapy : the journal of the American Society of Gene Therapy 19, 28-35, 
doi:10.1038/mt.2010.232 (2011). 
16 Boztug, K. et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. The New 
England journal of medicine 363, 1918-1927, doi:10.1056/NEJMoa1003548 (2010). 
17 Braun, C. J. et al. Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and 
genotoxicity. Science translational medicine 6, 227ra233, 
doi:10.1126/scitranslmed.3007280 (2014). 
18 Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-
Aldrich syndrome. Science 341, 1233151, doi:10.1126/science.1233151 (2013). 
19 Castiello, M. C. et al. B-cell reconstitution after lentiviral vector-mediated gene therapy in 
patients with Wiskott-Aldrich syndrome. The Journal of allergy and clinical immunology 
136, 692-702 e692, doi:10.1016/j.jaci.2015.01.035 (2015). 
20 Hacein-Bey Abina, S. et al. Outcomes following gene therapy in patients with severe 
Wiskott-Aldrich syndrome. Jama 313, 1550-1563, doi:10.1001/jama.2015.3253 (2015). 
BIBLIOGRAPHY 
132 
 
21 Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene 
therapy of human beta-thalassaemia. Nature 467, 318-322, doi:10.1038/nature09328 
(2010). 
22 Cartier, N. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked 
adrenoleukodystrophy. Science 326, 818-823, doi:10.1126/science.1171242 (2009). 
23 Biffi, A. et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic 
leukodystrophy. Science 341, 1233158, doi:10.1126/science.1233158 (2013). 
24 Gabriel, R., Schmidt, M. & von Kalle, C. Integration of retroviral vectors. Current opinion in 
immunology 24, 592-597, doi:10.1016/j.coi.2012.08.006 (2012). 
25 Cavazza, A., Moiani, A. & Mavilio, F. Mechanisms of retroviral integration and mutagenesis. 
Human gene therapy 24, 119-131, doi:10.1089/hum.2012.203 (2013). 
26 Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after 
gene therapy for SCID-X1. Science 302, 415-419, doi:10.1126/science.1088547 (2003). 
27 Howe, S. J. et al. Insertional mutagenesis combined with acquired somatic mutations 
causes leukemogenesis following gene therapy of SCID-X1 patients. The Journal of clinical 
investigation 118, 3143-3150, doi:10.1172/JCI35798 (2008). 
28 De Palma, M. et al. Promoter trapping reveals significant differences in integration site 
selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105, 2307-
2315, doi:10.1182/blood-2004-03-0798 (2005). 
29 Cesana, D. et al. Whole transcriptome characterization of aberrant splicing events induced 
by lentiviral vector integrations. The Journal of clinical investigation 122, 1667-1676, 
doi:10.1172/JCI62189 (2012). 
30 Moiani, A. et al. Lentiviral vector integration in the human genome induces alternative 
splicing and generates aberrant transcripts. The Journal of clinical investigation 122, 1653-
1666, doi:10.1172/JCI61852 (2012). 
31 Cathomen, T. & Joung, J. K. Zinc-finger nucleases: the next generation emerges. Molecular 
therapy : the journal of the American Society of Gene Therapy 16, 1200-1207, 
doi:10.1038/mt.2008.114 (2008). 
32 Maggio, I. & Goncalves, M. A. Genome editing at the crossroads of delivery, specificity, and 
fidelity. Trends Biotechnol 33, 280-291, doi:10.1016/j.tibtech.2015.02.011 (2015). 
33 Delacote, F. & Lopez, B. S. Importance of the cell cycle phase for the choice of the 
appropriate DSB repair pathway, for genome stability maintenance: the trans-S double-
strand break repair model. Cell cycle 7, 33-38 (2008). 
34 Agarwal, S., Tafel, A. A. & Kanaar, R. DNA double-strand break repair and chromosome 
translocations. DNA repair 5, 1075-1081, doi:10.1016/j.dnarep.2006.05.029 (2006). 
35 Wyman, C. & Kanaar, R. DNA double-strand break repair: all's well that ends well. Annual 
review of genetics 40, 363-383, doi:10.1146/annurev.genet.40.110405.090451 (2006). 
36 Fattah, F. J., Lichter, N. F., Fattah, K. R., Oh, S. & Hendrickson, E. A. Ku70, an essential gene, 
modulates the frequency of rAAV-mediated gene targeting in human somatic cells. 
Proceedings of the National Academy of Sciences of the United States of America 105, 
8703-8708, doi:10.1073/pnas.0712060105 (2008). 
37 Shrivastav, M., De Haro, L. P. & Nickoloff, J. A. Regulation of DNA double-strand break 
repair pathway choice. Cell Res 18, 134-147, doi:10.1038/cr.2007.111 (2008). 
38 Lieber, M. R. The mechanism of double-strand DNA break repair by the nonhomologous 
DNA end-joining pathway. Annual review of biochemistry 79, 181-211, 
doi:10.1146/annurev.biochem.052308.093131 (2010). 
39 Meek, K., Gupta, S., Ramsden, D. A. & Lees-Miller, S. P. The DNA-dependent protein kinase: 
the director at the end. Immunological reviews 200, 132-141, doi:10.1111/j.0105-
2896.2004.00162.x (2004). 
40 Weterings, E. & Chen, D. J. The endless tale of non-homologous end-joining. Cell Res 18, 
114-124, doi:10.1038/cr.2008.3 (2008). 
41 Davis, A. J. & Chen, D. J. DNA double strand break repair via non-homologous end-joining. 
Translational cancer research 2, 130-143, doi:10.3978/j.issn.2218-676X.2013.04.02 (2013). 
  BIBLIOGRAPHY 
 
133 
 
42 Iliakis, G. Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. 
Radiother Oncol 92, 310-315, doi:10.1016/j.radonc.2009.06.024 (2009). 
43 Mladenov, E. & Iliakis, G. Induction and repair of DNA double strand breaks: the increasing 
spectrum of non-homologous end joining pathways. Mutation research 711, 61-72, 
doi:10.1016/j.mrfmmm.2011.02.005 (2011). 
44 Wang, M. et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct 
NHEJ pathways. Nucleic acids research 34, 6170-6182, doi:10.1093/nar/gkl840 (2006). 
45 Zha, S., Boboila, C. & Alt, F. W. Mre11: roles in DNA repair beyond homologous 
recombination. Nature structural & molecular biology 16, 798-800, 
doi:10.1038/nsmb0809-798 (2009). 
46 Lee-Theilen, M., Matthews, A. J., Kelly, D., Zheng, S. & Chaudhuri, J. CtIP promotes 
microhomology-mediated alternative end joining during class-switch recombination. 
Nature structural & molecular biology 18, 75-79, doi:10.1038/nsmb.1942 (2011). 
47 Ellenberger, T. & Tomkinson, A. E. Eukaryotic DNA ligases: structural and functional 
insights. Annual review of biochemistry 77, 313-338, 
doi:10.1146/annurev.biochem.77.061306.123941 (2008). 
48 Sallmyr, A., Tomkinson, A. E. & Rassool, F. V. Up-regulation of WRN and DNA ligase IIIalpha 
in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks. 
Blood 112, 1413-1423, doi:10.1182/blood-2007-07-104257 (2008). 
49 Mladenov, E., Magin, S., Soni, A. & Iliakis, G. DNA double-strand break repair as 
determinant of cellular radiosensitivity to killing and target in radiation therapy. Front 
Oncol 3, 113, doi:10.3389/fonc.2013.00113 (2013). 
50 Cremer, T. & Cremer, C. Chromosome territories, nuclear architecture and gene regulation 
in mammalian cells. Nature reviews. Genetics 2, 292-301, doi:10.1038/35066075 (2001). 
51 Aylon, Y. & Kupiec, M. New insights into the mechanism of homologous recombination in 
yeast. Mutation research 566, 231-248, doi:10.1016/j.mrrev.2003.10.001 (2004). 
52 Bernstein, K. A. & Rothstein, R. At loose ends: resecting a double-strand break. Cell 137, 
807-810, doi:10.1016/j.cell.2009.05.007 (2009). 
53 Aly, A. & Ganesan, S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic 
viability. J Mol Cell Biol 3, 66-74, doi:10.1093/jmcb/mjq055 (2011). 
54 Escribano-Diaz, C. et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 
and BRCA1-CtIP controls DNA repair pathway choice. Molecular cell 49, 872-883, 
doi:10.1016/j.molcel.2013.01.001 (2013). 
55 Truong, L. N. et al. Microhomology-mediated End Joining and Homologous Recombination 
share the initial end resection step to repair DNA double-strand breaks in mammalian cells. 
Proceedings of the National Academy of Sciences of the United States of America 110, 
7720-7725, doi:10.1073/pnas.1213431110 (2013). 
56 Sartori, A. A. et al. Human CtIP promotes DNA end resection. Nature 450, 509-514, 
doi:10.1038/nature06337 (2007). 
57 Grabarz, A. et al. A role for BLM in double-strand break repair pathway choice: prevention 
of CtIP/Mre11-mediated alternative nonhomologous end-joining. Cell reports 5, 21-28, 
doi:10.1016/j.celrep.2013.08.034 (2013). 
58 Garate, Z., Davis, B. R., Quintana-Bustamante, O. & Segovia, J. C. New frontier in 
regenerative medicine: site-specific gene correction in patient-specific induced pluripotent 
stem cells. Human gene therapy 24, 571-583, doi:10.1089/hum.2012.251 (2013). 
59 Castella, M. et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA 
mutations. Blood 117, 3759-3769, doi:10.1182/blood-2010-08-299917 (2011). 
60 Sadelain, M., Papapetrou, E. P. & Bushman, F. D. Safe harbours for the integration of new 
DNA in the human genome. Nature reviews. Cancer 12, 51-58, doi:10.1038/nrc3179 
(2012). 
61 Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some 
multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377 (1996). 
62 Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. 
The New England journal of medicine 370, 901-910, doi:10.1056/NEJMoa1300662 (2014). 
BIBLIOGRAPHY 
134 
 
63 Rottman, J. B. et al. Cellular localization of the chemokine receptor CCR5. Correlation to 
cellular targets of HIV-1 infection. The American journal of pathology 151, 1341-1351 
(1997). 
64 Lim, J. K., Glass, W. G., McDermott, D. H. & Murphy, P. M. CCR5: no longer a "good for 
nothing" gene--chemokine control of West Nile virus infection. Trends in immunology 27, 
308-312, doi:10.1016/j.it.2006.05.007 (2006). 
65 Lombardo, A. et al. Site-specific integration and tailoring of cassette design for sustainable 
gene transfer. Nature methods 8, 861-869, doi:10.1038/nmeth.1674 (2011). 
66 Mussolino, C. et al. TALENs facilitate targeted genome editing in human cells with high 
specificity and low cytotoxicity. Nucleic acids research 42, 6762-6773, 
doi:10.1093/nar/gku305 (2014). 
67 Kotin, R. M. et al. Site-specific integration by adeno-associated virus. Proceedings of the 
National Academy of Sciences of the United States of America 87, 2211-2215 (1990). 
68 Henckaerts, E. & Linden, R. M. Adeno-associated virus: a key to the human genome? 
Future virology 5, 555-574, doi:10.2217/fvl.10.48 (2010). 
69 Hockemeyer, D. et al. Efficient targeting of expressed and silent genes in human ESCs and 
iPSCs using zinc-finger nucleases. Nature biotechnology 27, 851-857, doi:10.1038/nbt.1562 
(2009). 
70 DeKelver, R. C. et al. Functional genomics, proteomics, and regulatory DNA analysis in 
isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in 
the human genome. Genome research 20, 1133-1142, doi:10.1101/gr.106773.110 (2010). 
71 Zou, J. et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS 
cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 
117, 5561-5572, doi:10.1182/blood-2010-12-328161 (2011). 
72 Ramachandra, C. J. et al. Efficient recombinase-mediated cassette exchange at the AAVS1 
locus in human embryonic stem cells using baculoviral vectors. Nucleic acids research 39, 
e107, doi:10.1093/nar/gkr409 (2011). 
73 Smith, J. R. et al. Robust, persistent transgene expression in human embryonic stem cells is 
achieved with AAVS1-targeted integration. Stem cells 26, 496-504, 
doi:10.1634/stemcells.2007-0039 (2008). 
74 Yang, L. et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-
stem-cell-derived population. Nature 453, 524-528, doi:10.1038/nature06894 (2008). 
75 Rio, P. et al. Targeted gene therapy and cell reprogramming in Fanconi anemia. EMBO 
molecular medicine 6, 835-848, doi:10.15252/emmm.201303374 (2014). 
76 Ogata, T., Kozuka, T. & Kanda, T. Identification of an insulator in AAVS1, a preferred region 
for integration of adeno-associated virus DNA. Journal of virology 77, 9000-9007 (2003). 
77 Elliott, B. & Jasin, M. Double-strand breaks and translocations in cancer. Cell Mol Life Sci 
59, 373-385 (2002). 
78 Grizot, S. et al. Generation of redesigned homing endonucleases comprising DNA-binding 
domains derived from two different scaffolds. Nucleic acids research 38, 2006-2018, 
doi:10.1093/nar/gkp1171 (2010). 
79 Paques, F. & Duchateau, P. Meganucleases and DNA double-strand break-induced 
recombination: perspectives for gene therapy. Current gene therapy 7, 49-66 (2007). 
80 Chevalier, B. S. & Stoddard, B. L. Homing endonucleases: structural and functional insight 
into the catalysts of intron/intein mobility. Nucleic acids research 29, 3757-3774 (2001). 
81 Epinat, J. C. et al. A novel engineered meganuclease induces homologous recombination in 
yeast and mammalian cells. Nucleic acids research 31, 2952-2962 (2003). 
82 Riviere, J. et al. Variable correction of Artemis deficiency by I-Sce1-meganuclease-assisted 
homologous recombination in murine hematopoietic stem cells. Gene therapy 21, 529-532, 
doi:10.1038/gt.2014.20 (2014). 
83 Boch, J. & Bonas, U. Xanthomonas AvrBs3 family-type III effectors: discovery and function. 
Annu Rev Phytopathol 48, 419-436, doi:10.1146/annurev-phyto-080508-081936 (2010). 
84 Mussolino, C. & Cathomen, T. TALE nucleases: tailored genome engineering made easy. 
Curr Opin Biotechnol 23, 644-650, doi:10.1016/j.copbio.2012.01.013 (2012). 
  BIBLIOGRAPHY 
 
135 
 
85 Deng, D. et al. Structural basis for sequence-specific recognition of DNA by TAL effectors. 
Science 335, 720-723, doi:10.1126/science.1215670 (2012). 
86 Boch, J. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 
326, 1509-1512, doi:10.1126/science.1178811 (2009). 
87 Bitinaite, J., Wah, D. A., Aggarwal, A. K. & Schildkraut, I. FokI dimerization is required for 
DNA cleavage. Proceedings of the National Academy of Sciences of the United States of 
America 95, 10570-10575 (1998). 
88 Smith, J. et al. Requirements for double-strand cleavage by chimeric restriction enzymes 
with zinc finger DNA-recognition domains. Nucleic acids research 28, 3361-3369 (2000). 
89 Mussolino, C. et al. A novel TALE nuclease scaffold enables high genome editing activity in 
combination with low toxicity. Nucleic acids research 39, 9283-9293, 
doi:10.1093/nar/gkr597 (2011). 
90 Bhaya, D., Davison, M. & Barrangou, R. CRISPR-Cas systems in bacteria and archaea: 
versatile small RNAs for adaptive defense and regulation. Annual review of genetics 45, 
273-297, doi:10.1146/annurev-genet-110410-132430 (2011). 
91 Al-Attar, S., Westra, E. R., van der Oost, J. & Brouns, S. J. Clustered regularly interspaced 
short palindromic repeats (CRISPRs): the hallmark of an ingenious antiviral defense 
mechanism in prokaryotes. Biol Chem 392, 277-289, doi:10.1515/BC.2011.042 (2011). 
92 Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial 
immunity. Science 337, 816-821, doi:10.1126/science.1225829 (2012). 
93 Cho, S. W., Kim, S., Kim, J. M. & Kim, J. S. Targeted genome engineering in human cells with 
the Cas9 RNA-guided endonuclease. Nature biotechnology 31, 230-232, 
doi:10.1038/nbt.2507 (2013). 
94 Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in 
human cells. Nature biotechnology 31, 822-826, doi:10.1038/nbt.2623 (2013). 
95 Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M. & Joung, J. K. Improving CRISPR-Cas nuclease 
specificity using truncated guide RNAs. Nature biotechnology 32, 279-284, 
doi:10.1038/nbt.2808 (2014). 
96 Maeder, M. L. et al. Rapid "open-source" engineering of customized zinc-finger nucleases 
for highly efficient gene modification. Molecular cell 31, 294-301, 
doi:10.1016/j.molcel.2008.06.016 (2008). 
97 Maeder, M. L., Thibodeau-Beganny, S., Sander, J. D., Voytas, D. F. & Joung, J. K. 
Oligomerized pool engineering (OPEN): an 'open-source' protocol for making customized 
zinc-finger arrays. Nat Protoc 4, 1471-1501, doi:10.1038/nprot.2009.98 (2009). 
98 Pabo, C. O., Peisach, E. & Grant, R. A. Design and selection of novel Cys2His2 zinc finger 
proteins. Annual review of biochemistry 70, 313-340, 
doi:10.1146/annurev.biochem.70.1.313 (2001). 
99 Gabriel, R. et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. 
Nature biotechnology 29, 816-823, doi:10.1038/nbt.1948 (2011). 
100 Pattanayak, V., Ramirez, C. L., Joung, J. K. & Liu, D. R. Revealing off-target cleavage 
specificities of zinc-finger nucleases by in vitro selection. Nature methods 8, 765-770, 
doi:10.1038/nmeth.1670 (2011). 
101 Miller, J. C. et al. An improved zinc-finger nuclease architecture for highly specific genome 
editing. Nature biotechnology 25, 778-785, doi:10.1038/nbt1319 (2007). 
102 Doyon, Y. et al. Enhancing zinc-finger-nuclease activity with improved obligate 
heterodimeric architectures. Nature methods 8, 74-79, doi:10.1038/nmeth.1539 (2011). 
103 Kim, Y. G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to 
Fok I cleavage domain. Proceedings of the National Academy of Sciences of the United 
States of America 93, 1156-1160 (1996). 
104 Meng, X., Noyes, M. B., Zhu, L. J., Lawson, N. D. & Wolfe, S. A. Targeted gene inactivation in 
zebrafish using engineered zinc-finger nucleases. Nature biotechnology 26, 695-701, 
doi:10.1038/nbt1398 (2008). 
105 Carbery, I. D. et al. Targeted genome modification in mice using zinc-finger nucleases. 
Genetics 186, 451-459, doi:10.1534/genetics.110.117002 (2010). 
BIBLIOGRAPHY 
136 
 
106 Geurts, A. M. et al. Knockout rats via embryo microinjection of zinc-finger nucleases. 
Science 325, 433, doi:10.1126/science.1172447 (2009). 
107 Mashimo, T. et al. Generation of knockout rats with X-linked severe combined 
immunodeficiency (X-SCID) using zinc-finger nucleases. PloS one 5, e8870, 
doi:10.1371/journal.pone.0008870 (2010). 
108 Yang, D. et al. Production of apolipoprotein C-III knockout rabbits using zinc finger 
nucleases. J Vis Exp, e50957, doi:10.3791/50957 (2013). 
109 Hauschild, J. et al. Efficient generation of a biallelic knockout in pigs using zinc-finger 
nucleases. Proceedings of the National Academy of Sciences of the United States of 
America 108, 12013-12017, doi:10.1073/pnas.1106422108 (2011). 
110 Perez, E. E. et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using 
zinc-finger nucleases. Nature biotechnology 26, 808-816, doi:10.1038/nbt1410 (2008). 
111 Holt, N. et al. Human hematopoietic stem/progenitor cells modified by zinc-finger 
nucleases targeted to CCR5 control HIV-1 in vivo. Nature biotechnology 28, 839-847, 
doi:10.1038/nbt.1663 (2010). 
112 Lombardo, A. et al. Gene editing in human stem cells using zinc finger nucleases and 
integrase-defective lentiviral vector delivery. Nature biotechnology 25, 1298-1306, 
doi:10.1038/nbt1353 (2007). 
113 Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic stem 
cells. Nature 510, 235-240, doi:10.1038/nature13420 (2014). 
114 Merling, R. K. et al. An AAVS1-targeted minigene platform for correction of iPSCs from all 
five types of chronic granulomatous disease. Molecular therapy : the journal of the 
American Society of Gene Therapy 23, 147-157, doi:10.1038/mt.2014.195 (2015). 
115 Hoban, M. D. et al. Correction of the sickle cell disease mutation in human hematopoietic 
stem/progenitor cells. Blood 125, 2597-2604, doi:10.1182/blood-2014-12-615948 (2015). 
116 Skipper, K. A. & Mikkelsen, J. G. Delivering the goods for genome engineering and editing. 
Human gene therapy, doi:10.1089/hum.2015.063 (2015). 
117 Papapetrou, E. P., Zoumbos, N. C. & Athanassiadou, A. Genetic modification of 
hematopoietic stem cells with nonviral systems: past progress and future prospects. Gene 
therapy 12 Suppl 1, S118-130, doi:10.1038/sj.gt.3302626 (2005). 
118 Urnov, F. D. et al. Highly efficient endogenous human gene correction using designed zinc-
finger nucleases. Nature 435, 646-651, doi:10.1038/nature03556 (2005). 
119 Porteus, M. H. & Baltimore, D. Chimeric nucleases stimulate gene targeting in human cells. 
Science 300, 763, doi:10.1126/science.1078395 (2003). 
120 Orlando, S. J. et al. Zinc-finger nuclease-driven targeted integration into mammalian 
genomes using donors with limited chromosomal homology. Nucleic acids research 38, 
e152, doi:10.1093/nar/gkq512 (2010). 
121 Chen, F. et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-
finger nucleases. Nature methods 8, 753-755, doi:10.1038/nmeth.1653 (2011). 
122 Moehle, E. A. et al. Targeted gene addition into a specified location in the human genome 
using designed zinc finger nucleases. Proceedings of the National Academy of Sciences of 
the United States of America 104, 3055-3060, doi:10.1073/pnas.0611478104 (2007). 
123 Kuhn, A. N. et al. mRNA as a versatile tool for exogenous protein expression. Current gene 
therapy 12, 347-361 (2012). 
124 Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics--developing a new class of 
drugs. Nat Rev Drug Discov 13, 759-780, doi:10.1038/nrd4278 (2014). 
125 Shi, N. Q., Qi, X. R., Xiang, B. & Zhang, Y. A survey on "Trojan Horse" peptides: 
opportunities, issues and controlled entry to "Troy". J Control Release 194, 53-70, 
doi:10.1016/j.jconrel.2014.08.014 (2014). 
126 Wadia, J. S., Stan, R. V. & Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances 
escape of TAT-fusion proteins after lipid raft macropinocytosis. Nature medicine 10, 310-
315, doi:10.1038/nm996 (2004). 
  BIBLIOGRAPHY 
 
137 
 
127 Gaj, T., Guo, J., Kato, Y., Sirk, S. J. & Barbas, C. F., 3rd. Targeted gene knockout by direct 
delivery of zinc-finger nuclease proteins. Nature methods 9, 805-807, 
doi:10.1038/nmeth.2030 (2012). 
128 Chen, Z. et al. Receptor-mediated delivery of engineered nucleases for genome 
modification. Nucleic acids research 41, e182, doi:10.1093/nar/gkt710 (2013). 
129 Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J. S. Highly efficient RNA-guided genome editing 
in human cells via delivery of purified Cas9 ribonucleoproteins. Genome research 24, 1012-
1019, doi:10.1101/gr.171322.113 (2014). 
130 Zuris, J. A. et al. Cationic lipid-mediated delivery of proteins enables efficient protein-based 
genome editing in vitro and in vivo. Nature biotechnology 33, 73-80, doi:10.1038/nbt.3081 
(2015). 
131 Cai, Y., Bak, R. O. & Mikkelsen, J. G. Targeted genome editing by lentiviral protein 
transduction of zinc-finger and TAL-effector nucleases. Elife 3, e01911, 
doi:10.7554/eLife.01911 (2014). 
132 Mock, U. et al. Novel lentiviral vectors with mutated reverse transcriptase for mRNA 
delivery of TALE nucleases. Scientific reports 4, 6409, doi:10.1038/srep06409 (2014). 
133 Lei, Y. et al. Gene editing of human embryonic stem cells via an engineered baculoviral 
vector carrying zinc-finger nucleases. Molecular therapy : the journal of the American 
Society of Gene Therapy 19, 942-950, doi:10.1038/mt.2011.12 (2011). 
134 Anguela, X. M. et al. Robust ZFN-mediated genome editing in adult hemophilic mice. Blood 
122, 3283-3287, doi:10.1182/blood-2013-04-497354 (2013). 
135 Handel, E. M. et al. Versatile and efficient genome editing in human cells by combining 
zinc-finger nucleases with adeno-associated viral vectors. Human gene therapy 23, 321-
329, doi:10.1089/hum.2011.140 (2012). 
136 Ellis, B. L., Hirsch, M. L., Porter, S. N., Samulski, R. J. & Porteus, M. H. Zinc-finger nuclease-
mediated gene correction using single AAV vector transduction and enhancement by Food 
and Drug Administration-approved drugs. Gene therapy 20, 35-42, 
doi:10.1038/gt.2011.211 (2013). 
137 Rahman, S. H. et al. The nontoxic cell cycle modulator indirubin augments transduction of 
adeno-associated viral vectors and zinc-finger nuclease-mediated gene targeting. Human 
gene therapy 24, 67-77, doi:10.1089/hum.2012.168 (2013). 
138 Mazurier, F., Gan, O. I., McKenzie, J. L., Doedens, M. & Dick, J. E. Lentivector-mediated 
clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell 
compartment and culture-induced stem cell impairment. Blood 103, 545-552, 
doi:10.1182/blood-2003-05-1558 (2004). 
139 Wang, C. X. et al. Rapamycin relieves lentiviral vector transduction resistance in human 
and mouse hematopoietic stem cells. Blood 124, 913-923, doi:10.1182/blood-2013-12-
546218 (2014). 
140 Petrillo, C. et al. Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in 
hematopoietic stem and progenitor cells. Molecular therapy : the journal of the American 
Society of Gene Therapy 23, 352-362, doi:10.1038/mt.2014.193 (2015). 
141 Conde, J. et al. Revisiting 30 years of biofunctionalization and surface chemistry of 
inorganic nanoparticles for nanomedicine. Front Chem 2, 48, 
doi:10.3389/fchem.2014.00048 (2014). 
142 Bao, C. et al. A promising road with challenges: where are gold nanoparticles in 
translational research? Nanomedicine (Lond) 9, 2353-2370, doi:10.2217/nnm.14.155 
(2014). 
143 Lee, S. K., Han, M. S., Asokan, S. & Tung, C. H. Effective gene silencing by multilayered 
siRNA-coated gold nanoparticles. Small 7, 364-370, doi:10.1002/smll.201001314 (2011). 
144 Conde, J. et al. In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA 
coupled to inflammatory response in lung cancer mouse models. Biomaterials 34, 7744-
7753, doi:10.1016/j.biomaterials.2013.06.041 (2013). 
145 Conde, J. et al. Design of multifunctional gold nanoparticles for in vitro and in vivo gene 
silencing. ACS nano 6, 8316-8324, doi:10.1021/nn3030223 (2012). 
BIBLIOGRAPHY 
138 
 
146 Kamei, K. et al. Direct cell entry of gold/iron-oxide magnetic nanoparticles in adenovirus 
mediated gene delivery. Biomaterials 30, 1809-1814, 
doi:10.1016/j.biomaterials.2008.12.015 (2009). 
147 Yu, C. et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell 
stem cell 16, 142-147, doi:10.1016/j.stem.2015.01.003 (2015). 
148 Chu, V. T. et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-
induced precise gene editing in mammalian cells. Nature biotechnology 33, 543-548, 
doi:10.1038/nbt.3198 (2015). 
149 Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 
by inhibition of nonhomologous end joining. Nature biotechnology 33, 538-542, 
doi:10.1038/nbt.3190 (2015). 
150 Moldovan, G. L. et al. Inhibition of homologous recombination by the PCNA-interacting 
protein PARI. Molecular cell 45, 75-86, doi:10.1016/j.molcel.2011.11.010 (2012). 
151 Kee, Y. & D'Andrea, A. D. Molecular pathogenesis and clinical management of Fanconi 
anemia. The Journal of clinical investigation 122, 3799-3806, doi:10.1172/JCI58321 (2012). 
152 Fanconi, G. Familiäre infantile perniziosaartige Anämie (perniciziöses Blutbild und 
Konstitution). Jahrbuch für Kinderheikunde und Erziehung (Wien) 117, 257-280 (1927). 
153 Lobitz, S. & Velleuer, E. Guido Fanconi (1892-1979): a jack of all trades. Nature reviews. 
Cancer 6, 893-898, doi:10.1038/nrc2009 (2006). 
154 Bogliolo, M. & Surralles, J. Fanconi anemia: a model disease for studies on human genetics 
and advanced therapeutics. Curr Opin Genet Dev 33, 32-40, doi:10.1016/j.gde.2015.07.002 
(2015). 
155 Navarro, S., Rio, P. & Bueren, J. A. Perspectives on Gene Therapy for Fanconi Anemia. 
Expert Opin Orphan Drugs 3, 899-910, doi:10.1517/21678707.2015.1062752 (2015). 
156 Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nature reviews. 
Cancer 11, 467-480, doi:10.1038/nrc3088 (2011). 
157 Kim, H. & D'Andrea, A. D. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA 
pathway. Genes & development 26, 1393-1408, doi:10.1101/gad.195248.112 (2012). 
158 Kottemann, M. C. & Smogorzewska, A. Fanconi anaemia and the repair of Watson and 
Crick DNA crosslinks. Nature 493, 356-363, doi:10.1038/nature11863 (2013). 
159 Clauson, C., Scharer, O. D. & Niedernhofer, L. Advances in understanding the complex 
mechanisms of DNA interstrand cross-link repair. Cold Spring Harbor perspectives in 
medicine 3, a012732 (2013). 
160 Garaycoechea, J. I. & Patel, K. J. Why does the bone marrow fail in Fanconi anemia? Blood 
123, 26-34, doi:10.1182/blood-2013-09-427740 (2014). 
161 Auerbach, A. D. Fanconi anemia and its diagnosis. Mutation research 668, 4-10, 
doi:10.1016/j.mrfmmm.2009.01.013 (2009). 
162 Singh, T. R. et al. Impaired FANCD2 monoubiquitination and hypersensitivity to 
camptothecin uniquely characterize Fanconi anemia complementation group M. Blood 
114, 174-180, doi:10.1182/blood-2009-02-207811 (2009). 
163 Lim, E. T. et al. Distribution and medical impact of loss-of-function variants in the Finnish 
founder population. PLoS genetics 10, e1004494, doi:10.1371/journal.pgen.1004494 
(2014). 
164 Fanconi anaemia/Breast cancer, c. Positional cloning of the Fanconi anaemia group A gene. 
Nature genetics 14, 324-328, doi:10.1038/ng1196-324 (1996). 
165 Foe, J. R. et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. 
Nature genetics 14, 488, doi:10.1038/ng1296-488 (1996). 
166 Meetei, A. R. et al. X-linked inheritance of Fanconi anemia complementation group B. 
Nature genetics 36, 1219-1224, doi:10.1038/ng1458 (2004). 
167 Strathdee, C. A., Gavish, H., Shannon, W. R. & Buchwald, M. Cloning of cDNAs for Fanconi's 
anaemia by functional complementation. Nature 358, 434, doi:10.1038/358434a0 (1992). 
168 Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606-
609, doi:10.1126/science.1073834 (2002). 
  BIBLIOGRAPHY 
 
139 
 
169 Tavtigian, S. V. et al. The complete BRCA2 gene and mutations in chromosome 13q-linked 
kindreds. Nature genetics 12, 333-337, doi:10.1038/ng0396-333 (1996). 
170 Timmers, C. et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Molecular 
cell 7, 241-248 (2001). 
171 de Winter, J. P. et al. Isolation of a cDNA representing the Fanconi anemia 
complementation group E gene. American journal of human genetics 67, 1306-1308, 
doi:10.1016/S0002-9297(07)62959-0 (2000). 
172 de Winter, J. P. et al. The Fanconi anaemia gene FANCF encodes a novel protein with 
homology to ROM. Nature genetics 24, 15-16, doi:10.1038/71626 (2000). 
173 de Winter, J. P. et al. The Fanconi anaemia group G gene FANCG is identical with XRCC9. 
Nature genetics 20, 281-283, doi:10.1038/3093 (1998). 
174 Garcia-Higuera, I., Kuang, Y., Naf, D., Wasik, J. & D'Andrea, A. D. Fanconi anemia proteins 
FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Molecular and 
cellular biology 19, 4866-4873 (1999). 
175 Levitus, M. et al. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. 
Blood 103, 2498-2503, doi:10.1182/blood-2003-08-2915 (2004). 
176 Dorsman, J. C. et al. Identification of the Fanconi anemia complementation group I gene, 
FANCI. Cellular oncology : the official journal of the International Society for Cellular 
Oncology 29, 211-218 (2007). 
177 Sims, A. E. et al. FANCI is a second monoubiquitinated member of the Fanconi anemia 
pathway. Nature structural & molecular biology 14, 564-567, doi:10.1038/nsmb1252 
(2007). 
178 Smogorzewska, A. et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 
paralog required for DNA repair. Cell 129, 289-301, doi:10.1016/j.cell.2007.03.009 (2007). 
179 Ishiai, M. et al. FANCI phosphorylation functions as a molecular switch to turn on the 
Fanconi anemia pathway. Nature structural & molecular biology 15, 1138-1146, 
doi:10.1038/nsmb.1504 (2008). 
180 Meetei, A. R. et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nature genetics 
35, 165-170, doi:10.1038/ng1241 (2003). 
181 Meetei, A. R. et al. A human ortholog of archaeal DNA repair protein Hef is defective in 
Fanconi anemia complementation group M. Nature genetics 37, 958-963, 
doi:10.1038/ng1626 (2005). 
182 Rahman, N. et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer 
susceptibility gene. Nature genetics 39, 165-167, doi:10.1038/ng1959 (2007). 
183 Reid, S. et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and 
predispose to childhood cancer. Nature genetics 39, 162-164, doi:10.1038/ng1947 (2007). 
184 Xia, B. et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. 
Nature genetics 39, 159-161, doi:10.1038/ng1942 (2007). 
185 Zhang, F. et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Current 
biology : CB 19, 524-529, doi:10.1016/j.cub.2009.02.018 (2009). 
186 Vaz, F. et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nature 
genetics 42, 406-409, doi:10.1038/ng.570 (2010). 
187 Stoepker, C. et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a 
new Fanconi anemia subtype. Nature genetics 43, 138-141, doi:10.1038/ng.751 (2011). 
188 Kim, Y. et al. Mutations of the SLX4 gene in Fanconi anemia. Nature genetics 43, 142-146, 
doi:10.1038/ng.750 (2011). 
189 Bogliolo, M. et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause 
Fanconi anemia. American journal of human genetics 92, 800-806, 
doi:10.1016/j.ajhg.2013.04.002 (2013). 
190 Wang, A. T. et al. A Dominant Mutation in Human RAD51 Reveals Its Function in DNA 
Interstrand Crosslink Repair Independent of Homologous Recombination. Molecular cell 
59, 478-490, doi:10.1016/j.molcel.2015.07.009 (2015). 
191 Sawyer, S. L. et al. Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype. 
Cancer discovery, doi:10.1158/2159-8290.CD-14-1156 (2014). 
BIBLIOGRAPHY 
140 
 
192 Hira, A. et al. Mutations in the Gene Encoding the E2 Conjugating Enzyme UBE2T Cause 
Fanconi Anemia. American journal of human genetics 96, 1001-1007, 
doi:10.1016/j.ajhg.2015.04.022 (2015). 
193 Virts, E. L. et al. AluY-mediated Germline Deletion, Duplication and Somatic Stem Cell 
Reversion in UBE2T Defines a New Subtype of Fanconi Anemia. Human molecular genetics, 
doi:10.1093/hmg/ddv227 (2015). 
194 Alter, B. P. & Kupfer, G. in GeneReviews(R)   (eds R. A. Pagon et al.)  (1993). 
195 Shen, X. et al. Recruitment of fanconi anemia and breast cancer proteins to DNA damage 
sites is differentially governed by replication. Molecular cell 35, 716-723, 
doi:10.1016/j.molcel.2009.06.034 (2009). 
196 Enoiu, M., Jiricny, J. & Scharer, O. D. Repair of cisplatin-induced DNA interstrand crosslinks 
by a replication-independent pathway involving transcription-coupled repair and 
translesion synthesis. Nucleic acids research 40, 8953-8964, doi:10.1093/nar/gks670 
(2012). 
197 Wang, X. et al. Involvement of nucleotide excision repair in a recombination-independent 
and error-prone pathway of DNA interstrand cross-link repair. Molecular and cellular 
biology 21, 713-720, doi:10.1128/MCB.21.3.713-720.2001 (2001). 
198 Moldovan, G. L. & D'Andrea, A. D. How the fanconi anemia pathway guards the genome. 
Annual review of genetics 43, 223-249, doi:10.1146/annurev-genet-102108-134222 (2009). 
199 Kee, Y. & D'Andrea, A. D. Expanded roles of the Fanconi anemia pathway in preserving 
genomic stability. Genes & development 24, 1680-1694, doi:10.1101/gad.1955310 (2010). 
200 Ciccia, A. et al. Identification of FAAP24, a Fanconi anemia core complex protein that 
interacts with FANCM. Molecular cell 25, 331-343, doi:10.1016/j.molcel.2007.01.003 
(2007). 
201 Collins, N. B. et al. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA 
damage is important for FA pathway function. Blood 113, 2181-2190, doi:10.1182/blood-
2008-05-154294 (2009). 
202 Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a 
common pathway. Molecular cell 7, 249-262 (2001). 
203 Huang, M. et al. Human MutS and FANCM complexes function as redundant DNA damage 
sensors in the Fanconi Anemia pathway. DNA repair 10, 1203-1212, 
doi:10.1016/j.dnarep.2011.09.006 (2011). 
204 Zhang, J. & Walter, J. C. Mechanism and regulation of incisions during DNA interstrand 
cross-link repair. DNA repair 19, 135-142, doi:10.1016/j.dnarep.2014.03.018 (2014). 
205 Nojima, K. et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-
linking agents in vertebrate cells. Cancer research 65, 11704-11711, doi:10.1158/0008-
5472.CAN-05-1214 (2005). 
206 Gan, G. N., Wittschieben, J. P., Wittschieben, B. O. & Wood, R. D. DNA polymerase zeta 
(pol zeta) in higher eukaryotes. Cell Res 18, 174-183, doi:10.1038/cr.2007.117 (2008). 
207 Sharma, S., Helchowski, C. M. & Canman, C. E. The roles of DNA polymerase zeta and the Y 
family DNA polymerases in promoting or preventing genome instability. Mutation research 
743-744, 97-110, doi:10.1016/j.mrfmmm.2012.11.002 (2013). 
208 Minko, I. G. et al. Replication bypass of the acrolein-mediated deoxyguanine DNA-peptide 
cross-links by DNA polymerases of the DinB family. Chem Res Toxicol 21, 1983-1990, 
doi:10.1021/tx800174a (2008). 
209 Moldovan, G. L., Pfander, B. & Jentsch, S. PCNA, the maestro of the replication fork. Cell 
129, 665-679, doi:10.1016/j.cell.2007.05.003 (2007). 
210 Ulrich, H. D. Regulating post-translational modifications of the eukaryotic replication clamp 
PCNA. DNA repair 8, 461-469, doi:10.1016/j.dnarep.2009.01.006 (2009). 
211 Wang, L. C. & Gautier, J. The Fanconi anemia pathway and ICL repair: implications for 
cancer therapy. Critical reviews in biochemistry and molecular biology 45, 424-439, 
doi:10.3109/10409238.2010.502166 (2010). 
212 Wang, A. T. & Smogorzewska, A. SnapShot: Fanconi Anemia and Associated Proteins. Cell 
160, 354-354 e351, doi:10.1016/j.cell.2014.12.031 (2015). 
  BIBLIOGRAPHY 
 
141 
 
213 de Laat, W. L., Jaspers, N. G. & Hoeijmakers, J. H. Molecular mechanism of nucleotide 
excision repair. Genes & development 13, 768-785 (1999). 
214 Thoms, K. M., Kuschal, C. & Emmert, S. Lessons learned from DNA repair defective 
syndromes. Exp Dermatol 16, 532-544, doi:10.1111/j.1600-0625.2007.00559.x (2007). 
215 Gillet, L. C. & Scharer, O. D. Molecular mechanisms of mammalian global genome 
nucleotide excision repair. Chem Rev 106, 253-276, doi:10.1021/cr040483f (2006). 
216 Chang, D. J. & Cimprich, K. A. DNA damage tolerance: when it's OK to make mistakes. 
Nature chemical biology 5, 82-90, doi:10.1038/nchembio.139 (2009). 
217 Haynes, B., Saadat, N., Myung, B. & Shekhar, M. P. Crosstalk between translesion 
synthesis, Fanconi anemia network, and homologous recombination repair pathways in 
interstrand DNA crosslink repair and development of chemoresistance. Mutat Res Rev 
Mutat Res 763, 258-266, doi:10.1016/j.mrrev.2014.11.005 (2015). 
218 Ghosal, G. & Chen, J. DNA damage tolerance: a double-edged sword guarding the genome. 
Translational cancer research 2, 107-129, doi:10.3978/j.issn.2218-676X.2013.04.01 (2013). 
219 Fujiwara, Y. et al. Xeroderma pigmentosum groups C and F: additional assignments and a 
review of the subjects in Japan. Journal of radiation research 26, 443-449 (1985). 
220 Niedernhofer, L. J. et al. A new progeroid syndrome reveals that genotoxic stress 
suppresses the somatotroph axis. Nature 444, 1038-1043, doi:10.1038/nature05456 
(2006). 
221 Overmeer, R. M. et al. Replication protein A safeguards genome integrity by controlling 
NER incision events. J Cell Biol 192, 401-415, doi:10.1083/jcb.201006011 (2011). 
222 Geng, L., Huntoon, C. J. & Karnitz, L. M. RAD18-mediated ubiquitination of PCNA activates 
the Fanconi anemia DNA repair network. J Cell Biol 191, 249-257, 
doi:10.1083/jcb.201005101 (2010). 
223 Fu, D. et al. Recruitment of DNA polymerase eta by FANCD2 in the early response to DNA 
damage. Cell cycle 12, 803-809, doi:10.4161/cc.23755 (2013). 
224 Zhang, J., Zhao, D., Wang, H., Lin, C. J. & Fei, P. FANCD2 monoubiquitination provides a link 
between the HHR6 and FA-BRCA pathways. Cell cycle 7, 407-413 (2008). 
225 Davies, A. A., Huttner, D., Daigaku, Y., Chen, S. & Ulrich, H. D. Activation of ubiquitin-
dependent DNA damage bypass is mediated by replication protein a. Molecular cell 29, 
625-636, doi:10.1016/j.molcel.2007.12.016 (2008). 
226 Kim, H., Yang, K., Dejsuphong, D. & D'Andrea, A. D. Regulation of Rev1 by the Fanconi 
anemia core complex. Nature structural & molecular biology 19, 164-170, 
doi:10.1038/nsmb.2222 (2012). 
227 Huang, T. T. et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell 
Biol 8, 339-347, doi:10.1038/ncb1378 (2006). 
228 Nakanishi, K. et al. Human Fanconi anemia monoubiquitination pathway promotes 
homologous DNA repair. Proceedings of the National Academy of Sciences of the United 
States of America 102, 1110-1115, doi:10.1073/pnas.0407796102 (2005). 
229 Smogorzewska, A. et al. A genetic screen identifies FAN1, a Fanconi anemia-associated 
nuclease necessary for DNA interstrand crosslink repair. Molecular cell 39, 36-47, 
doi:10.1016/j.molcel.2010.06.023 (2010). 
230 Yamamoto, K. et al. Fanconi anemia protein FANCD2 promotes immunoglobulin gene 
conversion and DNA repair through a mechanism related to homologous recombination. 
Molecular and cellular biology 25, 34-43, doi:10.1128/MCB.25.1.34-43.2005 (2005). 
231 Zhang, N., Liu, X., Li, L. & Legerski, R. Double-strand breaks induce homologous 
recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, 
REV3, and the Fanconi anemia pathway. DNA repair 6, 1670-1678, 
doi:10.1016/j.dnarep.2007.06.002 (2007). 
232 Nakanishi, K. et al. Homology-directed Fanconi anemia pathway cross-link repair is 
dependent on DNA replication. Nature structural & molecular biology 18, 500-503, 
doi:10.1038/nsmb.2029 (2011). 
233 Adamo, A. et al. Preventing nonhomologous end joining suppresses DNA repair defects of 
Fanconi anemia. Molecular cell 39, 25-35, doi:10.1016/j.molcel.2010.06.026 (2010). 
BIBLIOGRAPHY 
142 
 
234 Pace, P. et al. Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. 
Science 329, 219-223, doi:10.1126/science.1192277 (2010). 
235 Bunting, S. F. et al. BRCA1 functions independently of homologous recombination in DNA 
interstrand crosslink repair. Molecular cell 46, 125-135, doi:10.1016/j.molcel.2012.02.015 
(2012). 
236 Murina, O. et al. FANCD2 and CtIP cooperate to repair DNA interstrand crosslinks. Cell 
reports 7, 1030-1038, doi:10.1016/j.celrep.2014.03.069 (2014). 
237 Unno, J. et al. FANCD2 binds CtIP and regulates DNA-end resection during DNA interstrand 
crosslink repair. Cell reports 7, 1039-1047, doi:10.1016/j.celrep.2014.04.005 (2014). 
238 Huang, M. et al. The FANCM/FAAP24 complex is required for the DNA interstrand 
crosslink-induced checkpoint response. Molecular cell 39, 259-268, 
doi:10.1016/j.molcel.2010.07.005 (2010). 
239 Yamamoto, K. et al. Fanconi anemia FANCG protein in mitigating radiation- and enzyme-
induced DNA double-strand breaks by homologous recombination in vertebrate cells. 
Molecular and cellular biology 23, 5421-5430 (2003). 
240 Howard, S. M., Yanez, D. A. & Stark, J. M. DNA damage response factors from diverse 
pathways, including DNA crosslink repair, mediate alternative end joining. PLoS genetics 
11, e1004943, doi:10.1371/journal.pgen.1004943 (2015). 
241 Callen, E. et al. A common founder mutation in FANCA underlies the world's highest 
prevalence of Fanconi anemia in Gypsy families from Spain. Blood 105, 1946-1949, 
doi:10.1182/blood-2004-07-2588 (2005). 
242 Schneider, M., Chandler, K., Tischkowitz, M. & Meyer, S. Fanconi anaemia: genetics, 
molecular biology, and cancer - implications for clinical management in children and 
adults. Clinical genetics 88, 13-24, doi:10.1111/cge.12517 (2015). 
243 Kelly, P. F. et al. Stem cell collection and gene transfer in Fanconi anemia. Molecular 
therapy : the journal of the American Society of Gene Therapy 15, 211-219, 
doi:10.1038/sj.mt.6300033 (2007). 
244 Ceccaldi, R. et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated 
p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell 
Stem Cell 11, 36-49, doi:10.1016/j.stem.2012.05.013 (2012). 
245 Tulpule, A. et al. Knockdown of Fanconi anemia genes in human embryonic stem cells 
reveals early developmental defects in the hematopoietic lineage. Blood 115, 3453-3462, 
doi:10.1182/blood-2009-10-246694 (2010). 
246 Rosenberg, P. S., Alter, B. P. & Ebell, W. Cancer risks in Fanconi anemia: findings from the 
German Fanconi Anemia Registry. Haematologica 93, 511-517, 
doi:10.3324/haematol.12234 (2008). 
247 Alter, B. P., Greene, M. H., Velazquez, I. & Rosenberg, P. S. Cancer in Fanconi anemia. Blood 
101, 2072, doi:10.1182/blood-2002-11-3597 (2003). 
248 Cioc, A. M., Wagner, J. E., MacMillan, M. L., DeFor, T. & Hirsch, B. Diagnosis of 
myelodysplastic syndrome among a cohort of 119 patients with fanconi anemia: 
morphologic and cytogenetic characteristics. American journal of clinical pathology 133, 
92-100, doi:10.1309/AJCP7W9VMJENZOVG (2010). 
249 Gregory, J. J., Jr. et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic 
reversion in lymphohematopoietic stem cells. Proceedings of the National Academy of 
Sciences of the United States of America 98, 2532-2537, doi:10.1073/pnas.051609898 
(2001). 
250 Waisfisz, Q. et al. Spontaneous functional correction of homozygous fanconi anaemia 
alleles reveals novel mechanistic basis for reverse mosaicism. Nature genetics 22, 379-383, 
doi:10.1038/11956 (1999). 
251 Soulier, J. et al. Detection of somatic mosaicism and classification of Fanconi anemia 
patients by analysis of the FA/BRCA pathway. Blood 105, 1329-1336, doi:10.1182/blood-
2004-05-1852 (2005). 
  BIBLIOGRAPHY 
 
143 
 
252 Ceccaldi, R. et al. Spontaneous abrogation of the G(2)DNA damage checkpoint has clinical 
benefits but promotes leukemogenesis in Fanconi anemia patients. The Journal of clinical 
investigation 121, 184-194, doi:10.1172/JCI43836 (2011). 
253 Auerbach, A. D., Rogatko, A. & Schroeder-Kurth, T. M. International Fanconi Anemia 
Registry: relation of clinical symptoms to diepoxybutane sensitivity. Blood 73, 391-396 
(1989). 
254 Seyschab, H. et al. Comparative evaluation of diepoxybutane sensitivity and cell cycle 
blockage in the diagnosis of Fanconi anemia. Blood 85, 2233-2237 (1995). 
255 Neveling, K., Endt, D., Hoehn, H. & Schindler, D. Genotype-phenotype correlations in 
Fanconi anemia. Mutation research 668, 73-91, doi:10.1016/j.mrfmmm.2009.05.006 
(2009). 
256 Saito, H., Hammond, A. T. & Moses, R. E. Hypersensitivity to oxygen is a uniform and 
secondary defect in Fanconi anemia cells. Mutation research 294, 255-262 (1993). 
257 Schindler, D. & Hoehn, H. Fanconi anemia mutation causes cellular susceptibility to 
ambient oxygen. American journal of human genetics 43, 429-435 (1988). 
258 Joksic, I. et al. Dysfunctional telomeres in primary cells from Fanconi anemia FANCD2 
patients. Genome integrity 3, 6, doi:10.1186/2041-9414-3-6 (2012). 
259 Kirwan, M. & Dokal, I. Dyskeratosis congenita, stem cells and telomeres. Biochim Biophys 
Acta 1792, 371-379, doi:10.1016/j.bbadis.2009.01.010 (2009). 
260 Leteurtre, F. et al. Accelerated telomere shortening and telomerase activation in Fanconi's 
anaemia. British journal of haematology 105, 883-893 (1999). 
261 Callen, E. et al. Breaks at telomeres and TRF2-independent end fusions in Fanconi anemia. 
Human molecular genetics 11, 439-444 (2002). 
262 Dufour, C. et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of 
Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood 102, 
2053-2059, doi:10.1182/blood-2003-01-0114 (2003). 
263 Rosselli, F., Sanceau, J., Gluckman, E., Wietzerbin, J. & Moustacchi, E. Abnormal 
lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro 
and in vivo spontaneous overproduction of tumor necrosis factor alpha. Blood 83, 1216-
1225 (1994). 
264 Schultz, J. C. & Shahidi, N. T. Tumor necrosis factor-alpha overproduction in Fanconi's 
anemia. American journal of hematology 42, 196-201 (1993). 
265 Ibanez, A. et al. Elevated levels of IL-1beta in Fanconi anaemia group A patients due to a 
constitutively active phosphoinositide 3-kinase-Akt pathway are capable of promoting 
tumour cell proliferation. The Biochemical journal 422, 161-170, doi:10.1042/BJ20082118 
(2009). 
266 Li, J. et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C 
murine stem cells. The Journal of clinical investigation 117, 3283-3295, 
doi:10.1172/JCI31772 (2007). 
267 Wajant, H., Pfizenmaier, K. & Scheurich, P. Non-apoptotic Fas signaling. Cytokine & growth 
factor reviews 14, 53-66 (2003). 
268 Osborn, L., Kunkel, S. & Nabel, G. J. Tumor necrosis factor alpha and interleukin 1 stimulate 
the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. 
Proceedings of the National Academy of Sciences of the United States of America 86, 2336-
2340 (1989). 
269 Jacome, A. et al. A simplified approach to improve the efficiency and safety of ex vivo 
hematopoietic gene therapy in fanconi anemia patients. Human gene therapy 17, 245-250, 
doi:10.1089/hum.2006.17.245 (2006). 
270 Mehta, P. A. et al. Etanercept treatment in Fanconi anaemia; combined US and Italian 
experience. British journal of haematology 158, 809-811, doi:10.1111/j.1365-
2141.2012.09250.x (2012). 
271 Zhang, X. et al. Defective homing is associated with altered Cdc42 activity in cells from 
patients with Fanconi anemia group A. Blood 112, 1683-1686, doi:10.1182/blood-2008-03-
147090 (2008). 
BIBLIOGRAPHY 
144 
 
272 Pilonetto, D. V. et al. FANCD2 Western blot as a diagnostic tool for Brazilian patients with 
Fanconi anemia. Brazilian journal of medical and biological research = Revista brasileira de 
pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 42, 237-243 
(2009). 
273 Vinciguerra, P., Godinho, S. A., Parmar, K., Pellman, D. & D'Andrea, A. D. Cytokinesis failure 
occurs in Fanconi anemia pathway-deficient murine and human bone marrow 
hematopoietic cells. The Journal of clinical investigation 120, 3834-3842, 
doi:10.1172/JCI43391 (2010). 
274 Schuler, D., Kiss, A. & Fabian, F. Chromosomal peculiarities and "in vitro" examinations in 
Fanconi's anaemia. Humangenetik 7, 314-322 (1969). 
275 Antonio Casado, J. et al. A comprehensive strategy for the subtyping of patients with 
Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. 
Journal of medical genetics 44, 241-249, doi:10.1136/jmg.2006.044719 (2007). 
276 Stucki, A. et al. Decreased rejection and improved survival of first and second marrow 
transplants for severe aplastic anemia (a 26-year retrospective analysis). Blood 92, 2742-
2749 (1998). 
277 Dufour, C. & Svahn, J. Fanconi anaemia: new strategies. Bone marrow transplantation 41 
Suppl 2, S90-95, doi:10.1038/bmt.2008.63 (2008). 
278 Shimamura, A. & Alter, B. P. Pathophysiology and management of inherited bone marrow 
failure syndromes. Blood reviews 24, 101-122, doi:10.1016/j.blre.2010.03.002 (2010). 
279 Velazquez, I. & Alter, B. P. Androgens and liver tumors: Fanconi's anemia and non-
Fanconi's conditions. American journal of hematology 77, 257-267, doi:10.1002/ajh.20183 
(2004). 
280 Scheckenbach, K. et al. Treatment of the bone marrow failure in Fanconi anemia patients 
with danazol. Blood Cells Mol Dis 48, 128-131, doi:10.1016/j.bcmd.2011.11.006 (2012). 
281 Guinan, E. C., Lopez, K. D., Huhn, R. D., Felser, J. M. & Nathan, D. G. Evaluation of 
granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in 
children with fanconi anemia. J Pediatr 124, 144-150 (1994). 
282 Rackoff, W. R. et al. Prolonged administration of granulocyte colony-stimulating factor 
(filgrastim) to patients with Fanconi anemia: a pilot study. Blood 88, 1588-1593 (1996). 
283 Gluckman, E., Berger, R. & Dutreix, J. Bone marrow transplantation for Fanconi anemia. 
Semin Hematol 21, 20-26 (1984). 
284 Zecca, M. et al. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell 
transplantation in children with Fanconi anemia. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow Transplantation 20, 
571-576, doi:10.1016/j.bbmt.2014.01.015 (2014). 
285 MacMillan, M. L. et al. Alternative donor hematopoietic cell transplantation for Fanconi 
anemia. Blood 125, 3798-3804, doi:10.1182/blood-2015-02-626002 (2015). 
286 Alter, B. P., Giri, N., Pan, Y., Savage, S. A. & Pinto, L. A. Antibody response to human 
papillomavirus vaccine in subjects with inherited bone marrow failure syndromes. Vaccine 
32, 1169-1173, doi:10.1016/j.vaccine.2013.11.048 (2014). 
287 Walsh, C. E. et al. Retroviral-mediated gene transfer for Fanconi anemia group A patients - 
a clinical trial. Blood 98, 718a (2001). 
288 Liu, J. M. et al. Engraftment of hematopoietic progenitor cells transduced with the Fanconi 
anemia group C gene (FANCC). Human gene therapy 10, 2337-2346, 
doi:10.1089/10430349950016988 (1999). 
289 Tolar, J. et al. Gene therapy for Fanconi anemia: one step closer to the clinic. Human gene 
therapy 23, 141-144, doi:10.1089/hum.2011.237 (2012). 
290 Gonzalez-Murillo, A. et al. Development of lentiviral vectors with optimized transcriptional 
activity for the gene therapy of patients with Fanconi anemia. Human gene therapy 21, 
623-630, doi:10.1089/hum.2009.141 (2010). 
291 Liu, G. H. et al. Modelling Fanconi anemia pathogenesis and therapeutics using integration-
free patient-derived iPSCs. Nature communications 5, 4330, doi:10.1038/ncomms5330 
(2014). 
  BIBLIOGRAPHY 
 
145 
 
292 Osborn, M. J. et al. Fanconi anemia gene editing by the CRISPR/Cas9 system. Human gene 
therapy 26, 114-126, doi:10.1089/hum.2014.111 (2015). 
293 Hussain, T. & Mulherkar, R. Lymphoblastoid Cell lines: a Continuous in Vitro Source of Cells 
to Study Carcinogen Sensitivity and DNA Repair. Int J Mol Cell Med 1, 75-87 (2012). 
294 Guhaniyogi, J. & Brewer, G. Regulation of mRNA stability in mammalian cells. Gene 265, 
11-23 (2001). 
295 Yanez-Munoz, R. J. et al. Effective gene therapy with nonintegrating lentiviral vectors. 
Nature medicine 12, 348-353, doi:10.1038/nm1365 (2006). 
296 Szymczak, A. L. et al. Correction of multi-gene deficiency in vivo using a single 'self-
cleaving' 2A peptide-based retroviral vector. Nature biotechnology 22, 589-594, 
doi:10.1038/nbt957 (2004). 
297 Yagasaki, H. et al. A cytoplasmic serine protein kinase binds and may regulate the Fanconi 
anemia protein FANCA. Blood 98, 3650-3657 (2001). 
298 Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. 
Journal of virology 72, 8463-8471 (1998). 
299 Burns, J. C., Friedmann, T., Driever, W., Burrascano, M. & Yee, J. K. Vesicular stomatitis 
virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and 
efficient gene transfer into mammalian and nonmammalian cells. Proceedings of the 
National Academy of Sciences of the United States of America 90, 8033-8037 (1993). 
300 Reiser, J. et al. Transduction of nondividing cells using pseudotyped defective high-titer HIV 
type 1 particles. Proceedings of the National Academy of Sciences of the United States of 
America 93, 15266-15271 (1996). 
301 Schenborn, E. & Groskreutz, D. Reporter gene vectors and assays. Mol Biotechnol 13, 29-
44, doi:10.1385/MB:13:1:29 (1999). 
302 Charrier, S. et al. Quantification of lentiviral vector copy numbers in individual 
hematopoietic colony-forming cells shows vector dose-dependent effects on the frequency 
and level of transduction. Gene therapy 18, 479-487, doi:10.1038/gt.2010.163 (2011). 
303 Romero, Z. et al. beta-globin gene transfer to human bone marrow for sickle cell disease. 
The Journal of clinical investigation, doi:10.1172/JCI67930 (2013). 
304 Perumbeti, A. et al. A novel human gamma-globin gene vector for genetic correction of 
sickle cell anemia in a humanized sickle mouse model: critical determinants for successful 
correction. Blood 114, 1174-1185, doi:10.1182/blood-2009-01-201863 (2009). 
305 Smith, J., Tho, L. M., Xu, N. & Gillespie, D. A. The ATM-Chk2 and ATR-Chk1 pathways in 
DNA damage signaling and cancer. Adv Cancer Res 108, 73-112, doi:10.1016/B978-0-12-
380888-2.00003-0 (2010). 
306 Lin, Y. & Waldman, A. S. Promiscuous patching of broken chromosomes in mammalian cells 
with extrachromosomal DNA. Nucleic acids research 29, 3975-3981 (2001). 
307 Kass, E. M. & Jasin, M. Collaboration and competition between DNA double-strand break 
repair pathways. FEBS letters 584, 3703-3708, doi:10.1016/j.febslet.2010.07.057 (2010). 
308 van Nierop, G. P., de Vries, A. A., Holkers, M., Vrijsen, K. R. & Goncalves, M. A. Stimulation 
of homology-directed gene targeting at an endogenous human locus by a nicking 
endonuclease. Nucleic acids research 37, 5725-5736, doi:10.1093/nar/gkp643 (2009). 
309 Wang, J. et al. Targeted gene addition to a predetermined site in the human genome using 
a ZFN-based nicking enzyme. Genome research 22, 1316-1326, doi:10.1101/gr.122879.111 
(2012). 
310 Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. 
Nature 475, 217-221, doi:10.1038/nature10177 (2011). 
311 Rahman, S. H., Maeder, M. L., Joung, J. K. & Cathomen, T. Zinc-finger nucleases for somatic 
gene therapy: the next frontier. Human gene therapy 22, 925-933, 
doi:10.1089/hum.2011.087 (2011). 
312 Ousterout, D. G. et al. Reading frame correction by targeted genome editing restores 
dystrophin expression in cells from Duchenne muscular dystrophy patients. Molecular 
therapy : the journal of the American Society of Gene Therapy 21, 1718-1726, 
doi:10.1038/mt.2013.111 (2013). 
BIBLIOGRAPHY 
146 
 
313 Meier, D. & Schindler, D. Fanconi anemia core complex gene promoters harbor conserved 
transcription regulatory elements. PloS one 6, e22911, doi:10.1371/journal.pone.0022911 
(2011). 
314 Saydaminova, K. et al. Efficient genome editing in hematopoietic stem cells with helper-
dependent Ad5/35 vectors expressing site-specific endonucleases under microRNA 
regulation. Mol Ther Methods Clin Dev 1, 14057, doi:10.1038/mtm.2014.57 (2015). 
315 Liu, J., Gaj, T., Wallen, M. C. & Barbas, C. F., 3rd. Improved cell-penetrating zinc-finger 
nuclease proteins for precision genome engineering. Molecular therapy. Nucleic acids 4, 
e232, doi:10.1038/mtna.2015.6 (2015). 
316 Catlin, S. N., Busque, L., Gale, R. E., Guttorp, P. & Abkowitz, J. L. The replication rate of 
human hematopoietic stem cells in vivo. Blood 117, 4460-4466, doi:10.1182/blood-2010-
08-303537 (2011). 
317 Hendel, A. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in 
human primary cells. Nature biotechnology, doi:10.1038/nbt.3290 (2015). 
318 Nakamura-Ishizu, A., Takizawa, H. & Suda, T. The analysis, roles and regulation of 
quiescence in hematopoietic stem cells. Development 141, 4656-4666, 
doi:10.1242/dev.106575 (2014). 
319 Wunderlich, M. et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG 
mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24, 1785-1788, 
doi:10.1038/leu.2010.158 (2010). 
320 Kumar, M., Keller, B., Makalou, N. & Sutton, R. E. Systematic determination of the 
packaging limit of lentiviral vectors. Human gene therapy 12, 1893-1905, 
doi:10.1089/104303401753153947 (2001). 
321 Fingar, D. C. et al. mTOR controls cell cycle progression through its cell growth effectors 
S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Molecular and cellular biology 
24, 200-216 (2004). 
 
   
 
 
 
Appendix I: Supplementary figures 
 
 
 
 

  APPENDIX I 
 
149 
 
 
Supplementary figure 1: Cloning strategy of FANCA-Puro donor. 
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